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Abstract 
 
Macroautophagy, here called autophagy, is a catabolic process that is required for cell 
homeostasis and cell survival under nutrient starvation, as well as development and 
immunity in higher eukaryotes. Characterised by the formation of double membrane-
bound vesicles, termed autophagosomes, macroautophagy results in degradation of 
intracellular proteins in the lysosome. Autophagy initiation leads to the formation of a 
double membrane phagophore, which expands and sequesters cytoplasm components 
before autophagosome closure and fusion with endosomes and lysosomes. 
Autophagosome formation requires the sequential and concerted action of a 
number of core autophagy proteins. First identified in yeast, characterisation of 
mammalian autophagy proteins has shed light on the molecular mechanisms of 
autophagy initiation and phagophore expansion. However, a number of key questions 
remain unanswered, including what the functions of the core autophagy proteins mAtg9 
and WIPI2 are. mAtg9 is the only transmembrane protein required for autophagy while 
WIPI2 is a PtdIns(3)P-binding protein. To address the function of these proteins, I used 
and explored immunoprecipitation - mass spectrometry based approaches to identify 
and characterise novel interactors. I showed that mAtg9 binds transferrin receptor and 
this interaction supports a model whereby mAtg9 traffics from a tubular-vesicular 
mAtg9 compartment, with recycling endosome-like characteristics, to support 
autophagosome formation. β-propeller proteins such as WIPI2 frequently act in 
mediating protein-protein interactions and so WIPI2 may recruit autophagy proteins to 
the PtdIns(3)P-positive site of autophagosome formation. I characterised the Atg16L1-
WIPI2b interaction and investigated possible regulation of WIPI2 function by 
phosphorylation. I used immunoprecipitation to map the interacting regions of WIPI2b 
and Atg16L1 and to demonstrate that these proteins interact directly. I produced binding 
mutants of each protein and subsequently characterised the function of Atg16L1-
WIPI2b binding, showing that the interaction is required for starvation- and pathogen-
induced autophagy. Preliminary data was also obtained on the phosphorylation of the C-
terminus of WIPI2 as a possible mechanism of WIPI2 function regulation. I propose a 
model in which WIPI2b is a PtdIns(3)P effector protein required for recruitment of the 
Atg12–5-16L1 complex to the site of autophagosome formation and LC3 lipidation. 
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Chapter 1. Introduction 
1.1 Protein degradation 
Proper cell function is achieved through transcriptional control of protein synthesis 
combined with protein turnover via protein degradation. Although this paradigm is well 
established now, it has not always been the case. For many years it was thought that the 
proteins of a cell were stable and not actively degraded. Work by Rudolf Schoenheimer 
in the late 1930s demonstrated that radioactive nitrogen was incorporated into the tissue 
of rats after feeding with 15N-labelled tyrosine while non-labelled protein was excreted, 
showing for the first time that ingested protein is not just required for metabolism, but is 
required for forming new proteins after protein degradation (Ciechanover, 2005). This 
idea of protein flux was controversial and it was not until the notion of a half-life of a 
protein was demonstrated that it was widely accepted. 
 Numerous landmark discoveries in the past 70 years have built up a complex 
picture of protein degradation. Both bulk and specific protein degradation occurs within 
the cell and is essential, in combination with regulated gene expression, for almost all 
cellular processes, from modulation of the proteome to enable adaption to changes in 
extracellular conditions, to cell differentiation, cellular homeostasis, protection against 
starvation, defence against pathogens and cell division. There are two major protein 
degradation pathways: lysosome- and proteasome-mediated degradation (Figure 1.1). 
Both of these pathways are tightly controlled and dysfunction of either results in serious 
pathologies. 
 
1.1.1 Lysosome-mediated protein degradation 
The lysosome was discovered in the laboratory of Christian de Duve when it was 
demonstrated that the enzymatic activity of the cellular fractions containing acid 
phosphatase increased following treatments that caused membrane disruption (Sabatini 
and Adesnik, 2013). Further characterisation of these cellular fractions revealed the 
presence of other hydrolases, all of which have a low optimal pH, and led to the theory 
of a membrane-bound organelle that was specialised for degradation of macromolecules. 
Chapter 1 Introduction 
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De Duve termed this organelle the lysosome (De Duve and Wattiaux, 1966). This 
discovery was achieved by biochemical means only; no microscopy was utilised in this 
initial characterisation of the lysosome. Further work by de Duve’s team and others 
using electron microscopy subsequently confirmed that lysosomes were dense, 
membrane bound organelles with an acidic pH. 
Subsequent morphological studies from numerous researchers began to shed 
light on how extracellular and intracellular proteins and other macromolecules are 
degraded. Studies following extracellular markers showed that material was 
endocytosed into single membrane-bound vesicles, which did not stain for lysosomal 
acid hydrolases, but which fused with lysosomes at later stages (De Duve and Wattiaux, 
1966). Endocytosis of extracellular and plasma membrane bound material and 
subsequent membrane trafficking events resulting in degradation of endocytosed 
material will not be discussed any further; I will instead concentrate on degradation of 
intracellular material.  
Morphological studies revealed the presence of acid phosphatase-stained, single 
membrane-bound organelles that contained cellular components such as bulk cytoplasm, 
endoplasmic reticulum (ER), and mitochondria (Ohsumi, 2014). Bulk cytoplasm and 
organelles were also seen in acid phosphatase negative double membrane-bound 
organelles, termed autophagosomes (De Duve and Wattiaux, 1966). We now know that 
a double membrane forms around bulk cytoplasm or organelles before self-fusing and 
subsequently fusing with the lysosome to form a degradative autolysosome, in which 
macromolecules are broken down and the resulting products are released into the 
cytoplasm for reuse. This process is termed macroautophagy, or simply autophagy, and 
will be discussed in more detail in subsequent sections. 
 Macroautophagy and the endocytic pathway are the major pathways by which 
material is delivered to the lysosome. However, there are an additional two forms of 
delivery, both types of autophagy, named microautophagy and chaperone-mediated 
autophagy (CMA). Intra-lysosomal vesicles have been identified in mammals and in 
yeast, and are thought to be a product of microautophagy (De Duve and Wattiaux, 1966, 
Li et al., 2012). Non-selective microautophagy involves the direct engulfment of 
cytoplasmic cargo at the surface of the lysosome through the formation of a finger-like 
insertion into the lysosome or vacuole (Mijaljica et al., 2011). Constriction of the neck 
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of this figure-like tube results in pinching off of a microautophagic vesicle into the 
lumen of the lysosome or vacuole. This microautophagosome and its contents are 
subsequently degraded, as for macroautophagosomes. Selective degradation of 
mitochondria, peroxisomes and the nucleus by microautophagy (micromitophagy, 
micropexophagy and micronucleophagy, respectively) have been seen in some yeast 
types (Mijaljica et al., 2011). This selective degradation is thought to occur either 
through the formation of finger-like projections by the microautophagosome around the 
organelle (as for micropexophagy) or through piece-meal digestion of small fragments 
of the organelle in contact with the vacuole (as for micronucleophagy) (Li et al., 2012). 
Selective micronucleophagy has not been observed in mammals. The function of 
microautophagy in mammals is unclear; it is thought to be required for survival during 
starvation, although there is no direct evidence for this (Li et al., 2012, Mijaljica et al., 
2011). A more widely accepted, but not necessarily the only, function of 
microautophagy is in the regulation of lysosome size. After macroautophagosome-
lysosome fusion results in increased lysosome size, invagination and pinching off of the 
lysosome membrane by microphagy acts in organelle homeostasis (Mijaljica et al., 
2011).  
 As well as delivery to the lysosome via membrane deformation and fusion 
events, certain proteins can be transported across the surface of the lysosome by 
chaperone-mediated autophagy (CMA) (Orenstein and Cuervo, 2010). CMA involves 
the targeted degradation of peptides containing a pentapeptide CMA consensus motif. 
This motif is recognised by the cytosolic protein chaperones, including heat shock 
cognate 70 protein (Hsc70). CMA substrates then bind the CMA receptor, lysosome-
associated membrane protein type 2A (LAMP-2A), on the lysosome surface. LAMP-2A 
subsequently oligomerises and allows translocation through the lysosome surface. 
Although constitutively active, CMA is upregulated during periods of cellular stress 
such as starvation and stress causing protein damage, similarly to macroautophagy 
(Orenstein and Cuervo, 2010). However, CMA is upregulated at a later stage of 
starvation than macroautophagy, suggesting that cells may switch from a global protein 
degradation to a targeted degradation mechanism, therefore ensuring that cells are not 
damaged by over-digestion of intracellular proteins and instead that only superfluous or 
unrequired proteins are targeted for degradation and recycling. 
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1.1.2 Proteasome-mediated protein degradation 
The discovery of lysosome-mediated protein degradation provided an explanation for 
how a cell could mediate intracellular protein and macromolecule degradation but not 
cause widespread damage, as would be caused by cytosolic hydrolases. However, the 
pathways described above did not provide an explanation for protein degradation seen 
in rabbit reticulate lysate, which contains no lysosomes, and other systems where 
lysosomal inhibitors had been used (Ciechanover, 2005). Investigations led to the 
discovery of the ubiquitin-proteasome system. Ubiquitin is a small protein, consisting of 
76 amino acids, that is covalently bonded to a lysine residue in a target protein. 
Addition of a polyubiquitin chain containing lysine-48 linkages between ubiquitin 
molecules results in protein targeting to the proteasome (Ciechanover, 2005). Addition 
of ubiquitin to a protein involves a cascade of enzymatic reactions: activation of 
ubiquitin by an ubiquitin-activating enzyme (E1 enzyme) is followed by transfer of the 
ubiquitin molecule to the active site of an ubiquitin conjugation (E2) enzyme. The final 
step is the recognition and bringing together of the E2 enzyme and the target protein by 
a specific ubiquitin ligase (E3 enzyme), which catalyses the transfer of ubiquitin from 
the active site of the E2 enzyme to the target protein. Following polyubiquitination, a 
protein is recognised by the proteasome – a barrel-shaped complex comprising of two 
end ‘caps’ that recognise ubiquitinated proteins and, after protein unfolding, allow entry 
into the core of the barrel. The core of the proteasome contains proteolytic activity and 
catalyses protein degradation at the protease active sites. Due to regulation of protein 
entry into the proteasome barrel by the cap domains, protein degradation can occur in 
the cytoplasm without causing widespread cellular damage (Ciechanover, 2005). The 
large number of different E3 enzymes present in cells allows this process to be highly 
specific and tightly regulated, resulting in the ubiquitin-proteasome system functioning 
in a huge number of tightly controlled cellular processes including cell cycle control 
and gene transcription. 
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My PhD project involves determining the function of WIPI2 in macroautophagy. 
Consequently, other forms of protein and macromolecule degradation will not be 
discussed further. 
 
 
Figure 1.1 Intracellular protein degradation 
Intracellular proteins can be degraded via lysosome- and proteasome-mediated protein 
degradation pathways. Lysosome-mediated intracellular protein degradation is termed 
autophagy (macroautophagy, microautophagy and chaperone-mediated autophagy). 
 
1.2 Macroautophagy 
Macroautophagy (hereafter called autophagy) is a cellular catabolic process that is 
conserved amongst all eukaryotes: from yeast to man. Literally meaning ‘self-eating’, 
autophagy is characterised by the nucleation and expansion of a double membrane 
(called a phagophore or isolation membrane) that surrounds bulk cytoplasm or 
organelles, before self-fusing to become an immature autophagosome. The outer 
membrane of the autophagosome subsequently fuses with organelles in the endocytic 
pathway, including endosomes, but most importantly lysosomes, forming a degradative 
autolysosome/mature autophagosome. As discussed previously, the lysosome lumen is 
acidic and contains numerous hydrolytic enzymes. Therefore, autophagosome-lysosome 
fusion results in the degradation of the autophagosome contents. Degradation products 
include amino acids and other macromolecules, and these are released into the cytosol 
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for reuse. Autophagy occurs in basal conditions, ensuring that old and damaged 
organelles and long-lived proteins are turned over, and is upregulated in response to cell 
stress such as amino acid starvation to promote cell survival. During starvation the 
macromolecules degraded via autophagy are reused for processes such as synthesis of 
essential proteins. 
 Although autophagy was originally characterised by electron microscopy in 
mammalian tissue and cells, the molecular components required for autophagy were 
first identified in yeast. Nitrogen starvation results in Saccharomyces cerevisiae 
sporulation and meiosis, indicating that nitrogen depletion results in a global turnover of 
protein in these cells in order to dramatically change their state. Consistently, Yoshinori 
Ohsumi found that S. cerevisiae mutants with impaired vacuole function accumulated 
autophagic bodies within the vacuoles after nitrogen starvation (Ohsumi, 2014). 
Ohsumi’s group used this accumulation of autophagic bodies (which was visible under 
light microscopy) as a read-out for gene mutants with an autophagy defect. Looking for 
mutants that failed to accumulate autophagic bodies in the vacuole after nitrogen 
starvation, they found the first autophagy defective mutant, apg-1 (Tsukada and Ohsumi, 
1993). This mutant died during long-term nitrogen starvation and this phenotype 
became the basis for a primary screen for autophagy mutants. Mutants obtained using 
this primary screen were verified using light microscopy to check for an accumulation 
of autophagy bodies in the vacuole and complementation analysis of over 100 verified 
mutants showed 15 complementation groups (Tsukada and Ohsumi, 1993). This list of 
mutants was added to by other groups using other readouts, including those screening 
for the Cvt pathway in which α-aminopeptidase I (Ape1) is delivered to the vacuole 
(Harding et al., 1995). The Cvt pathway involves sequestering specific cargo inside a 
double membrane-bound vesicle before delivery to the vacuole. The Cvt pathway and 
autophagy are morphologically similar and many of the genes identified in the screen 
for Cvt mutants are the same as those identified for autophagy. Cvt is used as a model 
for selective autophagy, although the pathway is not found in higher eukaryotes. Over 
30 autophagy-related (ATG) genes in S. cerevisiae have now been identified, 
representing bulk and selective autophagy. Of these, 18 are considered ‘core’ autophagy 
genes that are required for both starvation-induced and selective autophagy and are 
highly conserved. 
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 Gene isolation and characterisation of the proteins identified in yeast screens 
have not only advanced our understanding of autophagy in yeast, but have also been 
extremely informative for research on autophagy in higher eukaryotes. A number of 
homologues of S. cerevisiae autophagy proteins are thought to perform the same or 
similar functions in mammals, mice and other eukaryotes (Table 1.1). A recent screen 
for Schizosaccharomyces pombe autophagy genes has shown that the mechanism of 
autophagy is similarly conserved in other yeast (Sun et al., 2013). 
 The autophagy machinery identified by genetic screens falls into a number of 
functional groups. These are the Atg1 kinase complex, the PtdIns(3) kinase complex, 
PtdIns(3)P binding proteins (the Atg18-Atg2 complex), the ubiquitin-like conjugation 
systems and Atg9. Hierarchical analysis has demonstrated that these systems are 
recruited to the site of autophagosome formation in a sequential and concerted manner 
(Suzuki et al., 2007), and this hierarchy of action is well conserved in mammalian 
autophagy (Itakura and Mizushima, 2010). The autophagosome formation site in yeast 
is termed the pre-autophagosomal structure (PAS). Autophagy machinery is held in an 
inactive state by target of rapamycin (TOR), a serine/threonine kinase that 
phosphorylates and inactivates the Atg1 kinase complex (Kamada et al., 2000). TOR is 
inactivated by nitrogen starvation, releasing the inhibitory phosphorylation of Atg1 and 
Atg13, and allowing Atg1 kinase complex formation and translocation, along with the 
Vps34 type III PtdIns(3)P kinase complex II (Atg14-containing complex), to the PAS. 
Localisation of active Atg1 and PtdIns(3) kinase on the PAS results in PtdIns(3)P 
formation and recruitment of the PtdIns(3)P-binding Atg18-Atg2 complex (Obara et al., 
2008). The function of this complex is unclear, but it is thought to be required, along 
with the Atg1 kinase complex, for Atg9 trafficking between the PAS and Atg9 reservoir. 
Atg9 is the only transmembrane protein that is essential for autophagy (Noda et al., 
2000). Its function is currently unclear, but it is known to cycle between the PAS and 
Atg9 reservoir and so may be shuttling lipids or protein factors. The Atg12–5-16 
complex is recruited subsequently to, or concurrently with, Atg18-Atg2 recruitment. 
The Atg12–5 conjugate acts as an E3-like enzyme to enhance the activity of the Atg8 
lipidation machinery, therefore promoting Atg8 conjugation to 
phosphatidylethanolamine (PE) at the PAS. The exact function of lipidated Atg8 is 
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unknown, but is thought to be required for autophagosome membrane expansion and 
fusion (Nakatogawa et al., 2007). 
The aim of my PhD is to characterise the function of WIPI2, a mammalian 
autophagy protein. I will discuss the mammalian core autophagy machinery below, 
referring to yeast proteins where their functions or characteristics shed more light on the 
possible functions of their mammalian homologous. 
 
1.3 Molecular machinery 
1.3.1 Upstream inhibitor and initiation complexes 
Autophagy occurs at a basal rate in all cells to ensure cellular homeostasis and is also a 
key catabolic mechanism for the provision of essential intermediate metabolites during 
starvation. As such, it is extensively activated in periods of cellular stress such as amino 
acid, glucose or growth factor starvation, hypoxia, and low ATP levels. As well as 
being efficiently and rapidly switched on, autophagy must be effectively inhibited (to 
basal levels) to ensure against inappropriate intracellular digestion during non-starved 
conditions. As autophagy plays such a central role in response to nutrient starvation, it 
should not be surprising that the process is inhibited by mechanistic target of rapamycin 
complex 1 (mTORC1), which reflects the nutrient status of the cell, and activated by 
adenosine monophosphate-activated protein kinase (AMPK), which reflects the energy 
status of the cell. Active mTORC1 inhibits autophagy by inhibitory phosphorylation of 
the ULK complex, whereas AMPK activates autophagy through ULK and Beclin1 
phosphorylation. 
 mTORC1 is a serine/threonine kinase that acts as a nexus point, integrating 
nutrient and stress signals and controlling cell growth through processes including 
transcription and autophagy. mTORC1, like mTORC2, is a multisubunit complex which 
contains the serine/threonine protein kinase mTOR. mTORC1 and mTORC2 are 
regulated by growth factors, however mTORC1 also integrates signals from oxygen and 
amino acid supply, cellular stress and energy levels (Laplante and Sabatini, 2012). 
mTORC1 is active under normoxic conditions in the presence of nutrients and growth 
factors, and is inactivated by the removal of nutrients or growth factors, or under 
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hypoxic conditions. mTORC1 activity requires substrate recognition via Raptor 
(Nojima et al., 2003). mTORC1 activation is controlled through two branches: Rheb 
and the Rag GTPases. All upstream signalling inputs, with the noticeable exception of 
amino acid availability, signal through control of Rheb activity. Rheb is a small GTPase 
that is controlled by its GTPase activating protein (GAP), a complex consisting of 
heterodimeric TSC1/TSC2, and TDC1D17. Upstream inputs influence mTORC1 
activity by controlling TSC1/TSC2 activity, for example growth factors activate 
mTORC1 by phosphorylation and inactivation of TSC1/TSC2 by Akt. Active Rheb is 
essential for mTORC1 activation (Alers et al., 2012). Amino acid availability regulation 
of mTORC1 activation is achieved through the vacuolar H+-ATPase (V-ATPase) – 
Ragulator – Rag GTPase system, which controls mTORC1 proximity to lysosome-
localised Rheb (Sancak et al., 2008, Sancak et al., 2010, Zoncu et al., 2011, Bar-Peled et 
al., 2012). The Rag GTPases are heterodimers of RagA/B and Rag C/D, which directly 
bind Raptor when the Rag GTPase is active (Rag A/B are GTP loaded) (Sancak et al., 
2008). The Ragulator complex, which constitutively binds Rag GTPases, activates Rag 
GTPases when amino acids are present. The Ragulator is the GTPase exchange factor 
(GEF) for the Rag GTPases and is responsible for their lysosomal localisation (Sancak 
et al., 2010, Bar-Peled et al., 2012). The Ragulator is active in the presence of amino 
acids, but not after amino acid starvation. The mechanism of amino acid-dependent 
activation of the Ragulator complex is not fully understood, but involves V-ATPase 
(Zoncu et al., 2011). V-ATPase senses intra-lysosomal amino acid content and relays 
this signal to Ragulator though a change in the V-ATPase - Ragulator interaction (Bar-
Peled et al., 2012). In the presence of amino acids, Ragulator activates the Rag GTPases, 
enabling binding to Raptor and mTORC1 recruitment to the lysosome surface, where 
Rheb is localised. In this manner, mTORC1 activity is controlled by two factors: active 
Rheb on the lysosome surface and mTORC1 localisation to the lysosome through amino 
acid-dependent recruitment by the Rag GTPases (Figure 1.2). 
 AMPK is a key energy sensor in the cell and acts as a metabolic checkpoint by 
downregulating anabolic pathways while simultaneously upregulating metabolic 
pathways during periods of low cellular ATP levels. AMPK is a heterotrimeric complex 
and its activation requires phosphorylation within its catalytic α subunit by upstream 
kinases (Alers et al., 2012). Further modulation of AMPK activity is achieved through 
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AMP, ADP or ATP binding to its ɣ-subunit (Cheung et al., 2000, Xiao et al., 2011). 
AMP, ADP and ATP compete for binding of the ɣ-subunit and bind with different 
affinities: AMP/ADP bind the ɣ-subunit of AMPK more strongly than ATP does. 
During high AMP/ADP:ATP ratios, indicative of low intracellular energy, AMP and 
ADP outcompete ATP for AMPK binding and protect activated AMPK from  
dephosphorylation and subsequent inhibition. In addition, AMP binding allosterically 
further activates active AMPK. In cells with a high energy level, ATP will be abundant 
and the AMP/ADT:ATP ratio will low. Therefore, ATP will outcompete AMP or ADP 
for AMPK binding, removing protection from dephosphorylation and the allosteric 
activation by AMP, and so reducing AMPK activity. 
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Figure 1.2 mTORC1 activity control 
mTORC1 activation requires both active Rheb and Rag GTPase. (a) mTORC1 is active 
in the presence of amino acids and growth factors. Amino acids activate the Ragulator 
complex, through an unknown mechanism involving the V-ATPase, which 
subsequently leads to nucleotide exchange and activation on the Rag GTPases. Active 
Rag GTPases bind Raptor and recruit mTORC1 to the lysosome surface. Growth factor 
presence inhibits Rheb GAP TSC1/TSC2 complex, therefore activating Rheb and 
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subsequently mTORC1 on the lysosome. (b) mTORC1 is inactive in the presence of 
amino acids and absence of growth factors. Amino acids activate the Rag GTPases 
through the Ragulator complex and V-ATPase. Growth factor starvation activates the 
Rheb GAP TSC1/TSC2, subsequently inhibiting Rheb and inhibiting Rheb-mediated 
activation of mTORC1. (c) mTORC1 is inactive in the presence of growth factors but 
absence of amino acids. The inhibitory GAP activity of the TSC1/TSC2 complex is 
removed by growth factor presence, resulting in Rheb activation. However, mTORC1 is 
not on the lysosome as the Rag GTPases are not active and so cannot bind Raptor. 
Ragulator complex activation requires amino-acid dependent action of V-ATPase. 
 
1.3.2 ULK kinase complex 
S. cerevisiae Atg1 is a serine/threonine kinase that forms a starvation dependent 
complex with Atg13, and Atg17-Atg29-Atg31 (Kamada et al., 2000, Cao et al., 2009). 
Hypophosphorylated Atg13 directly binds Atg1 and Atg17, resulting in Atg1 kinase 
activation and complex localisation to the PAS through the Atg17-Atg29-Atg31 
complex (Kamada et al., 2000, Kabeya et al., 2005, Suzuki et al., 2007, Kawamata et al., 
2008). When active, TORC1 directly phosphorylates Atg13, reducing its affinity for 
both Atg1 and Atg17 (Kamada et al., 2010). Consequently, active TORC1 inhibits Atg1 
kinase and autophagy progression. 
 There are five mammalian Atg1 homologues: Unc-51 like kinase (ULK) 1/2/3/4 
and STK36, and of these ULK1 and ULK2 are closely related to the Caenorhabditis 
elegans Atg1 homologue UNC51 (Chan et al., 2007, Hara et al., 2008). ULK1 and 2 are 
serine/threonine kinases that have been shown to be required for autophagy and are 
thought to have at least partially redundant functions; ULK1 or ULK2 knockout MEFs 
show only a mild autophagy defect, while double knock out (ULK1-/- and ULK2-/-) 
MEFs show no starvation-induced autophagy (McAlpine et al., 2013). Of the two 
proteins, ULK1 is the better characterised.  
 ULK1/2 forms a complex with mammalian homologues of Atg13 (Atg13) and 
Atg17 (FIP200) along with Atg101, a protein not present in S. cerevisiae (Hara et al., 
2008, Chan et al., 2009, Jung et al., 2009, Hosokawa et al., 2009b). ULK1 directly 
binds Atg13, which further binds FIP200 and Atg101 directly. The resulting ULK1/2 
complex translocates to the phagophore formation site under starvation conditions. 
FIP200 is the most upstream protein in the autophagy cascade and is required for 
targeting downstream core autophagy machinery to the phagophore (Itakura and 
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Mizushima, 2010). In contrast to the S. cerevisiae Atg1 complex, the ULK1/2 complex 
is formed in both in both fed and starved conditions. Instead, the ULK complex displays 
a nutrient-dependent interaction with mTORC1: Raptor directly binds ULK1 in fed 
conditions, resulting in mTORC1-mediated phosphorylation of ULK1/2 and Atg13, and 
subsequently ULK1/2 kinase inhibition (Figure 1.3) (Hosokawa et al., 2009a). During 
nutrient deprivation, mTORC1 dissociates from ULK1/2, leading to ULK1/2 kinase 
activation, ULK1 autophosphorylation, direct phosphorylation of Atg13 and FIP200 by 
ULK1 and autophagy initiation through the phosphorylation of downstream targets 
(Jung et al., 2009, Chan et al., 2009). In addition to phosphorylation of members of the 
ULK1 complex, ULK1 also directly phosphorylates and inactivates mTORC1 itself 
(Figure 1.3) (Dunlop et al., 2011). Active ULK1 phosphorylates Raptor on multiple 
sites, causing a decrease in mTORC1 activity probably as a result of a reduced substrate 
binding by Raptor, thereby providing a positive feedback loop for efficient autophagy 
activation upon starvation. 
 ULK1 activity is further controlled by AMPK. AMPK binds to and directly 
phosphorylates ULK1, resulting in ULK1 kinase activation and autophagy initiation in 
conditions in which AMPK is active, such as low intracellular ATP levels (Figure 1.3) 
(Egan et al., 2011, Kim et al., 2011a). This AMPK-phosphorylation and activation of 
ULK1 provides the second mechanism to two-pronged pathway for autophagy 
activation by AMPK in conditions of low ATP levels; as well as directly activating 
ULK1, AMPK also phosphorylates Raptor and inhibits mTORC1 activity (Alers et al., 
2012). As described above, mTORC1 inactivation results in a loss of its inhibitory 
phosphorylation of ULK1/2 and Atg13 and therefore autophagy activation. AMPK 
binding to ULK1 is regulated by mTORC1: active mTORC1 phosphorylates ULK1 
within the region shown to bind AMPK, therefore disrupting binding (Kim et al., 
2011a).  
 The role of ULK1 in starvation-induced autophagy was first characterised seven 
years ago and although not fully understood, a clearer picture of mechanisms regulating 
its activity is emerging. However, how this kinase complex leads to autophagosome 
biogenesis is still not well understood. The number of ULK1/2 kinase targets identified 
is low, although it is known that ULK1 activates the Beclin1 PtdIns(3)P kinase complex 
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through direct phosphorylation while yeast Atg1 activates Atg9 through direct 
phosphorylation (see Chapter 1.3.3 and 1.3.6, respectively). 
 
 
Figure 1.3 Control of ULK1 activity by mTORC1 and AMPK 
The ULK kinase complex is held in an inhibited state by active mTORC1 which binds 
ULK and phosphorylates both ULK and Atg13. Amino acid starvation results in 
mTORC1 inhibition through upstream signalling cascades (Figure 1.2) and ULK 
phosphorylation of Raptor. Active ULK undergoes autophosphorylation and 
phosphorylates Atg13 and FIP200, resulting in activation of the ULK complex. During 
glucose starvation, AMPK phosphorylates Raptor, inhibiting mTORC1, while also 
phosphorylating and activating ULK. Red and green lines indicate inhibitory and 
activating phosphorylation, respectively. 
 
1.3.3 PtdIns(3)P kinase complexes 
PtdIns(3)P production on the PAS in yeast, or omegasome in mammalian cells, is 
required for recruitment of all autophagy proteins downstream of the PtdIns(3) kinase 
complex. Additionally, omegasome-localised PtdIns(3)P production is also required for 
stabilising the ULK kinase complex (Karanasios et al., 2013b). The functions of 
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PtdIns(3)P in autophagosome formation are not yet fully understood, but downstream 
PtdIns(3)P binding proteins have been identified and characterised to some extent (see 
Chapter 1.3.4). Very little PtdIns(3)P is found on the endoplasmic reticulum (ER) 
during normal cell growth conditions and the localised production of the ER-localised 
PtdIns(3)P pool in mammalian autophagy is a result of an autophagy-specific PtdIns(3) 
kinase. 
 PtdIns(3) kinases phosphorylate phosphatidylinositol on the 3’ position of the 
inositol ring. There are three classes of PtdIns(3) kinases: class I produces PtdIns(3,4)P2, 
PtdIns(3,4,5)P3 and a small amount of PtdIns(3)P. Primarily acting at the plasma 
membrane, this class is involved in receptor-mediated signalling. Class II PtdIns(3) 
kinases produce PtdIns(3)P and PtsIn(3,5)P2, however their functions are poorly 
understood. Class III PtdIns(3) kinase produces PtdIns(3)P only and is implicated in 
intracellular trafficking at multiple stages including endosome function, retrograde 
traffic from endosome to Golgi, multivesicular body (MVB) formation and autophagy 
(Foster et al., 2003). Unlike class I and II kinases, all eukaryotes have a single Class III 
PtdIns(3) kinase, the Vps34 PtdIns(3)P kinase (Foster et al., 2003). Yeast have two 
class III PtdIns(3)P kinase complexes formed of a core kinase complex of Vps34, 
Vps15 and Atg6 along with either Atg14 (complex I) or Vps38 (complex II). Complex I 
is required for PtdIns(3)P production for autophagy and complex II for the vacuolar 
sorting (Vps) pathway. 
 Mammalian cells have at least two Vps34 complexes, both of which contain the 
Atg6 homologue Beclin1, the first autophagy protein to be identified in mammals, and 
mammalian Vps15 (formerly p150) (Liang et al., 1999, Panaretou et al., 1997). Both 
Beclin1 and Vps15 directly bind Vps34 and are needed for PtdIns(3) kinase activity 
(Liang et al., 2006, Yan et al., 2009). Vps15 myristoylation at its N-terminus is thought 
to be involved in membrane targeting of the Vps34-Vps15 complex (Panaretou et al., 
1997). Beclin1 promotes the formation of the Vps34-Vps15 core complex and interacts 
with cofactors, including UVRAG, Atg14L, Ambra1, NRBF2 and Bif-1, to modulate of 
the activity of the Vps34 kinase and regulate of Vps34 activity or function (Liang et al., 
2006, Matsunaga et al., 2009, Fimia et al., 2007, Lu et al., 2014, Takahashi et al., 2007).  
 Mammalian Atg14 (Atg14L) shows weak homology to yeast Atg14 and is 
required for Vps34 PtdIns(3)P kinase activity in autophagy (Figure 1.4a) (Zhong et al., 
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2009, Kim et al., 2013, Russell et al., 2013). Atg14L and Beclin1 directly interact via 
their coiled coil domains and this interaction is required for Atg14L interaction with the 
Vps34-Vps15 complex, although additional direct binding to the Vps34-Vps15 complex 
by Atg14L1 has not been excluded (Matsunaga et al., 2010). Atg14L localises, with the 
Vps34 kinase complex, to the omegasome during starvation (Matsunaga et al., 2010). 
Although omegasome localisation of Atg14L is starvation-dependent, Atg14L is 
constitutively ER localised, independent of Vps34 activity or Beclin1 binding (Itakura 
et al., 2008, Matsunaga et al., 2010). Through its interaction with Beclin1, Atg14L is 
responsible for the ER-targeting of the Vps34 kinase complex and subsequent ER-
localised PtdIns(3)P during starvation-induced autophagy. Atg14L contains two signals 
for ER localisation: N-terminal cysteine repeats and a C-terminal BATS 
(BARKOR/Atg14L autophagosome targeting sequence) (Matsunaga et al., 2010, Fan et 
al., 2011). Although critical for Vps34 targeting to the ER and subsequent autophagy, 
ER recruitment via Atg14L cannot explain the trigger for autophagy as Atg14L 
localisation to the ER does not change with nutritional status of the cell, and Atg14L 
localisation to puncta representing omegasomes, but not the ER, is disrupted in ULK1 
kinase inhibited cells (Matsunaga et al., 2010).  
 In contrast to Atg14L, the function of the Beclin1 interacting protein UVRAG is 
widely debated. UVRAG was identified as a Beclin1 interacting protein, whose direct 
interaction with Beclin1 is mediated through a coiled coil interaction between the two 
proteins (Liang et al., 2006). Atg14L and UVRAG form distinct Vps34-Vps15-Beclin1 
complexes, possibly through a mutually exclusive binding to the same region of the 
Beclin1 coiled coil domain (Matsunaga et al., 2009). UVRAG is localised, with Vps34, 
to Rab9 containing endosomes involved in retrograde trafficking to the Golgi, and to a 
lesser extent on Rab5 and Rab7 positive endosomes, early endosomes and late 
endosomes, respectively. UVRAG colocalisation with autophagosomes has been 
observed, however this was found using transiently overexpressed proteins and has not 
been repeated in subsequent studies (Liang et al., 2006, Itakura et al., 2008, Matsunaga 
et al., 2009). Similarly, different groups have seen different effects of UVRAG 
overexpression and knockdown on autophagy. However, there is a consensus on the 
effect of UVRAG knockdown on endocytic degradation: UVRAG is required for the 
degradation of epidermal growth factor receptor (EGFR) (Matsunaga et al., 2009, Jiang 
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et al., 2014, Liang et al., 2008). UVRAG has weak homology with yeast Vps38 (Itakura 
et al., 2008). This and its possibly indirect role in autophagy suggest that UVRAG may 
be involved in endocytic sorting to the lysosome rather than in autophagic degradation 
(Figure 1.4b). 
 
 
Figure 1.4 The Atg14L- and UVRAG-containing Vps34 PtdIns(3)P kinase complexes 
Beclin1-Vps34-Vps15 core complexe can bind (a) Atg14L, forming complex I which is 
needed for omegasome-localised PtdIns(3)P production and therefore autophagy, and 
(b) UVRAG, forming complex II, the function of which is not clear, but is needed for 
proper EGFR degradation possibly as a result of involvement of complex II in 
retrograde trafficking or endocytic sorting to the lysosome. 
 
Rubicon binds to UVRAG and Rab7 in a mutually exclusive manner (Sun et al., 
2010). Active Rab7-GTP binds Rubicon and releases UVRAG to interact with the 
vacuolar/lysosomal homotypic fusion and vacuole protein sorting (HOPS) tethering 
complex (Figure 1.5) (Sun et al., 2010, Tabata et al., 2010, Liang et al., 2008). Until 
earlier this year it was thought that autophagosome-localised UVRAG binds HOPS and 
mediates autophagosome – lysosome fusion after release from inhibitory interaction 
with Rubicon by active Rab7 (Liang et al., 2008). However, identification of the 
interaction between Syntaxin (Stx) 17, a component of the SNARE complex required 
for autophagosome – lysosome fusion (Itakura et al., 2012), and HOPS showed that the 
Stx17-HOPS interaction is required for autophagosome maturation, but that UVRAG is 
not present in this complex and is not directly required for autophagosome formation or 
maturation (Jiang et al., 2014). Instead, HOPS and UVRAG, unlike Stx17, are both 
required for endocytic degradation (Liang et al., 2008, Jiang et al., 2014). This may be 
due to a direct requirement for the UVRAG-HOPS complex in late endosome – 
lysosome fusion or as a result of improper hydrolase delivery to the lysosome due to 
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impaired retrograde trafficking. Support for a role in late endosome – lysosome fusion 
includes the presence of UVRAG and Rubicon on Rab7-posisitve late endosomes and 
the negative effect of Rubicon on endosomal maturation (Sun et al., 2010). The function 
of Rab7-GTP in removing Rubicon-mediated inhibition of UVRAG-HOPS interaction 
could provide a mechanism for controlling late endosome – lysosome fusion (Sun et al., 
2010). Similarly, UVRAG is present on Rab9 positive endosomes, which represent 
retrograde traffic to the Golgi apparatus, and may therefore be a true mammalian 
homologue of Vps38 (Itakura et al., 2008). Involvement of UVRAG at either step of the 
endocytic degradation pathway may result in an indirect effect of UVRAG function on 
autolysosome degradation due to its function impacting delivery of hydrolases to the 
lysosome (Jiang et al., 2014). The involvement of the Vps34 PtdIns(3)P kinase in 
UVRAG-dependent trafficking events is not known, although Bif-1, a UVRAG 
interacting protein, and Rab7-GTP have been shown to increase the activity of the 
Beclin1-containing Vps34 PtdIns(3)P kinase during starvation (Takahashi et al., 2007, 
Tabata et al., 2010). Interestingly, the activity of the UVRAG-containing Vps34 
PtdIns(3)P kinase complex increases during starvation (Kim et al., 2013, Russell et al., 
2013), suggesting that, even if its function in autophagy is indirect, the UVRAG Vsp34 
kinase complex must be active for autophagy. 
 
 
Figure 1.5 UVRAG involvement in endocytic trafficking 
UVRAG interaction with the HOPS complex is inhibited by Rubicon, therefore 
inhibiting UVRAG function. Rab7-GTP releases this inhibition by binding Rubicon and 
allowing UVRAG-HOPS interaction and downstream functions. The requirement for 
the core Vps34 complex (Vps34, Vps15 and Beclin1) in this UVRAG function is yet to 
be studied. 
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 As described above, different Beclin1 interacting proteins can change and 
modulate the function of the Vps34 PtdIns(3) kinase complex. The activity of Vps34 
PtdIns(3)P kinase complexes are very tightly regulated. In starvation (amino acid and 
glucose) the activity of bulk Vps34 PtdIns(3)P kinase decreases, however that of 
Atg14L or UVRAG containing complexes increases (Russell et al., 2013, Kim et al., 
2013). Although regulation of the autophagy-specific (Atg14L containing) complex is 
not fully understood, at least three mechanisms of starvation-induced Vps34 PtdIns(3) 
kinase activation have been identified: 
1) During starvation, active ULK1 (and ULK2) kinase complex directly 
phosphorylates the N-terminus of Beclin1, resulting in increased Vps34 complex 
activity (Figure 1.6a) (Russell et al., 2013). This ULK1-mediated phosphorylation of 
Beclin1 is conserved in C. elegans but not S. cerevisiae and requires Atg14L, which 
acts as an adaptor. Although ULK1 kinase activity is required for localisation of the 
Beclin1 complex to forming autophagosomes (Matsunaga et al., 2010), Beclin1 
phosphorylation by ULK1 is not the signal required for this localisation; the Beclin1 
complex must be omegasome-localised for Atg14L to mediate the ULK1-Beclin1 
interaction and enable subsequent phosphorylation. Therefore, ULK1, or its 
downstream targets, acts both upstream and downstream of Vps34 localisation and, 
perhaps, the colocalisation of the Vps34 complex and ULK1 kinase complex at the 
omegasome acts as a coincidence detector for autophagosome progression. 
 2) Ambra1 is a highly conserved WD-40 protein that directly binds Beclin1 and 
is required for autophagy (Fimia et al., 2007). Ambra1 interacts with microtubules in a 
nutrient-dependent manner. During starvation, ULK1 phosphorylation of Ambra1 
results in Ambra1 dissociation from dynein intermediate chain (DIC) and subsequent 
translocation to the ER (Figure 1.6b) (Di Bartolomeo et al., 2010). Although Ambra1 
tethers the Vps34 complex away from the ER, Ambra1 depletion results in a loss of 
Beclin1 translocation to the ER in both fed and starved conditions and so it appears to 
be required for ER localisation of the Vps34 complex in a manner more complex and 
active than simply tethering and restraining the complex during non-autophagy 
conditions. It will be interesting to see what, if any, the interplay between Ambra1 and 
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Atg14L is in determining the omegasome-localisation of the Vps34 PtdIns(3) kinase 
complex during autophagy. 
 3) Glucose starvation alone results in an increase of Atg14L- or UVRAG-
associated Vps34, but a general decrease in bulk Vps34 activity. Glucose starvation 
results in an increase in AMP/ADP:ATP ratio and subsequently leads to AMPK 
activation. AMPK directly phosphorylates Vps34 and Beclin1 (Figure 1.6c) (Kim et al., 
2013). Beclin1 phosphorylation increases the activity of the Vps34 complex and 
therefore is required for autophagy. Atg14L binding to Beclin1, but not ER localisation, 
is required for AMPK-mediated Beclin1 phosphorylation, suggesting that Atg14L is 
again acting as an adaptor between a kinase and its target Beclin1. AMPK 
phosphorylation of Vps34 results in a glucose starvation-dependent reduction in 
Atg14L1- and UVRAG-free Vps34 complexes (the functions of these complexes have 
not been described). Vps34 phosphorylation has no effect on autophagy, and is in fact 
inhibited by Atg14L presence in the complex, but is needed for cell survival during 
glucose starvation. 
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Figure 1.6 Control of Atg14L-containing Vps34 PtdIns(3) kinase complex activity 
(a) Active ULK1 kinase complex binds Atg14L and activates the Vps34 PtdIns(3)P 
kinase by phosphorylating Beclin1. (b) During fed conditions, Ambra1 is associated 
with Vps34 and Beclin1 on microtubules through an interaction with Dynein. During 
starvation, active ULK1 phosphorylates Ambra1, inhibiting its interaction with Dynein 
and allowing translocation of the Ambra1-Beclin1-Vps34 complex to the ER. The 
localisation of Vps15 and Atg14L during this Ambra1-mediated relocalisation has not 
been published, but Atg14L is constitutively on the ER, and Vps15 is myristoylated so 
both proteins are shown docked to the ER membrane in all conditions. (c) Active 
AMPK phosphorylates Beclin1, leading to Vps34 PtdIns(3) kinase activation. 
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1.3.4 PtdIns(3)P binding proteins 
As described above, PtdIns(3)P production at the site of forming autophagosomes is 
essential for starvation-induced autophagy. The role that this phosphoinositide plays is 
not well understood but the general consensus is that it acts to recruit downstream 
proteins. A number of PtdIns(3)P binding proteins involved in autophagy have been 
identified, but their functions and mechanisms of action are currently unclear. These 
proteins include the β-propellers that bind phosphoinositides (PROPPIN) family, and 
double FYVE domain-containing protein 1 (DFCP1) in mammals. 
 
1.3.4.1 DFCP1 
DFCP1 contains both an ER-targeting domain and two PtdIns(3)P binding FYVE 
domains (Axe et al., 2008). Autophagy activation leads to DFCP1 localisation to the 
pool of ER-localised PtdIns(3)P produced by the Atg14L-containing Vps34 PtdIns(3) 
kinase  complex (Matsunaga et al., 2010, Axe et al., 2008). These DFCP1 labelled 
structures are termed omegasomes and are PtdIns(3)P-enriched platforms from which 
autophagosome biogenesis is nucleated (Axe et al., 2008). Omegasomes are dynamic, 
initially forming as small punctate domains, which expand into ring-shaped structures 
before collapsing into small punctate domains again. Coinciding with omegasome 
expansion and collapse, LC3- and Atg5-positive phagophores form within the centre of 
the omegasome before expanding and exiting the omegasome. Once exited, the forming 
autophagosome matures and becomes acidified. DFCP1 function is currently unknown; 
DFCP1 depletion has no effect on autophagy and it is likely to play a non-essential 
function in autophagy because there is no known yeast homologue. However, DFCP1 
overexpression results in autophagosome inhibition, possibly by sequestering 
omegasome-localised PtdIns(3)P from other PtdIns(3)P-binding proteins (Axe et al., 
2008). 
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1.3.4.2 The PROPPIN family 
The PROPPIN family of WD-40 motif-containing proteins are conserved between yeast 
and mammals and bind PtdIns(3)P and PtdIns(3,5)P2 through the atypical 
phosphoinositide binding FRRG motif. There are three PROPPINs identified in S. 
cerevisiae (Atg18, Atg21 and Hsv2) and S. pombe (Atg18a, b and c), two in C. elegans 
(Atg18 and Epg-6) and four in mammalian cells (WIPI1, 2, 3 and 4). Crystallisation of 
the Atg18 homologue Hsv2 from Kluyveromyces marxianus has revealed that 
PROPPINs form seven-bladed β-propellers with a non-Velcro propeller closure (Krick 
et al., 2012, Baskaran et al., 2012, Watanabe et al., 2012). The conserved FRRG motif 
forms two PtdIns(3)P binding sites in blades 5 and 6 of the β-propeller (Figure 1.7). 
Protein attachment to membranes is enhanced by a hydrophobic loop positioned in 
blade 6 (Krick et al., 2012, Baskaran et al., 2012). WD-40 domains are the most 
common protein-protein interaction domains in the eukaryotic genome (Xu and Min, 
2011), and as such it is likely that the function of the PROPPIN family will be to 
mediate protein-protein and protein-lipid interactions. The PROPPINs are positioned on 
the membrane so that they lie with their side touching and their faces of the β-propeller 
perpendicular to the membrane (Figure 1.7). Most protein interactions with WD-40 
proteins are mediated by the loops between the β-sheets within each blade of the β-
propeller. Therefore, this orientation ideally positions the loops of blades not involved 
in membrane binding for protein interactions when the PROPPIN is membrane bound. 
 S. cerevisiae Atg18 is essential for autophagy and the Cvt pathway (Barth et al., 
2001), Atg21 functions in autophagy and the Cvt pathway but is only essential for the 
Cvt pathway (Stromhaug et al., 2004, Meiling-Wesse et al., 2004), and poorly 
characterised Hsv2 (Ygr223c) is known to function in micronucleophagy (Krick et al., 
2008). Atg18 and Atg21 have non-redundant functions. Atg21 acts before vesicle 
closure and its loss reduces Atg8 lipidation, and recruitment of Atg8 and Atg5 to the 
PAS during the Cvt pathway and starvation-induced autophagy (Stromhaug et al., 2004, 
Nair et al., 2010, Meiling-Wesse et al., 2004). PtdIns(3)P binding by Atg21 is essential 
for its function in the Cvt pathway (Krick et al., 2006, Nair et al., 2010), but is 
dispensable for autophagy (Nair et al., 2010). To date, the function of Atg21 is 
unknown and Atg18 is the only identified Atg21 binding partner (Nair et al., 2010), 
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although this interaction is disputed (Meiling-Wesse et al., 2004). Further work to 
identify binding partners will shed light on the function of this protein.  
A number of Atg18 binding proteins have been identified, including Atg2, Vac7 
and Vac14. Atg18 binds Atg2 through the loops between β-sheets in blade two, which is 
on the opposite side of the protein to the membrane binding FRRG motif and membrane 
insertion loop in blades 5 and 6 (Watanabe et al., 2012, Rieter et al., 2013). The Atg18-
Atg2 complex is essential for autophagy and has been implicated in Atg9 trafficking 
from the PAS and protection of Atg8-PE from premature Atg4-mediated deconjugation 
(Nair et al., 2010). PAS localisation of Atg18 is dependent on both PtdIns(3)P and Atg2 
binding (Obara et al., 2008, Rieter et al., 2013), suggesting that Atg18 recruitment is 
tightly controlled by this cooperative mechanism. However, the function of Atg2 is not 
just to ensure Atg18 PAS localisation; Atg18 localised to the PAS cannot compensate 
for Atg2 loss (Kobayashi et al., 2012). The requirement of Atg18 for Atg2-PAS 
localisation is controversial, with reports of Atg18 loss both reducing (Obara et al., 
2008) and having no effect on localisation of Atg2 to the PAS (Rieter et al., 2013). It 
may be that these differences are due to variations in the sensitivities of the techniques 
used and that Atg18 loss has a partial effect on Atg2 localisation. Consistently, Atg2 
targeted to the PAS can only partially rescue autophagy in Atg18Δ strains (Kobayashi et 
al., 2012), indicating that Atg18 is involved in mediating Atg2 localisation and in 
additional autophagy functions. Loss of either Atg18 or Atg2 results in increased Atg8 
lipidation and increased Atg8 and Atg16 PAS-localisation in fed and starved conditions, 
suggesting that the complex functions in dissociation of these proteins from the PAS.  
As well as its localisation to the PAS, Atg18 is found on endosomes and 
vacuoles (Obara et al., 2008). Vacuole localisation is dependent on PtdIns(3,5)P2 
binding and the presence of the vacuole-localised Atg18 binding partner Vac7. Atg18 is 
required for proper vacuole morphology through modulation of PtdIns(3,5)P2 
production. Atg18 recruitment to the vacuole surface through PtdIns(3,5)P2 and Vac7 
binding may result in Vac7 sequestration from and therefore inhibition of the PtdIns(3)P 
5-kinase Fab1 (Efe et al., 2007). Interestingly, in Pichia pastoris (a methylotrophic 
yeast) Atg18 binding to PtdIns(3,5)2 and subsequent regulation of vacuolar morphology 
is regulated by Atg18 phosphorylation (Tamura et al., 2013). Phosphorylation within 
the loop between blades 6 and 7 of Atg18 reduces the affinity of Atg18 for 
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PtdIns(3,5)P2 and subsequently reduces binding to the vacuolar membrane. This 
phosphorylation is the only reported post-translational modification mediating control 
of PROPPIN phosphatidylinositol binding and although it is not required for 
macroautophagy, phosphoregulation of Atg18 is required for optimal micropexophagy. 
Conservation of the Pichia pastoris Atg18 phosphorylation site in higher eukaryotes, 
including in human WIPI1, suggests other PROPPIN proteins may be regulated in a 
similar manner (Tamura et al., 2013). 
Unlike in S. cerevisiae, all three of S. pombe PROPPINs are required for 
autophagy (Sun et al., 2013). In a similar manner to Atg18 and Atg2 deletion in S. 
cerevisiae, Atg18b and c deletions accumulate Atg8 puncta. However, Atg18a deletions 
and Atg18a-FTTG mutants (which cannot bind PtdIns(3)P) have no Atg8 puncta. 
Interestingly, Atg18a interacts with Atg5 and it is probable that Atg18a acts as a 
platform to mediate the PtdIns(3)P-dependent recruitment of the Atg12–5-16 complex, 
although this remains to be shown. 
Mammalian cells have four PROPPIN proteins: the WD repeat domain 
phosphoinositide-interacting (WIPI) proteins WIPI1, 2, 3 and 4. WIPI1 and WIPI2 are 
evolutionarily more closely related to Atg18 than WIPI3 and WIPI4 are (Polson et al., 
2010), however it remains to be determined which of the proteins are functionally 
conserved. All four isoforms have a 7-bladed β-propeller and a conserved PtdIns(3)P 
binding domain and membrane insertion loop (Figure 1.8 a). WIPI2 is required for 
autophagy, functioning downstream of the Atg14L-containing Vps34 PtdIns(3)P kinase 
complex, but upstream of LC3 lipidation. Similarly to DFCP1, WIPI2 forms punctate 
and ring-shaped structures after starvation. WIPI2 puncta colocalise with DFCP1 and 
Atg16L1, but not with acidified autophagosomes, and WIPI2 rings are often intertwined 
with or very closely associated with DFCP1 rings (Polson et al., 2010). WIPI2 has six 
isoforms, WIPI2a, b, c, d, δ and e (Figure 1.8 b). Of these, the localisation of WIPI2a-d 
starvation-induced puncta has been analysed. WIPI2b and d form starvation-induced 
puncta, where as WIPI2a and c do not (Mauthe et al., 2011). This difference in 
localisation can be assigned to the presence of an 18 amino-acid insert between β-sheets 
one and two of the first blade of WIPI2a and c (Figure 1.8b and 1.9); presence of the 
insert renders the protein unable to form puncta, suggesting that this insert may be 
inhibiting an interaction critical to puncta formation or disrupting proper protein folding.  
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WIPI1 is not as widely expressed as WIPI2 and its function is not well 
established (Polson et al., 2010, Mauthe et al., 2011), although it is known to function 
downstream of the Atg14L PtdIns(3) kinase complex but upstream of the Atg5 and 
Atg7 pathways (Itakura and Mizushima, 2010, Mauthe et al., 2011). Overexpression of 
WIPI1 displaces WIPI2 from forming autophagosomes, presumably by competing with 
WIPI2 for PtdIns(3)P binding, resulting in autophagy inhibition (Polson et al., 2010). 
This demonstrates that WIPI1 and WIPI2 have non-redundant functions in autophagy. 
The function of WIPI3 in autophagy is not known, however WIPI4 is thought to 
act in conjunction with Atg2 (Velikkakath et al., 2012). There are two Atg2 homologues 
in mammalian cells with redundant functions: Atg2a and Atg2b (Velikkakath et al., 
2012). Depletion of both of these results in the formation of LC3-positive, unclosed 
autophagosomes and increased LC3 lipidation (Velikkakath et al., 2012). Similarly, 
WIPI4 knockdown blocks autophagosome exit from the omegasome, resulting in 
enlarged DFCP1 rings with LC3-positive phagophores at their centre (Lu et al., 2011). 
The accumulation of LC3 at phagophores and LC3 lipidation in WIPI4 and Atg2 
knockdowns is similar to atg18Δ and Atg2Δ strains in S. cerevisiae, suggesting that 
although not evolutionarily closely related, WIPI4 may be functionally related to Atg18. 
C. elegans has one WIPI1/WIPI2-like protein, Atg18, and one WIPI3/WIPI4 protein. 
The C. elegans WIPI4 homologue EPG-6 directly binds Atg2 and functions 
downstream of LGG-1 (LC3 homologue) lipidation, possibly during autophagosome 
closure (Lu et al., 2011). The EPG-6-Atg2 complex is required for Atg9 distribution, 
again suggesting that WIPI4 homologues have similar functions to Atg18. The function 
of Atg18 in C. elegans is unknown, but it is thought to act before EPG-6 (Lu et al., 
2011). 
The functions of the PROPPIN family during autophagy are poorly understood. 
It is probable that the functions of these proteins will be in the formation of protein-
protein interactions and the anchoring of subsequent complexes to membranes in a 
phosphatidylinositol-dependent manner. Identification of interacting partners will shed 
light on the function of this family of core autophagy proteins. 
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Figure 1.7 Model of PROPPIN structure 
The PROPPIN proteins form 7-bladed β-propellers with an FRRG motif in blade 5 that 
forms two PtdIns(3)P binding pockets on blades 5 and 6, and a hydrophobic membrane 
insertion loop in blade 6 (Krick et al., 2012, Baskaran et al., 2012, Watanabe et al., 
2012). 
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Figure 1.8 Schematic of human WIPI and WIPI2 proteins 
(a) WIPI1-4 have a well conserved FRRG/LRRG PtdIns(3)P-binding motif in blade 5 
(shown in green) of the 7-blade WD-40 repeat. All four homologues also have a 
hydrophobic membrane insertion loop in blade 6 (shown by dashes). WIPI1 and WIPI2 
have extended C-termini compared to WIPI3 and WIPI4. (b) There are six WIPI2 
isoforms. WIPI2a, b, c and d have a seven-blade structure, whereas WIPI2δ and e are 
missing the first blade. All sequence represented by black dashes or boxes are identical. 
WIPI2a and c have an 18 amino acid insert between β-sheets 1 and 2 of the first blade 
of the β-propeller. WIPI2a and b have an 11 amino insert in their C-terminus. WIPI2δ 
and e have different N-termini to WIPI2a, b, c and d. Blue box represents the epitope 
used for production of the monoclonal antibody A2A and polyclonal antibody STO 280, 
while the purple box represents the epitope used for production of antibodies STO 313-
318 (Chapter 5.2) 
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Figure 1.9 Alignment of human WIPI2 and homologues 
Comparison of ATG18_KULA, Kluyveromyces lactis Atg18; ATG18_YEAST, 
Saccharomyces cerevisiae Atg18; ATG18_SCHPO Schizosaccharomyces pombe 
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ATG18a; WIPI1_HUMAN, WIPI1a ; WIPI2_HUMAN, WIPI2b; Hydra, Hydra 
magnipapillata Atg18; Amphime don, Amphimedon queenslandica Atg18, non-
bilaterians from the Great Barrier; Capsaspora ,Capsaspora owczarzaki Atg18, 
unicellular animal; Salpingoeca, Salpingoeca rosetta Atg18, unicellular animal 
Choanoflagellate; ATG21_YEAST, Saccharomyces cerevisiae Atg21; 
ATG21_KLULA, K. lactis Atg21; ATG21_SCHPO, S. pombe Atg21 (Atg18b); 
HSV2_KLULA K. lactis Hsv1; HSV2_SCHPO S. pombe Hsv2 (Atg18c); 
ATG18_NEUCR, Neurospora crassa Atg18, fungi; ATG18_ARATH, Arabidopsis 
thaliana Atg18, plant. The alignment was generated using Jalview. Sequences and 
sequence numbering are from Uniprot. Scale numbering is from WIPI2b. Normalized 
consensus histogram is shown below alignment indicating % conservation. Residues in 
each column are coloured by function and intensity proportional to conservation above 
20%. Coloured bars above a position indicate a highly conserved solvent-exposed loop, 
green; PtdIns(3)P-binding residue, red. A purple bar indicates where there are animal-
specific substitutions. Inverted triangles are positions where non-conserved insertions 
were hidden to reduce the size of the figure. Positions of residues required for Atg2 
binding by Atg18 (F65 S66, P78 R79) are numbered according to WIPI2b. Atg16L1 
binding residues are R108 and R125 (Chapter 3). The location of the WPII2a loop 
insertion and the possible WIPI2 phosphorylation site (S295) (Chapter 5) are labelled. 
The conserved RFFG motif is boxed, the hydrophobic loop is labelled, and the β-sheets 
and β-propeller blades are numbered. Analysis, alignment and figure provided by 
Michael Wilson. 
 
1.3.5 Ubiquitin-like conjugation systems 
There are two ubiquitin-like conjugation systems, conserved from yeast to man, that are 
essential for autophagosome formation. The Atg12 conjugation system results in the 
formation of the Atg12–5 conjugate, while the Atg8 (LC3/GABARAP) conjugation 
systems results in Atg8 conjugation to the lipid phosphatidylethanolamine (PE). A large 
proportion of the core autophagy machinery is involved in these systems, and the 
functions and the resultant mechanisms of the two ubiquitin-like conjugation pathways 
are well conserved. Although Atg12 and Atg8 (and their mammalian counterparts) have 
no clear sequence homology to ubiquitin, structural analyses show that they contain a 
ubiquitin fold, and so are termed ‘ubiquitin-like proteins’ (Ubl). 
 
1.3.5.1 The Atg12 conjugation system 
Atg12 is covalently bound to Atg5 through the sequential action of two proteins, Atg7 
and Atg10 (Figure 1.10 a). Atg7, an E1-like enzyme, activates the C-terminal glycine of 
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Atg12 by binding it via the catalytic cysteine of Atg7 in an ATP-dependent manner, 
forming a thioester bond (Mizushima et al., 1998). Atg7 then catalyses the transfer of 
Atg12 to the E2-like enzyme, Atg10, by binding Atg10 and promoting Atg12 transfer to 
the active site of Atg10. Atg10, without the action of an E3-like enzyme, subsequently 
binds Atg5 and catalyses the covalent linkage between the C-terminal glycine of Atg12 
and an internal lysine within Atg5 (Mizushima et al., 1998). No free (monomeric) Atg5 
or Atg12 is detected in cells, meaning that it likely that Atg12 and Atg5 are 
constitutively conjugated. The sequence of events for Atg12 conjugation is very similar 
between yeast and mammalian proteins. 
 Once formed, the Atg12–5 conjugate forms a complex with Atg16L1 (Atg16 in 
yeast) as a consequence of Atg5-Atg16L1 binding (Mizushima et al., 2003). Atg16L1 
homodimerises though its coiled coil domain, forming an Atg12–5-16L1 complex with 
a 2:2:2 stoichiometry. This complex is also formed through Atg16 homodimerisation in 
yeast, although yeast Atg16 lacks the C-terminal WD-40 domain present in higher 
eukaryotic Atg16 homologues. The Atg12–5-16(L1) complex acts as an E3-like enzyme 
in the conjugation of Atg8/LC3 to PE by bringing activated Ubl protein LC3 (in 
conjugation with Atg3) into close proximity to the target substrate 
(phosphatidylethanolamine, PE) through an Atg12-Atg3 interaction (Figure 1.11) 
(Fujita et al., 2008). Atg12–5 is able to catalyse LC3–PE conjugation in vitro, however 
the mechanism for this catalysis is not well understood (Sakoh-Nakatogawa et al., 2013, 
Noda et al., 2013). 
 
1.3.5.2 The Atg8 conjugation system 
There is one Atg8 protein in yeast, whereas in higher eukaryotes and mammalian cells 
the family has diverged and contains at least eight Atg8 family members, which can be 
split into two subfamilies: GATE-16/GABARAP and LC3. Unless specified otherwise, 
‘LC3’ will refer to all mammalian Atg8 family members. The conjugation pathway for 
each of these proteins is thought to be the same and conserved between yeast and 
humans. 
 Unlike Atg12, LC3 must be C-terminally cleaved by Atg4 before activation by 
the E1-like enzyme, Atg7 (Figure 1.10 b). Again, S. cerevisiae has one Atg4 cysteine 
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protease, whereas higher eukaryotes have multiple Atg4 homologues, with four (Atg4A, 
B, C and D) in humans (Marino et al., 2003). The differential functions of these human 
homologues are not completely understood, but it is thought that they have different 
specificities for different Atg8 family members. Atg4-mediated cleavage exposes a C-
terminal glycine. Once processed by Atg4, LC3 is termed LC3-I and is present in the 
cytosol. 
 Processed LC3 is then bound and activated by Atg7, the same E1-like enzyme 
that activates Atg12, in an ATP-dependent manner. As during Atg12 activation, Atg7 
forms a thioester bond between the C-terminal glycine of LC3 and the Atg7 active site, 
and binds to the E2-like enzyme Atg3 to catalyse the transfer of the C-terminal LC3 
glycine to the active site of Atg3 (Kabeya et al., 2000, Ichimura et al., 2000). Atg3 
binds Atg12, resulting in recruitment of Atg3–LC3 to the membrane and the formation 
of an amide bond between the C-terminal lysine of LC3 and PE (Figure 1.11). LC3 
conjugated to PE is termed LC3-II. 
 LC3-II decorates both the inside and outside of the forming autophagosome. 
External LC3 is cleaved from the autophagosome surface by the Atg4 proteases. The 
functions for this cleavage of LC3 after autophagosome closure is not properly 
understood, but a study in S. cerevisiae using mutant Atg8ΔR, which does not need 
initial activating cleavage by Atg4, in an atg4Δ strain has shown that Atg8 
deconjugation is required for autophagosome formation and expansion, and may serve 
as a signal for Atg14 release from the PAS (Nair et al., 2012). 
The functions of Atg8 proteins are unclear. LC3 is thought to be required for 
phagophore expansion, while GATE-16/GABARAP is required for autophagosome 
closure (Weidberg et al., 2010). Furthermore, Atg8 has been shown to mediate hemi-
fusion of liposomes in vitro, although this finding may represent a technical artefact 
(Nakatogawa et al., 2007, Nair et al., 2012). Atg8 proteins act in the recruitment of 
specific cargo for autophagic digestion; yeast Atg8 binds Atg32 (an outer mitochondrial 
membrane-spanning protein) and this interaction is required for mitophagy in yeast. 
Similarly, numerous mammalian LC3-binding proteins have been identified, such as 
p62 and NDP52 that act as cargo adaptors in during xenophagy (Chapter 1.6). These 
Atg8- and LC3-binding proteins interact with Atg8 or LC3 as a result of a consensus-
binding motif: Atg8-interacting motifs (AIMs) in yeast or LC3-interacting regions 
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(LIRs) in mammals. In mammals, phosphorylation of these motifs regulates recruitment 
of cargo and adaptors to forming autophagosomes, therefore providing targeted 
degradation of autophagy substrates. Recent findings that some core autophagic 
machinery also have AIM/LIR motifs has raised the possibility that Atg8/LC3 lipidation 
may serve to provide a positive feedback mechanism whereby lipidated Atg8/LC3 can 
recruit upstream complexes, reinitiating further Atg8/LC3 lipidation and membrane 
expansion. 
Because LC3 on the inner surface of autophagosomes is not removed during 
maturation, LC3 is widely used as an autophagy readout. Lipidated LC3 is termed LC3-
II and migrates more rapidly than LC3-I by SDS-PAGE and so the two forms of LC3 
can be visualised and quantified by western blot. Furthermore, LC3-positive vesicles 
can be detected by staining and immunofluorescence or electron microscopy and is 
frequently used for visualisation of autophagosomes. As LC3 is present on 
autophagosome membrane from formation to degradation in the lysosome, LC3 can be 
used as a marker for all stages of autophagy. GFP-LC3 is frequently used for visualising 
phagophores and autophagosomes, but the acidic environment of autolysosomes 
quenches the GFP signal. RFP-GFP-LC3 can be used to visualise autolysosomes and 
distinguish between immature and mature autophagosomes: LC3-positive vehicles 
appear yellow when they are not acidified (immature autophagosomes) and become red 
once autophagosomes fuse with the lysosome (mature autophagosomes). 
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Figure 1.10 Ubiquitin-like conjugation systems 
(a) Atg12–5 conjugation is catalysed by the E1-like protein Atg7 and the E2-like 
protein Atg10. (b) LC3 is activated by C-terminal cleavage mediated by Atg4. Atg7 and 
Atg3 then act as E1-like and E2-like proteins, respectively, in the conjugation of LC3 to 
PE. 
 
1.3.5.3 Atg16L1 binding partners 
As described above, the Atg12 –5-16L1 complex acts as in E3-like enzyme in LC3 
lipidation (Fujita et al., 2008). Atg12–5-16L1 localises to the phagophore, but not on 
closed autophagosomes (Mizushima et al., 2003). Therefore, Atg12–5-16L1 staining 
can be used to identify the phagophore, but not mature autophagosomes. Molecular 
dissection of the complex has revealed that Atg16L1 is responsible for membrane 
localisation, through its central coiled coil domain containing region, and therefore 
determines the site of Atg3–LC3 recruitment and subsequently LC3 lipidation (Figure 
1.11) (Fujita et al., 2008). Atg16L1 recruitment to the phagophore depends on 
PtdIns(3)P production at the omegasome, however no intrinsic membrane or 
PtdIns(3)P-binding has been found in Atg16L1 (or Atg12 and Atg5) and there is no 
known binding partner of Atg16L1 that can explain this PtdIns(3)P-dependent 
recruitment. Similarly in yeast, Atg16 localisation depends on PtdIns(3)P presence at 
the PAS and there is currently no explanation for this, although Atg5 has been shown to 
bind liposomes in an in vitro reconstitution experiment (Romanov et al., 2012). 
Recently, a global screen for autophagy proteins in S. pombe has shown that Atg5 can 
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bind Atg18a (Chapter 1.3.4.2) (Sun et al., 2013). This interaction may provide the 
mechanism for PtdIns(3)P-dependent recruitment in this system, however the molecular 
mechanism of PtdIns(3)P-dependent recruitment of the Atg12–5-16L1 complex is a 
long standing question within the autophagy field. 
 Atg5 binds the N-terminal region of Atg16L1. Besides Atg5, a number of 
Atg16L1 binding proteins have been identified. These include, Rab33B, FIP200 and 
ubiquitin (Fukuda and Itoh, 2008, Nishimura et al., 2013, Gammoh et al., 2013, Fujita et 
al., 2013). Atg16L1 can be split into three regions: the N-terminal Atg5 binding domain, 
the middle region which contains the coiled coil domain required for homodimerisation 
and the C-terminal WD-40 domain (Figure 1.12). Atg16L1 directly binds active 
Rab33B through the coiled coil domain of Atg16L1 (Fukuda and Itoh, 2008). Rab33B 
is a Golgi-localised Rab protein that is required for Golgi – ER retrograde trafficking. 
Overexpressed Rab33B is able to recruit Atg16L1 to the Golgi during fed conditions 
(Fukuda and Itoh, 2008). During starvation conditions or upon expression of GTP-
locked Rab33B mutants, Rab33B and Atg16L1 colocalise in puncta. This suggests that 
Rab33B may be involved in determining Atg16L1 localisation. Both Rab33B and its 
GAP, OATL1, have been shown to be required for proper autophagy flux (Itoh et al., 
2011). Overexpression of either protein results in an increase in LC3 lipidation and 
delayed autophagosome fusion. As well as inactivating Rab33B, OATL1 directly binds 
LC3, GABARAP and GATE-16 through a LIR domain (Itoh et al., 2011). Both the 
GAP activity and LIR motif of OATL1 are required for proper autophagy. However, it 
is unclear whether Rab33B and OATL1 function directly in this process. Instead, 
perturbation of their action in retrograde trafficking may indirectly affect 
autophagosome degradation, as may be true of UVRAG. Consistent with this, GATE-16 
and GABARAP function in intra-Golgi transport and ER-Golgi transport, respectively 
(Sagiv et al., 2000, Nakamura et al., 2008). It is conceivable that OATL1-LC3 and 
Rab33B-mediated Golgi localisation of the Atg12–5-16L1 complex may be required in 
some manner for intracellular membrane trafficking, rather than for autophagosome 
formation (Itoh et al., 2011). 
 Atg16L1 directly binds FIP200 and ubiquitin through its coiled coil and WD-40 
domains, respectively, and these interactions are thought to be involved, at least in part, 
in recruiting the Atg12–5-16L1 complex during starvation- and pathogen-induced 
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autophagy (Nishimura et al., 2013, Gammoh et al., 2013, Fujita et al., 2013). The 
minimal FIP200 binding domain (FBD) has been mapped to Atg16L1 230-246 (Figure 
1.12). However, the three studies detailing the FIP200-Atg16L1 interaction use 
different deletion mutants of FIP200 and so have subtly different results. Atg16L1 
deletion mutants of 230-300 or 229-242 cannot rescue starvation induced autophagy in 
Atg16L1Δ/Δ MEFs (which contain Atg16L1 with a deleted coiled coil domain resulting 
in total autophagy inhibition) (Nishimura et al., 2013, Gammoh et al., 2013), whereas 
Atg16L1 with amino acids 239-242 mutated to alanine can rescue autophagy unless 
combined with a mutant of Atg16L1 unable to bind ubiquitin (Fujita et al., 2013) 
Similarly, ubiquitin binding has been shown to be required for starvation-induced 
autophagy only when FIP200 binding is disrupted. Finally, Atg16L1 1-230 that cannot 
bind FIP200 can rescue autophagy in Atg16L1Δ/Δ MEF cells. This, combined with the 
inability of FIP200 or ubiquitin-mediated recruitment to explain the PtdIns(3)P binding 
dependence of Atg16L1 recruitment, suggests that an additional interaction may also be 
responsible for Atg16L1 recruitment. 
 Mammalian cells contain two isoforms of S. cerevisiae Atg16, Atg16L1 and 
Atg16L2. As described above, Atg16L1 is essential for autophagy. However, despite 
sharing the same domain structure as Atg16L1, forming homodimers with itself, 
heterodimers with Atg16L1 and binding the Atg12–5 conjugate through an N-terminal 
interaction with Atg5, Atg16L2 is not functional in starvation-induced autophagy 
(Ishibashi et al., 2011). Like Atg16L1, ectopic localisation of the N-terminal Atg16L2 
Atg5-interacting domain can act as an E3-like enzyme, with Atg12–5, and promote 
plasma membrane-localised LC3 conjugation. However, the coiled coil domain of 
Atg16L2 cannot bind the phagophore membrane (Ishibashi et al., 2011). The region of 
Atg16L1 through which the protein binds the phagophore membrane has been mapped 
to amino acids 229-242, a region poorly conserved in Atg16L2. This region is 
responsible for binding FIP200, making this protein an ideal candidate for Atg16L1 
recruitment (Nishimura et al., 2013, Gammoh et al., 2013, Fujita et al., 2013). 
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Figure 1.11 The Atg12–5-16L1 complex acts as an E3-like complex 
The Atg12–5-16L1 complex is recruited to PtdIns(3)P positive autophagosome 
membranes through an unknown mechanism, possibly through an unidentified 
PtdIns(3)P-binding protein. The Atg12–5-16L1 complex subsequently recruits Atg3–
LC3, and catalyses LC3 lipidation. The Atg12–5-16L1 complex is present in a 2:2:2 
stoichiometry due to Atg16L1 homodimerisation (not shown in figure). 
 
 
Figure 1.12 Schematic of Atg16L1 
Atg16L1 binds Atg5 through its N-terminus (white box), forms homodimers and binds 
Rab33B through its coiled coil-domain (black box) and binds ubiquitin through its WD-
40 motif (striped box). FIP200 binding and the region required for LC3 spot formation 
have been mapped to a region between the coiled coil domain and WD-40 motif. 
 
1.3.6 mAtg9 
Atg9 is the only conserved transmembrane protein within the core set of autophagy 
proteins that is required for autophagy (Young et al., 2006). Yeast Atg9 and its 
mammalian homologue (mAtg9) have six transmembrane domains with cytosol 
exposed N- and C- termini. While the transmembrane domains of Atg9 and mAtg9 are 
conserved, the N- and C-termini are not (Orsi et al., 2012). As the only membrane 
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spanning protein of the core autophagy proteins, it is widely thought that mAtg9 may be 
acting to deliver membrane or protein components essential for autophagosome 
formation, however the function of mAtg9 remains elusive. mAtg9 colocalises with the 
trans Golgi network (TGN), recycling and late endosomes, and to a small degree early 
endosomes (Orsi et al., 2012, Young et al., 2006). Both recycling endosomes and Golgi 
have been implicated in the search for the source of the autophagosome membrane (see 
Chapter 1.4) and it is possible that mAtg9 is shuttling membrane or protein between 
these organelles and the forming autophagosome. Additionally, Atg9 is required for the 
PAS localisation of Atg2, Atg8, Atg14 and Atg18 in yeast (Suzuki et al., 2007). 
Consistent with this, direct phosphorylation of Atg9 by Atg1 is required for Atg18 
recruitment and subsequent progression of autophagy (Papinski et al., 2014). It is 
unclear if mAtg9 similarly acts in autophagy machinery recruitment; autophagosome 
formation is reduced in Atg9 KO MEFs, however loss of mAtg9 does not affect the 
composition of formed autophagosomes (Orsi et al., 2012). 
 Mammalian and yeast Atg9 cycle between the site of autophagosome formation 
(the omegasome and PAS, respectively) during starvation. Yeast Atg9 is localised 
within an Atg9 reservoir that is composed of bundles of vesicles and tubules (Mari et al., 
2010). Upon nutrient withdrawal, the Atg9 reservoir translocates to the PAS in a 
manner dependent on its interaction with Atg17 (FIP200 homologue) and Atg1 (Sekito 
et al., 2009). Recycling of Atg9 from the PAS requires the Atg18-Atg2 complex 
(Reggiori et al., 2004). Similarly, mAtg9 is found in a mainly juxtanuclear localisation 
on clusters of tubules and vesicles (corresponding to the yeast Atg9 reservoir), which 
colocalise with markers of the trans Golgi network (TGN), early, late and recycling 
endosomes during fed conditions (Orsi et al., 2012, Young et al., 2006). Nutrient 
starvation results in mAtg9 dispersion to a peripheral localisation, where it is found in 
close proximity to forming autophagosomes (Orsi et al., 2012). mAtg9 shuttles between 
these compartments, but does not become a stable component of the autophagosome. 
Instead, autophagosomes and mAtg9 vesicles come into contact via ‘kiss-and-run’ 
interactions (Orsi et al., 2012). The mechanism of mAtg9 trafficking between its 
juxtanuclear localisation and forming autophagosomes is well conserved. As in yeast, 
mAtg9 dispersion after starvation requires ULK1 and PtdIns(3)P production, while its 
recycling depends on the Atg18 homologue WIPI2 (Young et al., 2006, Orsi et al., 
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2012). As well as the core autophagy machinery, other proteins are thought to be 
involved in mAtg9 trafficking. Bif-1, a curvature-driving protein that can bind UVRAG 
(see Chapter 1.3.4) is required for Golgi tubulation and mAtg9 dispersion from the 
TGN after starvation (Takahashi et al., 2011).  
mAtg9 dispersion upon starvation is required for autophagy and control of its 
trafficking may provide mechanisms through which autophagy can be modulated in 
response to specific stimuli, as may be the case through the p38 MAP kinase pathway 
(Webber and Tooze, 2010). p38-interacting protein (p38IP) interacts with the C-
terminus of mAtg9 and is required for mAtg9 starvation-induced trafficking. The 
interaction between p38IP and mAtg9 is negatively regulated by active p38 (a mitogen-
activated protein kinase, MAPK), and so inactivation of the p38 MAP kinase pathway 
leads to increased autophagy (Webber and Tooze, 2010).  
Atg9 plays a key role in autophagy: atg9Δ mutant S. cerevisiae are incapable of 
forming autophagosomes, while mAtg9 is required during early neonatal starvation in 
mice – a period for which survival depends on autophagy – and Atg9 KO MEFs display 
a reduced autophagy response (Saitoh et al., 2009). Further characterisation of Atg9 
interacting partners, be they protein or lipid, will shed further light on the function and 
regulation of this protein. 
 
1.3.7 Summary of mammalian autophagy proteins 
Table 1.1 Summary of mammalian autophagy proteins 
Mammalian 
Atg protein 
Function Yeast 
homologue 
References 
ULK1/2 Serine/threonine kinase Atg1 (Chan et al., 2007) 
Atg2a, b Binds WIPI4 Atg2 (Velikkakath et al., 
2012) 
Atg3 E2-like protein involved in 
conjugation of Atg8 proteins to 
PE 
Atg3 (Tanida et al., 2002) 
Atg4A, B, C 
and D 
Activation of Atg8 proteins for 
conjugation to PE, and cleavage 
of Atg8-PE 
Atg4 (Marino et al., 
2003) 
Atg5 Conjugated to Atg12 and acts as 
an E3-like protein in Atg8-PE 
conjugation 
Atg5 (Mizushima et al., 
2001) 
Beclin1 Core component of the Vps34- Atg6 (Liang et al., 1999) 
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Vps15 PtdIns(3) kinase complex 
Atg7 Acts as an E1-like protein in 
Atg12–5 and Atg8–PE 
conjugation cascades 
Atg7 (Tanida et al., 2001) 
LC3 Conjugated to PE. Possibly 
involved in phagophore 
elongation 
Atg8 (Kabeya et al., 
2004, Weidberg et 
al., 2010) 
GATE16/ 
GABARAP 
Conjugated to PE. Possibly 
involved in autophagosome 
closure 
Atg8 (Kabeya et al., 
2004, Weidberg et 
al., 2010) 
mAtg9 Transmembrane protein Atg9 (Young et al., 2006) 
Atg10 Acts as an E2-like protein in 
Atg12–5 conjugation 
Atg10 (Mizushima et al., 
1998) 
Atg12 Conjugated to Atg5 and acts as 
an E3-like protein in Atg8-PE 
conjugation 
Atg12 (Mizushima et al., 
1998) 
Atg13 Core component of the ULK 
kinase complex 
Atg13 (Chan et al., 2009) 
Atg14L Autophagy-specific component 
of the Vps34-Vps15 PtdIns(3) 
kinase complex 
Atg14 (Sun et al., 2008) 
Atg16L1 Forms a complex with Atg12–5 
and acts as an E3-like protein in 
Atg8-PE conjugation 
Atg16 (Mizushima et al., 
2003) 
FIP200 Core component of the ULK 
kinase complex 
Atg17 (Hara et al., 2008) 
WIPI1/2/3/4 Binds PtdInd(3)P  Atg18 
Atg21 
Hsv2 
(Proikas-Cezanne et 
al., 2004, Polson et 
al., 2010, 
Velikkakath et al., 
2012) 
 
1.4 Autophagosome membrane biogenesis 
Autophagy initiation results in the formation of numerous autophagosomes, indicating a 
concerted effort in de novo lipid synthesis and membrane mobilisation. The debate over 
the source of the autophagosome membrane has been running for decades and has still 
not reached a final conclusion. Advances in knowledge of the mammalian autophagy 
pathway and in detection of forming autophagosomes by electron and fluorescence 
microscopy have advanced understanding the position in the cell where 
autophagosomes form and the source of the expanding membrane. The current 
consensus is that the majority of autophagosomes are formed from omegasomes on the 
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ER and at sites of ER and mitochondria contact. The discovery of DFCP1 led to the 
description of omegasomes as PtdIns(3)P-enriched subdomains of the ER from where 
the phagophore and forming autophagosomes emanate (Axe et al., 2008). The ULK1 
and Atg14L positive Vps34 complexes both localise to the omegasome (Karanasios et 
al., 2013b, Matsunaga et al., 2010). Together with the identification of phagophores 
cradled between two ER cisternae (probably the omegasome) (Hayashi-Nishino et al., 
2009, Yla-Anttila et al., 2009), this strongly suggests that the ER is the site at which 
autophagosomes originate from. More recently, autophagosome formation at ER and 
mitochondria contact sites has been described (Hamasaki et al., 2013). Physical contact 
between the ER and mitochondria are important for processes such as calcium 
signalling and lipid transfer between the ER and mitochondria (Lamb et al., 2013). Core 
autophagy proteins such as Atg5 and Atg14L are found at these sites and disruption of 
contact sites impairs autophagosome formation. The de novo formation of the 
phagophore membrane is supported by the fact that the ER is the main site for lipid 
synthesis in the cell and that the ER and mitochondria contact sites contain specific lipid 
synthesis enzymes in both mammals and yeast (van Meer et al., 2008). However, de 
novo lipid synthesis for phagophore expansion remains to be demonstrated. 
 Although the ER is the only organelle shown to act as a source for 
autophagosomes by electron microscopy, membrane contribution to growing and 
maturing autophagosomes from additional organelles, including the ERGIC, mAtg9-
associated TGN and endosomes and the plasma membrane, has been demonstrated 
indirectly. mAtg9 resides on the tubular vesicular clusters that colocalise with the TGN, 
recycling and endosome compartments during fed conditions and disperse from the 
TGN localisation to endosomal positions during starvation (Orsi et al., 2012). mAtg9 is 
required for autophagy and mAtg9 vesicles transiently contact growing 
autophagosomes. Although its function is not known, it may be involved in shuttling 
protein or lipids between compartments which is it associated with (the TGN, recycling 
and early endosomes) and growing autophagosomes. The ER-Golgi intermediate 
compartment (ERGIC) is required for autophagosome formation and purified ERGIC is 
able to support LC3 lipidation (Ge et al., 2013), suggesting this compartment may act as 
a membrane source. Evidence for the involvement of the plasma membrane as a 
membrane source for autophagosome formation comes from the identification of 
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Clathrin heavy chain and AP-2 as Atg16L1 interactors (Ravikumar et al., 2010). 
Atg16L1 vesicles are formed as a result of Clathrin-mediated endocytosis and these 
vesicles undergo VAMP7, syntain7- and syntaxin8-dependent homotypic fusion before 
becoming LC3-positive (Moreau et al., 2011). It has been proposed that these Atg16L1- 
and LC3-positive vesicles represent phagophores.  
 The membrane reorganisation and lipid synthesis required during autophagy 
could well involve both de novo lipid synthesis and membrane delivery from additional 
compartments by vesicle trafficking. Vesicle transport would allow for the delivery of 
additional proteins to the autophagosome, which may provide an explanation for the 
acidification of autophagosomes without fusion with an acidic compartment (Dunn, 
1990, Axe et al., 2008).  
 
1.5 Autophagy in health and disease 
Basal autophagy is required for turning over old and damaged long-lived proteins and 
organelles. Therefore, autophagy is required for protection against a number of diseases 
resulting from deregulated protein and organelle turnover and has been implicated in a 
number of pathologies including cancer, neurodegenerative diseases and diabetes (Jiang 
and Mizushima, 2014, Quan et al., 2012). 
 A number of core autophagy proteins have been implicated in suppression of 
tumorigenesis. Monoallelic deletion of Beclin1 results in increased sporadic tumours 
(Aita et al., 1999). Concurrently, Beclin1 is commonly deleted in breast, ovarian and 
prostate cancer. Re-expression of Beclin1 restores autophagy in the MCF7 breast cancer 
cell lines, leading to a reduction in proliferation and inhibition of tumorigenesis of these 
cells (Liang et al., 1999). The expression of autophagy proteins Atg5 and WIPI1 are 
also altered in human cancers (Liu et al., 2013, Proikas-Cezanne et al., 2004). 
Autophagy clears damaged and long-lived proteins and organelles and it is widely 
accepted that this action protects against reactive oxygen species (ROS) and 
proteotoxicity, which can contribute to cancer development (White, 2012). Impaired 
autophagy therefore lessens protection against these factors, increasing the incidence of 
tumour formation. In addition to impaired autophagy resulting in increased ROS 
through dysfunctional mitophagy, in cells with impaired autophagy the pro-survival 
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antioxidant-defence pathway is switched on (White, 2012). p62 binds and sequesters 
KEAP1 from its binding partner NRF2, therefore releasing NRF2 from inhibition by 
KEAP1 and allowing the transcription factor NRF2 to translocate to the nucleus and 
activate antioxidant-defence genes (White, 2012). Transcriptional control by NRF2 is 
tightly controlled through modification of KEAP1 or p62 transcriptional control in 
normal cells. However, p62 accumulation in autophagy defective cells means that 
antioxidant-defence genes are constitutively switched on and tumorigenesis is promoted 
(White, 2012). Therefore, autophagy can act as a tumour suppressive mechanism and 
impaired autophagy can promote oncogenic actions of other proteins, such as NRF2. 
 Conversely, autophagy can promote survival of stressed cancer cells. Cancer 
cells in hypoxic environments within tumours show high levels of autophagy and 
inhibition of autophagy in these cells promotes cancer cell death. The mechanisms by 
which autophagy supports tumour survival are not fully understood and are likely to 
differ between different cancer types and tumour environments (White, 2012). As well 
as promoting tumour cell survival, autophagy is upregulated and promotes cell survival 
during metastasis (White, 2012). Therefore, autophagy functions in both preventing 
cancer initiation, and supporting cancer cell survival and metastasis. 
 Sporadic mutations in the WIPI4 gene results in severely reduced WIPI4 protein 
expression and leads to the development of static encephalopathy of children with 
neurodegeneration in adulthood (SENDA) (Saitsu et al., 2013). SENDA is a severe 
neurological disorder that causes early-onset spastic paraplegia and mental retardation. 
Later in life, in their early 30’s, patients experience sudden on-set Parkinson’s and 
dystonia (Jiang and Mizushima, 2014). Cells from patients with WIPI4 mutations show 
impaired autophagy, with impaired LC flux and increased formation of LC3 and Atg9 
positive autophagosomes, probably representing unclosed autophagosomes (Saitsu et al., 
2013). Why the effects of these WIPI4 mutations are only manifested in the brain is 
unclear, but may reflect cell type differences, perhaps long-lived neurons are 
particularly vulnerable to autophagy loss. 
 A point mutation in Atg16L1 resulting in a threonine to alanine substitution at 
position 300 is strongly associated with Crohn’s disease. Crohn’s disease is a major 
inflammatory bowel disease, a long-term pathology that causes inflammation of the 
digestive system. Atg16L1 T300A is more susceptible to caspase-3-mediated 
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degradation than wild type Atg16L1. Caspase-3 is activated by conditions including 
metabolic and nutrient stress and pathogen infection. In cells with Atg16L1 T300A 
mutants, caspase-3 activation results in impaired basal autophagy due to Atg16L1 
T300A cleavage, which subsequently causes sustained cellular stress, resulting in 
inflammation and Crohn’s disease progression (Murthy et al., 2014). This illustrates 
how basal autophagy is essential to cellular homeostasis and the effect disruption of this 
can have at the organism level. 
 
1.6 Xenophagy 
Xenophagy is the selective degradation of intracellular pathogens by autophagy. As for 
other forms of selective autophagy, this process involves identification of the pathogen 
by cargo receptors and the core autophagy machinery for subsequent autophagosome 
formation. Invading bacteria that are targeted for degradation are identified by the 
infected cell and subsequently marked in some form for recognition by cargo receptors. 
These ‘eat-me’ signals include ubiquitination, diacylglycerol (DAG) and exposed 
glycans from damaged membranes. There are a number of known cargo receptors for 
bacterial autophagy and these are p62, nuclear domain 10 protein 52 (NDP52), 
neighbour of BRCA1 gene 1 (NBR1), optineurin (OPTN) and galectin-8. Ubiquitination 
is probably the best understood mechanism of bacterial targeting, but whether this is 
ubiquitination of a host or bacterial proteins is unknown. NDP52, p62 and OPTN 
recognise ubiquitin through their various ubiquitin-binding domains and bind LC3 
though LIR motifs. These cargo receptors are not redundant, and they display ubiquitin-
linkage and Atg8 homologue preferences, therefore allowing additional layers of 
regulation and control of this process (Gomes and Dikic, 2014). DAG, a lipid second 
messenger, is localised to the Salmonella containing vesicle (SCV) through an unknown 
mechanism and subsequently may drive autophagy initiation via the JNK-pathway. 
During infection of cells, damage of endosomes is often caused, exposing glycans. 
Galectin-8 binds exposed glycans and through a direct interaction recruits NDP52 
(Thurston et al., 2012). NDP52 then binds ubiquitinated protein in the vicinity of the 
bacteria and leads to bacterial sequestration through its interaction with LC3. 
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Furthermore, NDP52 can bind TANK binding kinase 1 (TBK1) (Thurston et al., 2009), 
which phosphorylates OPTN and increases its affinity for LC3 (Wild et al., 2011). 
 Intracellular bacteria grow and replicate either in the cytosol or in membrane-
bound compartments. Shigella and Listeria are examples of cytosolic bacteria, whereas 
Salmonella resides and replicates in specialised vesicles. Intracellular bacteria have 
evolved a number of mechanisms in order to avoid degradation by either the endocytic 
or autophagic pathways. Salmonella inhibit SCV targeting to the lysosome though an 
unknown mechanism, while cytosolic bacteria Shigella avoid detection by the 
autophagy machinery by mechanisms such as expression of virulence factors that 
outcompete Atg5-Tecpr1 (Tectonin β-propeller repeat-containing protein) for VirG 
binding, therefore avoiding targeting to the autophagosome (Gomes and Dikic, 2014). 
However, a subpopulation of bacteria is recognised and targeted for degradation by 
xenophagy. Salmonella is used extensively to study xenophagy, both at the whole 
organism level and in cellular systems. 
 Salmonella invade non-phagocytic cells through injection of virulence factors 
via their type three-secretion systems (TTSS) to induce plasma membrane ruffling and 
subsequent uptake into a vesicle (Gorvel and Meresse, 2001). The SCV very quickly 
becomes decorated with early and recycling endosome markers, probably through direct 
fusion with these compartments (Gorvel and Meresse, 2001, Finlay and Brumell, 2000). 
Within one hour the SCV is uncoupled from the endocytic pathway and is labelled by 
late endosome and lysosome markers, including the LAMP proteins, through an 
unknown mechanism requiring Rab7 but not involving lysosome fusion (Finlay and 
Brumell, 2000). Although Salmonella has evolved mechanisms to avoid eventual 
targeting to the lysosome, some SCVs are damaged by the TTSS and the Salmonella 
become exposed to the cytosol and/or the cell detects exposed glycans. This results in 
ubiquitination and detection by cargo receptors, culminating in Salmonella degradation 
through xenophagy (Birmingham et al., 2006).  
 Xenophagy requires the core autophagy machinery. Deletion or depletion of 
these proteins results in hyperproliferation of Salmonella, culminating in cell or 
organism death (Jia et al., 2009, Birmingham et al., 2006). Xenophagy activity in 
infected cells peaks after one hour, before returning to very low basal levels 
(Birmingham et al., 2006, Tattoli et al., 2012). Salmonella-induced membrane damage 
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causes amino acid depletion from the cells though an unknown mechanism, leading to 
mTORC1 inhibition and autophagy activation (Tattoli et al., 2012). mTORC1 activation 
is restored by amino acid recovery after one hour. Again, this occurs through a poorly 
understood Salmonella-driven mechanism. Bacterial autophagy occurs at PtdIns(3)P 
enriched domains of the ER, in which DFCP1, Atg14L and LC3 surround the SCV 
(Huang et al., 2011).  
The functions of the core autophagy machinery in xenophagy are currently not well 
understood. Under wild type conditions, autophagic sequestration of the SCV results in 
a double membrane-bound autophagosome surrounding the single SCV membrane 
enclosing the Salmonella. As expected, the Atg12–5-16L1 complex and the E1- and E2-
like enzymes are required for LC3 targeting to the SCV (Kageyama et al., 2011). 
However, SCVs in Atg7 KO cells are surrounded by a double membrane, which is 
thought to be unclosed, showing that LC3 is not required for expansion of the 
phagophore around the SCV. These cells are defective in autophagy and Salmonella 
replication is not restricted (Kageyama et al., 2011). The requirement for mAtg9, 
functional ULK1 kinase complex, and the Atg14L PtdIns(3) kinase complex is not clear. 
mAtg9 and FIP200 knockout cells have Salmonella-targeted LC3. However, this LC3 is 
targeted, and presumably lipidated, directly to the SCV membrane, as there is no double 
phagophore present. These LC3-lipidated SCVs seem not to be functional for 
autophagy-mediated Salmonella degradation, as Atg9 or FIP200 KO results in increased 
Salmonella infection (Kageyama et al., 2011). Additionally, the role of PtdIns(3)P in 
LC3 recruitment to the SCV is not understood. A number of groups have reported that 
LC3 recruitment is reduced, although not inhibited by PtdIns(3)P-loss (Huang et al., 
2011, Birmingham et al., 2006), while others have reported that PtdIns(3)P is 
dispensable (Kageyama et al., 2011). Unlike in starvation-induced autophagy, LC3 
recruitment appears not to be absolutely dependent on PtdIns(3)P production, and 
instead PtdIns(3)P deficiency may manifest itself as a subtle defect in LC3 recruitment. 
Similarly, the requirement for FIP200 in LC3 recruitment is more complex than in 
starvation-induced autophagy. FIP200 and ubiquitin both directly bind Atg16L1. 
FIP200 and ubiquitin binding of Atg16L1, along with some other currently unidentified 
Atg16L1 binding protein, are required for LC3 recruitment to the SCV (Fujita et al., 
2013). The requirement for FIP200 and ubiquitin binding of Atg16L1 seems to be 
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redundant in xenophagy. Indeed, it appears as though recruitment of the Atg12–5-16L1 
complex is more complicated than in starvation-induced autophagy, perhaps reflecting 
the more complex nature of xenophagy. Evolution of Atg16L1 in higher eukaryotes 
may reflect these complex and redundant mechanisms as yeast Atg16 do not contain the 
WD-40 domain shown to be required for ubiquitin binding (Fujita et al., 2013). 
Atg16L1 binding to ubiquitin may facilitate LC3 recruitment directly to the SCV, 
without the requirement for a double membrane phagophore. This interaction is similar 
to Atg5 binding to VirG – a Shigella virulence protein – which is required for 
xenophagy of Shigella (Ogawa et al., 2011). It is probable that there are other members 
of the core autophagy machinery that similarly mediate interactions with target bacteria. 
 
1.7 Aims and objectives 
Since the identification of the first mammalian autophagy protein in the late 1990s there 
has been rapid progress in the identification of other autophagy proteins and dissection 
of their molecular functions. It has become clear that autophagy is highly regulated and 
involves the concerted and sequential action of core autophagy proteins. Although a lot 
of progress has been made, there are still a number of unanswered questions regarding 
the core autophagy machinery. In this study I aimed to address the outstanding 
questions of what the functions of mAtg9 and WIPI2 are. mAtg9 is the only 
transmembrane protein required for autophagy and so mechanistic understanding of its 
function may shed light on the membrane dynamics involved in autophagosome 
formation. WIPI2 is WD-40 domain-containing, PtdIns(3)P-binding protein required for 
autophagy. PtdIns(3)P production is absolutely essential for autophagy and is required 
for recruitment of core autophagy proteins, including those involved in LC3 lipidation, 
to the forming autophagosome. There is currently no link between PtdIns(3)P 
production and recruitment of downstream proteins. As a WD-40 domain protein, 
WIPI2 may act as a platform to recruit downstream core autophagy proteins in a 
PtdIns(3)P-dependent manner. A fuller understanding of autophagy may open new 
avenues for therapeutic manipulation of this process. 
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Chapter 2. Materials & Methods 
2.1 Cell Biology 
2.1.1 Cell culture 
Cell culture flasks, dishes and plates were obtained from Corning, and Dulbecco’s 
Modified Eagle Medium (DMEM) and fetal bovine serum (FCS) from Sigma. Earle’s 
Balanced Salt Solution (EBSS) (5.56 mM D-glucose, 123.08 mM NaCl, 5.37 mM KCl, 
1.82 mM CaCl2, 0.81 mM MgSO4, 0.99 mM Na2HPO4, 13.10 mM NaHCO3), trypsin 
(0.25% trypsin in Tris Saline) and versene (0.02% (w/v) EDTA in PBSA) were 
produced by Cell Services at the LRI. 
 HeLa, HEK293A and HEK293A derivatives were maintained in DMEM 
supplemented with 10% FCS and 4.8 mM L-glutamine under humidified conditions at 
37 ºC in 10% CO2. Stably expressing GFP-LC3 HEK293A line (2GL9 cells) is as 
previously described (Chan et al., 2009) and is not maintained under selection. GFP-
WIPI2b stably expressing HEK293A cell line was produced by Hannah Polson (Dooley 
et al., 2014) and this cell line is maintained under 400 µg/mL geneticin (Life 
Technologies). MEF cell lines were maintained in DMEM supplemented with 20% FCS 
and 4.8 mM L-glutamine under humidified conditions at 37 ºC in 10% CO2. FIP200-­‐/-­‐	  and	  matched	  wild	  type	  immortalized	  MEF	  cell	  lines	  were	  a	  kind	  gift	  from	  Jun-­‐Lin	  Guan	  (Gan	  et	  al.,	  2006),	  Atg16Δ/Δ	  and	  matched	  immortalized	  MEF	  cell	  lines	  were	  kind	  gift	  from	  Shizuo	  Akira	  (Saitoh	  et	  al.,	  2008),	  (Kuma	  et	  al.,	  2004)and	  TSC2-­‐/-­‐	  and	  matched	  immortalized	  MEF	  cell	  lines	  were	  a	  kind	  gift	  frim	  Ivan	  Gout	  (Zhang	  et	  al.,	  2003).	  	  
Cells were grown until 80-90% confluent and were passaged by washing once in 
versene before incubation in 0.08% trypsin to detach cells. For maintenance, detached 
cells were diluted 1:10 (HEK and HeLa cell lines) or 1:5 (MEF cell lines). Cells were 
used until a passage number of 25, after which they were discarded. If used for 
transfection, MEF cell lines were used for a maximum of 5 passages after recovery from 
frozen, after which the transfection efficiency became too low. Cells were frozen in 
90% FCS, 10% DMSO. Generally, trypsinised cells from a confluent T-150 flask were 
centrifuged (1000 rpm, 4 minutes, room temperature) and resuspended in 10 mL of 
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90:10 FCS:DMSO mixture. Aliquots of 1 mL were frozen. When defrosting, these 
aliquots were resuspended into T-75 flasks for HEK and HeLa cell lines, or T-25 flasks 
for MEF cells lines.  
 Where indicated as ‘fed’ or ‘starved’, cells are incubated in fresh DMEM or 
EBSS, respectively, for two hours (unless otherwise stated) after washing twice with the 
relevant medium (DMEM or EBSS). Where indicated, cells were treated with 100 nM 
Bafilomycin A1 (Calbiochem), or 100 nM wortmannin (Calbiochem) for the duration of 
the starvation treatment. To reduce detachment of HEK293A cells and derivative cell 
lines, poly-D-lysine (Sigma, USA) was used to coat the wells of 6-, 12- and 24-well 
plates when cells were cultured in these vessels. Poly-D-lysine coating was not required 
for HeLa or MEF cell lines in any dish or plates, or for HEK293A and derivatives in 
dishes. 
2.1.2 Transfection 
All siRNA was used at a final concentration of 50 nM.  
2.1.2.1 Oligofectamine transfection 
Oligofectamine (Life Technologies) was used for siRNA transfection of HEK293A and 
HeLa cell lines. The following is for transfection in a 6 cm plate, and bigger or smaller 
transfections were scaled according to dish surface area ratios. 4.5 X 105 cells were 
plated the day before oligofectamine transfection so that on they day of transfection 
(‘hit 1’) they would be approximately 40% confluent. Solution A: 6 µL of 
Oligofectamine was added to 34 µL of OptiMem (a reduced serum cell culture medium, 
Life Technologies). Solution B: 5 µL of siRNA at a stock concentration of 20 µM was 
added to 360 µL of Opitmem. Solutions A and B were incubated separately for 10 
minutes at room temperature before mixing together and incubating a further 20 
minutes at room temperature. All mixtures were tapped after they were made up to 
ensure proper mixing, and briefly spun down after mixing to ensure that liquid was not 
in the lid of containers. The A and B mix was added to cells which had had DMEM 
medium replaced with 3600 µL OptiMem, resulting in a final volume of 2 mL 
optiMem-oliofectamine-siRNA mix. Cells were incubated in this mix at 37 ºC for 4-6 
hours.  
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2.1.2.2 Lipofectamine transfection 
Lipofectamine2000 (Life Technologies) was used for siRNA and plasmid transfections 
of HEK293A and HeLa cell lines that are above 70% confluent. Lipofectamine2000 is 
toxic to cells below this confluency. Cells were plated to be 80% confluent on the day 
of transfection. For transfection of plasmid DNA for immunoprecipitation of 
overexpressed proteins, 10 cm plates were seeded with 4 X 106 HEK293A (or 
derivative) cells the day before Lipofectamine2000 transfection. Cell numbers for 
smaller dish sizes were scaled according to plate surface area ratios. Generally, 
Lipofectmaine2000 was used for transfection of cells treated with Oligofectamine the 
previous day, for a two-hit siRNA protocol (see below). The following was the reaction 
mixture for transfecting a 6 cm dish. Mixes for differently sized dishes were scaled 
according to surface area ratios. Mix ‘A’ was formed of 6 µL of Lipofectamine2000 in 
1 mL OptiMem. Mix ‘B’ is formed of 5 µL siRNA (stock of 20 µM) and/or 1 µg of 
plasmid DNA in 500 µL of Optimem. Mixes A and B were incubated separately at 
room temperature for 10 minutes before mixing and further incubating for 30 minutes at 
room temperature. All mixtures were tapped after they were made up to ensure proper 
mixing, and briefly spun down after mixing to ensure lipid was not in the lid of 
containers. Cells were incubated in the AB mixture, after aspirating the DMEM they 
were grown in, for at least 6 hours (but not longer than 8 hours) before replacing the 
mix with fresh DMEM.  
 
2.1.2.3 Two-hit knockdown  
Day one: plate cells for correct confluency for Oligofectamine treatment the following 
day. 
Day two: Oligofectamine transfection of siRNA. 
Day three: Lipofectamine2000 transfection of siRNA. If rescuing the knockdown, then 
at this stage siRNA resistant plasmid DNA is also transfected with the siRNA. 
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Day four: re-plate cells from dishes (normally 6 cm) into 12- and 24-well plates for 
western blot and immunoflourescence assays. These plates were poly-D-lysine coated if 
HEK293A, or derivative, cell lines were used. 
Day five: Autophagy assays: starvation/drug treatments 72 hours after initial 
knockdown. 
 
2.1.2.4 JetPRIMEtransfection 
JetPRIME (PolyPlus Transfection) was used for transfection of MEF cell lines that were 
at least 70% confluent. Note that jetPRIME is toxic to cells below this confluency. The 
mix of transfection agent and DNA concentration was optimised for the lowest toxicity 
with the highest expression. For transfection in a 24-well plate, 2.4 X 104 MEF cells 
were plated per well the day prior for transfection. For a single well of a 24-well plate: 
0.5 µg of plasmid DNA was diluted into 75 µL of jetPRIME buffer. The mixture was 
vortexed for 10 s and spun down. 1 µL of jetPRIME was added to the buffer-DNA 
mixture, and the resulting mixture was vortexed for a further 10 s before being spun 
down and incubated for 10 minutes at room temperature. The jetPrime mixture was 
added dropwise to cells in 0.5 mL of DMEM. Cells were incubated for 4 hours in the 
DMEM-jetPRIME mix before the medium was replaced with fresh DMEM. For 
different well or plate sizes, both the number of cells seeded and the transfection mixes 
were scaled up according to surface area ratios of the plates: twice the volume of 
jetPRIME mix (jetPRIME, DNA and buffer) and twice the number of cells were used 
for transfection in a 12-well plate.  
 
2.1.2.5 siRNA duplexes 
siRNA was reconstituted in 1X siRNA buffer (Thermo Scientific) (60 mM KCl, 6 mM 
HEPES pH 7.5, 0.2 mM MgCl2). 
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Table 2.1 siRNA used in this thesis 
Target gene siRNA Target sequence Supplier 
(RISC-free 
control) 
D-001220-0 N/A Dharmacon 
Atg2a J-026591-17 AGUUGGAGGUGGCGGGACA Dharmacon 
Atg2a J-026591-18 CGUAAUGAGCACAGGCGAU Dharmacon 
Atg2a J-026591-19 GCAAGGAGGUCUACGAGAG Dharmacon 
Atg2a J-026591-20 CCAACAAUGUGGUACACGU Dharmacon 
Atg2b J-016822-18 GUAAAGAAAUGCCUCGAAA Dharmacon 
Atg2b J-016822-19 GAACUUACGUUACCAAAUA Dharmacon 
Atg2b J-016822-20 CAAUAGAGCAGUACCGGAA Dharmacon 
Atg2b J-016822-22 CCAUGUGUCUAGUGGAGUA Dharmacon 
FIP200 J-021117-05 GGAGUGGGCUGGUGCUUUA Dharmacon 
FIP200 J-021117-06 AAACUACGAUUGACACUAA Dharmacon 
FIP200 J-021117-07 GCAAAGAAAUUAGGGAAUC Dharmacon 
FIP200 J-021117-08 UAAACUUGACGGACUAAUA Dharmacon 
ULK1 D-005049-04 UGUAGGUGUUUAAGAAUUG Dharmacon 
WIPI2 J-020521-09 CGACAGUCCUUUAGCGGCA Dharmacon 
WIPI2 J-020521-12 GGACCGGGUACUUCGGGAA Dharmacon 
WIPI2 Hs_WIPI2_4 CTCGCTAGCCACAATTCAGAA Qiagen 
 
2.1.3 Salmonella growth 
Salmonella typhimurium SL 1344 was a kind gift from David Holden. All Salmonella 
work was carried out under a laminar flow hood in a containment level 2 facility. A 
scraping of Salmonella was removed from the -80 ºC DMSO stock (see Chapter 2.3.9) 
using a pipette tip and was incubated in 3 mL of LB (1% Bacto-Tryptone (w/v), 0.5% 
yeast extract, 1.7 M NaCl, LRI), shaking overnight in a 37 ºC water bath. To control for 
other bacterial contamination, 3 mL of LB with no Salmonella was prepared and 
incubated at the same time. The following morning, assuming that the 3 mL of control 
LB was clear, 90 µL of the overnight Salmonella culture was added to 3 mL of pre-
warmed LB. This culture was incubated, shaking at 37 ºC in a water bath, until the 
bacteria reached mid-log growth (OD600 2-2.5). The optical density (OD) was measured 
by diluting the Salmonella culture 1:10 (100 µL in 900 µL of LB). An OD of 0.2-0.25 
corresponds to 2-2.5 when this dilution is accounted for. LB was used as the blank and 
the absorbance at 600 nm was read using a spectrometer. From the OD600, the number 
of Salmonella per mL was estimated (OD X 109 per mL).  
Chapter 2 Materials and Methods 
 
 68 
 
2.1.4 Salmonella infection 
Salmonella was used to infect HeLa or MEF cells in 24 well plates. HeLa cells were 
treated with siRNA as described in Chapter 2.1.2.3, and re-plated on day 4 at a cell 
density of 7 X 104 cells per well of a 24-well plate for Salmonella infection the 
following day. MEF cells were plated into 24-well plates and transfected the day before 
Salmonella infection as described in Chapter 2.1.2.4. Salmonella infection was carried 
out at a multiplicity of infection (MOI) of 100 for infection of HeLa cells and 50 for 
MEF cells. The volume of Salmonella culture at mid-log phase (see Chapter 2.1.3 
above) needed for achieving this MOI was calculated using the OD600 reading and an 
estimation of the cell number. I estimated that there were 1 X 105 HeLa cells per well 
(as 7 X 104 were plated per well the evening before infection) and roughly 3.5 X 104 
MEF cells per well (2.4 X 104) plated the previous day. To calculate the volume of 
Salmonella culture (in mL) that was required for each well, the MOI was multiplied by 
the estimated number of cells and then divided by the number of bacteria per mL. LB-
Salmonella mix was added to each well by diluting it into 1 mL of DMEM and adding 
this to the cells (after removing existing DMEM from the well). Plates were then spun 
at 2000 rpm at room temperature for 10 minutes in a plate-carrying centrifuge with 
swing-out arms before incubation at 37 ºC under humidified conditions with 10% CO2. 
Cells were then washed once in PBSA before addition of 1mL DMEM with 50 µg/mL 
gentamicin (Sigma) and incubation at 37 ºC for a further hour. This constitutes infection 
for 1 hour. After infection, plates were put on ice and cells were washed twice with 
PBSA before fixing as usual for immunofluorescence (see Chapter 2.2.10) or cell lysis 
for colony counting.  
For colony counting, cells were lysed using 0.1% Triton X-100 in PBSA. After 
aspiration of PBSA from washing, 150 µL of lysis buffer was added to each well. Lysis 
buffer was pipetted up and down and the pipette tip was use to scrape across the well 
surface to maximise cell lysis. Once lysed, 100 µL of lysis buffer was added to 900 µL 
of LB in an Eppendorf tube and placed on ice (tube 1). Two further 1:10 serial dilutions 
were made by adding 100 µL from tube 1 into 900 µL of LB (forming tube 2), and 
subsequently diluting 100 µL from tube 2 into 900 µL of LB (forming tube 3). All tubes 
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were incubated on ice until all wells had been lysed and serial dilutions made. 100 µL of 
each LB-cell lysate mix was then spread on LB plates and incubated at 37 ºC over night. 
The following day colonies were counted from plates containing 30-300 colonies. This 
assay assumes that each colony formed represents a single colony forming unit (c.u.f.), 
i.e. a living Salmonella bacterium. Colony counting was performed in triplicate for each 
condition of Salmonella infection (e.g. RF and WIPI2 KD).  
For wortmannin treatment during Salmonella infection, wortmannin was added to 
medium at a final concentration of 100 nM for 15 minutes prior to infection and for the 
duration of infection. 
 
2.2 Biochemistry 
2.2.1 Antibodies 
Table 2.2 Primary antibodies 
Antigen Species Antibody Supplier Dilution Notes 
Actin Rabbit ab8227 Abcam WB 1:2000  
Atg5 Rabbit  CosmoBio WB 1:200  
Atg9 Rabbit STO218 CRUK WB 1:1000* 
IP:1:200* 
 
Atg9 Hamster 14F2  WB 1:1000  
Atg16 Rabbit STO285 CRUK IF 1:250* 
WB 1:250* 
IF: digitonin 
permeabilize 
Atg16 Rabbit  CosmoBio IF 1:400 
WB 1:1000 
IF: digitonin 
permeabilize 
Atg16 Mouse 1F12 MBL IF 1:400 
WB 1:1000 
IF: digitonin 
permeabilize 
Calreticulin Chicken  Abcam IF 1:200  
EEA1 Mouse BD  WB 1:2500  
FIP200 Rabbit  Bethyl 
Labs 
WB 1:2000 Incubate 
overnight 
FLAG Rabbit  Sigma   
FLAG Mouse M2 Sigma IF 1:4000 Reduced 
background with 
preclearing 
GFP Rabbit  Abcam WB 1:5000  
HA Mouse HA.11 Covance WB 1:1000  
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LAMP1 Mouse CD107A BD IF 1:400  
LC3B Rabbit ab48394 Abcam IF 1:2500 
WB 1:2500 
Methanol fix for 
IF 
RFP 
(mCherry) 
Rabbit  MBL WB 1:1000  
Myc Mouse 9E10 CRUK WB 1:500 
IP: 1:200 
 
p62 C-
terminus 
Guinea 
Pig 
GP62-C Progen IF 1:300 
 
 
p62 Mouse  BD WB 1:500 Incubate 
overnight 
Stx13 Rabbit  Synaptic 
systems 
WB 1:1000  
TfR Mouse  Invitrogen WB 1:500  
Ubiquitin Mouse FK2 MBL IF 1:200  
ULK1 Rabbit STO250 CRUK WB 1:100  
WIPI2 Rabbit STO280 CRUK IF 1:400* 
WB 1:250 
Use whole 
serum for 
western blot 
WIPI2 Mouse 2A2 Dundee 
Cell 
Products 
IF 1:4000 
WB 1:1000 
IP: 1:200 
 
*, affinity purified antibody 
 
Table 2.3 Secondary antibodies 
Antigen Conjugated to Supplier Dilution 
Rabbit IgG HRP GE Healthcare WB 1:4000 
Mouse IgG HRP GE Healthcare WB 1:4000 
Hamster IgG HRP GE Healthcare WB  1:4000 
Rabbit IgG Alexa Fluor 488 Life Technologies IF 1:1000 
Rabbit IgG Alexa Fluor 555 Life Technologies IF 1:1000 
Rabbit IgG Alexa Fluor 647 Life Technologies IF 1:1000 
Mouse IgG Alexa Fluor 488 Life Technologies IF 1:1000 
Mouse IgG Alexa Fluor 555 Life Technologies IF 1:1000 
Mouse IgG Alexa Fluor 647 Life Technologies IF 1:1000 
Guinea pig IgG Alexa Fluor 555 Life Technologies IF 1:1000 
Chicken IgG Alexa Fluor 488 Life Technologies 1:1000 
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2.2.2 Cell lysis for western blot 
For cell lysis before immunoprecipitation see Chapter 2.2.5. For analysis of knockdown, 
expression, LC3 lipidation or p62 degradation, cells were lysed in 1% Triton TNTE (1% 
Triton X-100, 20 mM Tris HCl pH 7.5, 150 mM NaCl, 5 mM EDTA) supplemented 
with 1X complete protease inhibitor cocktail (Roche) on ice. 100 µL of lysis buffer was 
used for a single well of a 12-well plate, and volumes were adjusted for other sized 
plates or dishes based on their relative surface area. Cells were incubated, on ice, in the 
lysis buffer for approximately 3 minutes before scraping the cells off with a pipette tip 
and repeated washing of the wells with the lysis buffer. The lysis buffer from each well 
was then transferred to a clean Eppendorf tube and spun at maximum speed (13 000 
rpm) for 15 minutes to pellet the nuclei. The clarified lysate was transferred to clean 
Eppendorf tubes and 5X SDS sample buffer (15% SDS (w/v), 213.5 mM Tris-HCl pH 
6.8, 50% glycerol (w/v), 16% β-mercaptoethanol, bromophenol blue) was added to a 
final concentration of 1X. Samples were heated at 65 ºC for 10 minutes before loading 
onto SDS-PAGE gels for electrophoresis and protein transfer (see below). 
 When required, Bio-Rad protein assay dye solution (Bio-Rad) was used to 
determine protein concentration to correct for uneven loading. Serial dilutions of an IgG 
standard (Bio-rad) in lysis buffer were made up to 800 µL with dH2O and added to 200 
µL of dye solution for the production of a standard curve. The protein content of 
samples was determined by making up small volume of the sample to 800 µL with 
water, as for the standard IgG, and adding 200 µL of dye solution. Both the protein 
sample mixes and the standard mixes were vortexed and incubated at room temperature 
for 15-60 minutes before measuring the absorbance at 595 nm using a spectrometer. 
 
2.2.3 SDS-PAGE and protein transfer 
SDS-PAGE was performed using NuPAGE 4-12% Bis-Tris precast mini or midi protein 
gels (Life Technologies). Gels were run at 200 V in MOPS (Life technologies, 20 X 
stock: 50 mM MOPS, 50 mM Tris Base, 0.1% SDS, 1 mM EDTA, pH 7.7) or MES 
(Life technologies, 20 X stock: 50 mM MES, 50 mM Tris Base, 0.1% SDS, 1 mM 
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EDTA, pH 7.3) until the dye front reached the bottom of the gel (the time taken was 
approximately 40 minutes - 1 hour depending on the size of the gel). MES was 
generally used for the running buffer, apart from for crosslinking experiments in 
Chapter 3.2. 
 Proteins were transferred to PDVF (polyvinylidene fluoride) membrane 
(Millipore) using wet transfer. PDVF membrane was pre-wet in methanol before rinsing 
in transfer buffer (0.2% methanol, 150 mM glycine, 20 mM tris base). Thick blot paper 
(Sigma) and transfer sponges were also pre-wet in transfer buffer. Proteins were 
transferred onto the membrane at 27. V for 1 hour 30 min. Protein transfer to the 
membrane was visualised using Ponceau S solution (Sigma) – the membrane was 
incubated in the stain for ≥ 10 minutes while rocking at room temperature. Excess stain 
was removed by repeated washing in water. After scanning the Ponceau-stained 
membrane, the stain was removed by repeated washing in PBSA. 
 
2.2.4 Western blotting and detection 
The following incubation periods are all at room temperature (unless otherwise 
specified) and on a rocker. If dry, PDVF membranes were re-wet in methanol and 
rinsed in PBSA. Membranes were incubated in in 5% powder milk (w/v) (Marvel) 0.1% 
PBSA-tween (PBST) for one hour for blocking. Following blocking, membranes were 
incubated in primary antibodies diluted as indicated in Table 2.2 in 5% milk (w/v) 0.1% 
PBST for one hour, unless indicated otherwise in Table 2.2. Where noted that an 
antibody was used overnight, this incubation was at 4 ºC. After incubation in primary 
antibody, the membrane was washed once quickly in 0.1% PBST, once for 10 minutes 
in PBST and twice for 5 minutes. Membrane were then incubated in HRP-conjugated 
secondary antibodies (see Table 2.3) for 40 minutes - 1 hour in 5% milk 0.1% PBST 
before washing in 0.1% PBST as for washing after primary antibody incubation, but 
with an additional two 5 minute washes (total of four 5 minute washes). Following 
washing, membranes were transferred to a glass plate and covered in ECL (Amersham, 
GE healthcare) for 2 minutes before exposing to film (Amersham Hyperfilm ECL, GE 
healthcare). Exposure times varied between western blots. For validation of 
phosphospecific antibodies, the above protocol was followed apart from: western blots 
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were blocked in 5% BSA (w/v) dissolved in 0.1% TBS-tween (TBST), washed in 
0.1%TBST and primary and secondary antibodies were diluted in 1% BSA in 0.1% 
TBST. 
 For re-probing the same membrane, membranes were incubated in Restore 
Western Blot Stripping Buffer (Thermo Scientific) for 15 minutes while rocking at 
room temperature. Membranes were subsequently washed in 1% PBST once quickly 
and four times for 5 minutes before blocking in 5% milk 0.1% PBST for 40 minutes and 
then continuing with primary and secondary antibody incubations and washes as above. 
 
2.2.5 Immunoprecipitation 
For immunoprecipitation of endogenous protein, cells were grown to 80-100% 
confluency in 10 cm dishes and for immunoprecipitation of overexpressed protein, cells 
were transfected as described in Chapter 2.1.2.2 and were used for immunoprecipitation 
the following day. Cells were washed twice in PBSA (7 mL per wash) and then scraped 
in 1 mL of ice-cold lysis buffer supplemented with 1X complete protease inhibitor 
(Roche) and incubated for 10 minutes on ice for cell lysis. CHAPS (50 mM Tris HCl 
pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% CHAPS (w/v)) was used for lysis and 
washing of endogenous Atg9 immunoprecipitation (not crosslinked). RIPA buffer (150 
mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Trs HCl pH 7.5) 
was used for cell lysis and bead washing of crosslinked Atg9 before mass spectrometry 
analysis. 0.3% Triton X-100 TNTE (20 mM Tris HCl pH 7.5, 150 mM NaCl, 0.3% 
Triton X-100, 5 mM EDTA) was used for cell lysis and bead washing for 
immunoprecipitation of myc-tagged proteins. 1% Triton X-100 (20 mM Tris HCl pH 
7.5, 150 mM NaCl, 1% Triton X-100, 5 mM EDTA) was used for cell lysis and bead 
washing of DSP-crosslinked proteins. NP-40 based buffers were used for cell lysis and 
washing for GFP-Trap and FLAG IP (see below). Once lysed, cells were spun at 13 000 
rpm for 15 minutes at 4 ºCto pellet the nuclei. 
 This following protocol is for immunoprecipitation of endogenous Atg9, 
endogenous WIPI2 (but not co-immunoprecipitation with Atg16L1), and myc-tagged 
proteins. For each immunoprecipitation, 40 µL of protein A bead slurry (for rabbit 
antibodies), or protein G bead slurry (for mouse antibodies) (both Sigma) was washed 
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three times in 1 mL of PBSA and once in relevant lysis buffer in a 1.5 mL Eppendorf 
tube. The beads were subsequently resuspended in 100 µL of lysis butter and incubated 
with the relevant antibody for ten minutes on ice, followed by washing once in 1 mL of 
lysis buffer before the clarified cell lysate was added. Immunoprecipitation mixes were 
rotated for one hour at 4 ºC and were subsequently washed three times in 1 mL of 
relevant wash buffer. After removal of the final wash, beads were resuspended in 50 µL 
of 2 X SDS sample buffer before visualisation by western blot. 
 For immunoprecipitation of endogenous WIPI2 after DSP-treatment (see 
Chapter 2.2.8) and cell lysis, the clarified lysate for each immunoprecipitation was 
incubated with WIPI2 monoclonal antibody by rotating overnight at 4 ºC. Subsequently, 
washed protein G beads (washed as described above) were added to the lysate-antibody 
mix and the immunoprecipitation mixture rotated at 4 ºC for 2 hours. Beads were 
washed four times in 1 mL 1% Triton X-100 TNTE and the beads resuspended in 50 µL 
of 2X SDS sample buffer with 50 mM dithiothreitol (DTT) and boiled at 100 ºC for 10 
minutes to cleave the crosslinker. 
 For RFP-, GFP-Trap and FLAG immunoprecipitation, cells from a confluent 10 
cm dish were washed as described above and then scraped in 1 mL of cold PBSA, the 
cells were pelleted (1000 rpm at 4 ºC in a bench top centrifuge) and the PBSA removed 
from the cell pellet. The pellet of cells was subsequently lysed in 400 µL of GFP-Trap 
lysis buffer (10 mM Tris HCl pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 0.5% NP-40) on 
ice for 15 minutes and spun at 13 000 rpm at 4 ºC to pellet nuclei. The clarified lysate 
was added to 500 µL of GFP-Trap dilution buffer (10 mM Tris HCl pH 7.5, 150 mM 
NaCl, 0.5 mM EDTA). RFP- and GFP-Trap immunoprecipitations were pre-cleared 
with blocked agarose beads (Chromtek). 20 µL of blocked agarose bead slurry was used 
for each RFP- or GFP-Trap, washed once in 1 mL PBSA and resuspended in 100 µL 
GFP-Trap dilution buffer before being added to the cell lysate. RFP- and GFP-Traps 
were precleared for 40 minutes, rotating at 4 ºC. 40 µL of supernatant from the pre-clear 
was used as ‘start’ sample and the remaining was added to RFP- or GFP-Trap beads 
(both ChromTek). 15 µL of Trap beads were used for each immunoprecipitation and 
were washed and resuspended in dilution buffer as for the blocked agarose beads. RFP- 
or GFP-tagged proteins were immunoprecipitated with the relevant Trap beads for one 
hour while by rotating at 4 ºC. FLAG M2 Affinity Gel (Sigma) was used for 
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immunoprecipitation of FLAG-tagged proteins. 20 µL agarose slurry was used per 
immunoprecipitation. The slurry was washed in the same manner as for Trap beads 
before adding to the FLAG-tagged cell lysates (with no preclear) and rotating at 4 ºC for 
one hour. RFP, GFP, and FLAG immunoprecipitations were all washed three times in 1 
mL of GFP-Trap lysis buffer before adding 50 µL of 2 X SDS buffer and heating at 65 
ºC for 10 minutes. 
 
2.2.6 Immunoprecipitation from mixed lysates 
In my hands, expression of tagged proteins could be very variable after co-transfection. 
Therefore, in experiments involving co-immunoprecipitation of overexpressed proteins, 
proteins were overexpressed in different cell populations before mixing cell lysates to 
try and even out protein expression. Briefly, cells were lysed as detailed for GPF-Trap 
(Chapter 2.2.5) and clarified lysate was produced. The clarified lysates from cells 
expressing tagged proteins were then used for pre-clearing with blocked agarose beads 
(see GFP-Trap details in Chapter 2.2.5) and 40 µL of ‘start’ sample was taken. Pre-
cleared cell lysates were then mixed with those from cells expressing different proteins, 
and immunoprecipitation was performed from these mixtures. ‘Start’ samples were not 
mixed. See below for more detail. 
 
2.2.6.1 FLAG-Atg16L1 and FLAG-Atg16L2 co-immunoprecipitation with GFP-
tagged proteins 
Plasmids coding for GFP, GFP-WIPI1a, GFP-WIPI2b, FLAG-Atg16L1 and FLAG-
Atg16L2 were separately transfected in 10 cm plates (see Chapter 2.1.2.2). Cell 
washing and production of clarified lysates, preclearing and removal of ‘start’ sample 
before mixing lysates was performed as detailed above and in Chapter 2.2.5. GFP, GFP-
WIPI1a and GFP-WIPI2b containing cell lysates were individually split evenly into two 
new Eppendorf tubes (on ice). One of each of the GFP-tagged protein lysates was then 
mixed with a third of the FLAG-tagged Atg16L1 and Atg16L2 containing cell lysate. 
GFP-Trap was performed form these mixtures as normal. 
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2.2.6.2 Fine mapping of Atg16L1 binding sites using point mutants 
A total of 11 FLAG-tagged Atg16L1 and Atg16L2 constructs were used to test for co-
immunoprecipitation with GFP-WIPI2b or endogenous FIP200. A 10 cm plate was used 
for transfection with each FLAG-tagged Atg16 construct (see Chapter 2.1.2.2) along 
with 4 X 10 cm plates of HEK293A cells stably expressing GFP-WIPI2b. Following 
cell lysis, production of clarified cell lysates and removal of ‘start’ samples (before 
mixing samples), cell lysates expressing FLAG-tagged proteins were split into two. 
Half of this sample was used for immunoprecipitation using FLAG Affinity Gel 
(Sigma) (see Chapter 2.2.5) to test for endogenous FIP200 co-immunoprecipitation. The 
other half of the FLAG-tagged lysates were each mixed with cell lysate from cells 
stably expressing GFP-WIPI2b. This lysate had been pooled from the 4 X 10 cm plates, 
before being split into 11 equal parts for mixing with the 11 FLAG-tagged lysates. In 
summary, cell lysate from roughly a third of a 10 cm plate of HEK293A cells stably 
expressing GFP-WIPI2b was mixed with cell lysate from a half of a 10 cm plate of 
HEK293A cells transiently over expressing FLAG-tagged Atg16 proteins. 
 
2.2.6.3 Charge-change rescue experiment 
In this experiment, four FLAG-tagged Atg16L1 constructs were mixed with four GFP-
tagged WIPI2b constructs in all possible permutations (Figure 3.25a). A single 10 cm 
plate was transiently transfected with each construct. Following cell lysis, production of 
clarified cell lysates and ‘start’ removal (before mixing), these lysates were split into 
quarters and each quarter was mixed with a different quarter of cell lysates containing 
over expressed protein with the corresponding tag (i.e. a quarter of GFP-tagged WIPI2 
containing cell lysate would be mixed with a quarter of FLAG-tagged Atg16L1 
containing cell lysate). The mixes were then used for GFP-Trap as usual.  
 
2.2.7 In vitro translation coupled with immunoprecipitation 
Immunoprecipitation of GFP- or myc-tagged proteins followed by co-
immunoprecipitation of in vitro translated Atg16L1 constructs was used to demonstrate 
Chapter 2 Materials and Methods 
 
 77 
interactions. Immunoprecipitation and GFP-Trap were performed as described above.
 TNT Quick Couple Transcription/Translation Systems (Promega) was used for 
in vitro translation of the T7 promoter-controlled constructs indicated in figures. 40 µL 
of TNT master mix was used with 0.5 µg of plasmid DNA, and 2 µL of 35S-methonine 
(PerkinElmer) at 10mCi/mL in a final volume of 50 µL. The reaction was incubated 
while shaking at 30 ºC for 90 minutes.  
 A 10 cm plate of HEK203A cells was used for GFP-Trap or 
immunoprecipitation (see above) and the final products (after final washes) of 
immunoprecipitation were resuspended in 500 µL of wash buffer (GFP-Trap lysis 
buffer). 20 µL of in vitro translation product was added to the 500 µL of 
immunoprecipitation and the resulting mixture was rotated at 4 ºC for one hour. The 
beads were subsequently washed three times in wash buffer and the beads resuspended 
in 2X SDS sample buffer and the products analysed by SDS-PAGE followed by 
autoradiography and western blot. 
 
2.2.8 Crosslinking  
Dithiobis[succinimidyl propionate]/ Lomant’s reagent (DPS) (ProteoChem), Bis[2-
(succinimidooxycarbonyloxy)ethyl]sulfone (BSOCOES) (ProteoChem) and 
Disuccinimidlk suberate (DSS) (ProteoChem) are all amine-reactive, cell permeable 
crosslinkers that were used according to manufacturer’s instructions. Plates of cells 
were washed on ice with PBSA twice before crosslinking. Protease inhibitors were not 
used during crosslinking of whole cells. When first dissolving crosslinkers, DMSO over 
a molecular sieve (anhydrous/‘dry’ DMSO) was used. 
BSOCOES was dissolved in dry dimethyl sulfoxide (DMSO) (Sigma) to obtain 
a stock solution of 20 mM concentration immediately before use. This stock solution 
was diluted in PBSA to give a total volume of 6 mL. Final concentrations of BSOCOES 
that were used are as indicated in figures. The 6 mL of crosslinker was directly added to 
HEK293A cells in 10 cm dishes. After incubation on ice for 30 minutes, cells were 
washed in 1 M Tris HCl, pH 7.5, to quench the crosslinker. Cells were then washed in 
PBSA and lysed as usual for western blot. 
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DSS crosslinker was similarly made up to 20 mM in dry DMSO immediately 
before use. This stock solution was then diluted in PBSA to obtain a final solution of 2 
mM. Incubation time for crosslinking was optimised using HEK293A cells in 6 cm 
plates, with 2 mL of DSS solution added to each plate. Crosslinking was quenched by 
adding Tris HCl pH 7.5 to a final concentration of 100 mM and incubating for 15 
minutes. For DSS treatment before Atg9 immunoprecipitation, 4 X 15 cm plates of 
HEK293A cells were treated with DSS (15 mL per plate) and incubated on ice for 1 
hour before quenching and cell lysis and Atg9 immunoprecipitation. 
DSP was made up to an initial concentration of 10 mM using dry DMSO 
immediately before use before further dilution in PBSA to the concentrations indicated 
in figures and figure legends. HEK293A cells from a 10 cm plate were scraped into 1.5 
mL Eppendorf tubes using 1 mL of ice cold PBSA and spun down (1000 rpm, 4 ºC, 2 
minutes) to pellet the cells. The cells were resuspended in 1 mL of PBSA-DSP mix and 
incubated on ice for 30 minutes. The tubes were flicked occasionally to resuspend cells. 
Crosslinking was quenched by adding 1 M Tris HCl pH 7.5 to a final concentration of 
20 mM and incubating on ice for a further 15 minutes. Cells were then spun down and 
lysed as usual. 
 
2.2.9 Mass spectrometry 
DSS crosslinking followed by endogenous Atg9 immunoprecipitation was used for 
mass spectrometry. Final washes of Atg9 immunoprecipitates were carried out in sterile 
conditions (under a laminar-flow hood) and SDS-PAGE was performed using a clean 
gel tank and sterile MOPS running buffer. SDS-PAGE gel was run as usual, until the 
dye front exited the gel, and the gel was stained using GelCode Blue Stain Reagent 
(Thermo Scientific), a colloidal Coomassie based dye. Lanes were cut into 1 mm slices 
for tryptic digest and mass spectrometry analysis. Each 1 mm slice was placed in a 
single well of a 96 well plate, covered in sterile water and transported to the LRI Mass 
Spectrometry facility. Digest and analysis was done by the LRI mass spectrometry 
facility. 
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2.2.10 Immunofluorescence labelling and confocal microscopy 
HEK293A, HeLa and MEF cells were plated onto glass coverslips (LRI) in 12- or 24-
well plates (these were coated in poly-D-lysine for HEK293A cells) for 
immunofluorescence (IF). For IF after Salmonella infection, cells were plated at 
densities described in Chapter 2.1.4. Otherwise, for IF after siRNA treatment, 
HEK293A cells were plated at 1.4 X 105 cells per well of a 12-well plate, and 7 X 104 
cells per well of a 24-well plate the day before fixing. MEF cells were plates at a 
density of 8 X 104 cells per well of a 12-well plate.  
 Cells on coverslips were washed twice in PBSA while incubated on ice. All 
subsequent steps and solutions are at room temperature, unless otherwise stated. Cells 
were fixed in 3% paraformaldehyde (agar scientific) in PBS supplemented with 0.01 
mM MgCl2 and 0.01 mM CaCl2 for twenty minutes. Typically, cells were then washed 
twice in PBSA before permeabilization with room temperature methanol for five 
minutes. For Atg16L1 staining, cells fixed with PFA were permeabilized using 
digitonin (50 µg/mL) for 5 minutes at room temperature. Following permeabilization, 
cells were washed twice with PBSA and then blocked for one hour in 5% BSA fraction 
V (Roche) in PBSA. Primary antibodies were diluted as indicated in Table 2.2 in 1% 
BSA in PBSA. Coverslips were inverted onto 100 µL drops of primary antibody mix 
and incubated in a humidified container for 1 hour. Coverslips were washed once in 1% 
BSA in PBSA before being inverted onto drops of 100 µL in secondary antibody, 
diluted as indicated in Table 2.3, in 1% BSA. Cells were incubated with secondary 
antibody for between 40 minutes and 1 hour. If used, Hoechst (Sigma) was added with 
the secondary antibody at 1:200. Finally, coverslips were washed once in 1% BSA, 
twice in PBSA and once in water before mounting onto glass microscope slides 
(Thermo Scientific) with 5 µL of Mowiol 4-88 (CalBiochem). 
 Confocal images were taken with a Zeiss Axioplan 2 LSM710 laser-scanning 
microscope with a 63X, 1.4, oil-immersion objective or a 40X, 1.3, oil-immersion 
objective (Carl Zeiss MicroImaging, Inc). Generally, a 40X objective was used for 
capturing images for LC3 or WIPI2 puncta counting, while a 63X objective was used 
for imaging Salmonella. Confocal images were taken with a slice thickness of 0.7 µm 
(normally for spot counting) or 1 µm (Salmonella images). Laser setting were kept 
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constant for imaging each condition of an experiment. Images were processed using Zen 
2009 software. 
 
2.2.11 ELISA 
96-well MaxiSorp Immuno Plates (Nunc) protein-binding plates were used for ELISA. 
Plates were coated by diluting peptide to the final concentrations indicated in figures or 
figure legends in a final volume of 50 µL of Binding Buffer (0.1 M NaHCO3, 0.2 M 
Na2CO3, 0.2 M NaHCO3). Plates containing peptide in Binding Buffer were covered 
and incubated overnight at 4 ºC. After incubation, unbound peptide was washed from 
wells by washing three times with 0.1% Tween in Tris-buffered saline (TBS). Between 
washes, fluid was removed from plates by flicking well and patting dry on paper towel. 
Wells were subsequently filled with 150 µL Blocking Buffer (TBS/0.1% Tween, 1% 
BSA fraction V (Roche)) and incubated at room temperature for 1 hour. Plates were 
flicked well and patted dry on paper towels to remove Blocking Buffer. Subsequently, 
primary antibody was diluted in Blocking Buffer at the concentrations described in 
figures and 100 µL of diluted primary antibody was added to each well. Primary 
antibody was incubated for 1 hour and wells were then washed three times in TBS/0.1% 
Tween. Secondary antibody was diluted 1:4000 in Blocking Buffer and added to wells 
for 1 hour at room temperature. Wells were washed four times in TBS/0.1% Tween 
before 75 µL of ELISA substrate, o-phenylenediamine dihydrochloride (OPD) (Sigma), 
was added per well. The reaction was stopped after 10 minutes by adding 50 µL of 2 M 
HCl per well. ELISA plates were read at 490 nm using a SpectraMax Plus absorbance 
micro plate reader (Spectramax Plus (Molecular Devises)). When performing peptide 
competition, competing peptide(s) were added at a final concentration of 1 µg/mL to 
primary antibody solutions and incubated at room temperature, rocking, for 10 minutes 
before adding the primary antibody-peptide mix to the ELISA plate. 
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2.3 Molecular biology 
2.3.1 PCR 
Polymerase chain reaction (PCR) was typically performed using KOD hot start DNA 
polymerase (Novagen). 
 
PCR mix: 
10X Buffer for KOD Hot Start DNA Polymerase 5 µL 
25 mM MgSO4     3 µL 
dNTPs (2 mM each)     5 µL 
Forward primer (10 µM)    1.5 µL 
Reverse primer (10 µM)    1.5 µL 
Template plasmid     10 ng 
KOD Hot Start Polymerase    1 µL 
AccuPrime      5 µL 
Nuclease-free water     to 50 µL 
 
Components (apart from DNA, primers (Sigma) and AccuPrime (Life Technologies)) 
are from the KOD Hot Start Kit (Novagen).  
 
PCR cycle: 
Segment Cycles Temperature (ºC) Time 
1 1 95 2 min 
2 30 95 20 sec 
55 10 sec 
65 25 s/kb 
3 1 4 ∞ 
 
 
PCR products were purified using DNA agarose gel electrophoresis (Chapter 2.3.2) if 
there were multiple PCR products, or using QIAquick PCR purification Kit (Qiagen) 
(spin column purification) according to the manufacturer’s instructions. When spin 
column purifying, PCR products were eluted in 30 µL elution buffer (EB) (Qiagen).  
 
Chapter 2 Materials and Methods 
 
 82 
2.3.2 DNA agarose gel electrophoresis  
0.8% agarose (Invitrogen) was dissolved in 1 X Tris-acetate-EDTA (TAE) buffer (LRI) 
by heating using a microwave. One drop of 0.625 mg/mL ethidium bromide (Amresco) 
was added per 50-100 mL of molten agarose and the mixture was chilled slightly in 
water before pouring into a holder with well comb to set. DNA was added to 5X 
loading buffer (Qiagen) and loaded into wells. Hyperladder I (Bioline) was used as a 
size standard. DNA bands were imaged using a UV irradiator (GeneFlash, SynGene 
BioImaging). If required, DNA bands were excised using a clean sample, while 
visualising using a UV lamp, and purified using QIAquick Gel Extraction Kit (Qiagen) 
according to the manufacturer’s instructions. DNA was eluted from the column using 
30 µL EB (Qiagen) and incubating at room temperature for 2 minutes before eluting.  
 
2.3.3 Restriction enzyme digestion 
DNA in the form of plasmids and PCR products were digested using the relevant 
restriction enzymes from New England Biolabs (NEB) according to the manufacturer’s 
instructions.  
 
Generally, the following mix was used: 
DNA    1 µg 
10X NEBuffer   5 µL 
100X BSA (if required) 0.5 µL 
Restriction enzyme  10 units 
Nuclease-free water  to 50 µL 
 
Reactions were incubated for at least an hour at the optimum temperature. If double 
digestions were required, the best compromise was chosen in terms of NEBuffer. If no 
suitable buffer were available or if the incubation temperatures were different, serial 
digestions were performed with DNA purification between each digest. Double 
digestions were used to prevent re-ligation of the vector, with no insert, during DNA 
ligation. 
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2.3.4 DNA phosphatase treatment 
To prevent religation of the vector, cut vector was treated with DNA calf intestinal 
phosphatase (CIP) (NEB) after restriction digestion. 10 units of CIP was added to the 
restriction digestion and incubated for 37 ºC for 1 hour. 
 
2.3.5 Ligation 
DNA fragments were ligated typically using T4 DNA Ligase (NEB) according to the 
manufacturer’s instructions. 
 
Ligation mix: 
10X T4 DNA Ligase Buffer  2 µL 
Vector DNA (3 kb)   50 ng  
Insert DNA (1 kb)   50 ng  
T4 DNA Ligase   1 µL 
Nuclease-free water   to 20 µL 
 
Ligations were usually incubated at 16 ºC overnight. A vector to insert ratio of 1:3 is 
shown above. If ligations were unsuccessful with a 1:3 ratio and a higher insert ration 
was tried, or if vector and insert sizes differed from those shown above, DNA amounts 
were calculated using an online calculator (NEBioCalculator). Total DNA concentration 
was kept below 10 ng/µL 
 
2.3.6 Site directed mutagenesis 
For site directed mutagenesis (SDM) QuickChange Multi Site-Directed Kit (Agilent 
Technologies) was used according to the manufacture’s instructions, with very minor 
adjustments. Briefly, primers were designed to incorporate single or multiple base pair 
changes (see Table 2.4). These primers were used for production of circular PCR 
products using an enzyme mix containing high fidelity PfuTurbo DNA polymerase and 
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nick-sealing ‘components’. See below for PCR mix and cycle. Following PCR, the 
original plasmid template was degraded by incubation Dpn I, and the resulting mix was 
used to transform XL10-GOLD ultracompetent cells (see Chapter 2.3.7). Colonies 
formed were used for miniprep production, verified by sequencing and then used for 
maxiprep production.  
 
PCR mix: 
Note, a half or a third of the recommended volumes work well. Half reactions are 
shown below. 
10X QuickChange Multi reaction buffer 1.25 µL 
Quick Solution    0.25 µL 
Template DNA    25 ng 
Mutagenic primer    50 ng 
dNTP      0.5 µg 
QuickChange Multi enzyme blend  0.5 µL 
dH2O to 12.5 µL 
 
PCR cycle: 
Segment Cycles Temperature (ºC) Time 
1 1 95 1 min 
2 30 95 1 min 
55 1 min 
65 2 min/kb 
3 1 4 ∞ 
 
2.3.7 Bacterial transformation 
Chemically competent DH5α E. coli (Life Technologies), stored at -80 ºC, was 
defrosted on ice. 50 µL of DH5α was used per transformation. DNA was incubated with 
the bacteria for 30 minutes on ice. For transformation of ligation products, 10 µl of 
ligation mixture was added to the bacteria, and for transformation of plasmid DNA, 0.5 
µg of DNA was added to the bacteria. Following incubation on ice, the bacteria were 
heat shocked at 42 ºC for 40 seconds before incubating on ice for 1 minute. 200 µL of 
SOC (2% trypton (w/v), 0.5% yeast extract (w/v), 10.0 mM NaCl, 2.7 mM KCl, 21.0 
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mM MgCl2, 20.8 mM MgSO4, 20 mM D-glucose, LRI) was added to the bacteria and 
the bacteria were recovered by incubating at 37 ºC in a shaking incubator for 1 hour. 
Bacteria were plated onto LB-agar plates (1% Bacto-Tryptone (w/v), 0.5% yeast extract, 
1.7 M NaCl, 1.5% agar, LRI) containing the appropriate antibiotic (either ampicillin or 
kanamycin) at 50 µg/µL. For transformation of ligation products, the full 250 µL of 
bacteria-SOC mixture was plated, whereas 50 µL of plasmid transformation was plated. 
Bacteria were incubated overnight at 37 ºC to allow formation of colonies. 
 XL10-Gold Ultracompetent Cells (Agilent) were used for transformation of 
SDM products. The procedure for these bacteria is the same as for DH5α, apart from 
that 25 µL, rather than 50 µL, can be used per transformation and 1 µL of β-
Mercaptoethanol is mixed into chilled bacteria by tapping, and the mixture incubated on 
ice for ten minutes before addition of DNA. 3 µL of SDM product was used for each 
transformation. Bacteria on plates were incubated for at least 16 hours to allow visible 
colonies to form. 
 
2.3.8 Preparation of plasmid DNA 
Colonies from bacterial plates were picked and used in 5 mL LB (1% Bacto-Tryptone 
(w/v), 0.5% yeast extract, 1.7 M NaCl, LRI) plus relevant antibiotics at a concentration 
of 50 µg/µL for miniprep plasmid DNA production. These cultures were grown in a 
shaking incubator at 37 ºC for at least 8 hours. Bacteria were pelleted at 4000 rpm for 
20 minutes at 4 ºC and the supernatant discarded. When a large number of minipreps 
were being processed the miniprep service at the LRI equipment park was used. For 
small numbers of minipreps, Qiaprep Miniprep Kit (Qiagen) was used according to the 
manufacturer’s instructions. DNA was eluted in 50 µL EB buffer.  
 For production of larger quantities of sequence-verified plasmids, maxipreps 
were performed. Bacterial colonies were picked from transformation plates or from 
DMSO or glycerol stocks and were added to 250 mL of LB medium with added 
antibiotic and incubated for 24 hours while shaking at 37 ºC. Bacterial pellets were 
pelleted at 4000 rpm for 20 minutes at 4 ºC and the supernatant discarded. Qiagen 
Plasmid Maxi Kit was then used according to the manufacturer’s instructions for 
purification of plasmid DNA. After precipitation and washing, DNA was redissolved in 
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500 µL TE (Tris-EDTA) buffer. The concentration of DNA was subsequently measured 
using a spectrophotometer (NanoDrop, Thermo Scientific) and the DNA made up to 1 
µL/µL with TE. Aliquots were stored at -20 ºC for long-term storage, or at 4 ºC if the 
aliquot was in regular use.  
 
2.3.9 DMSO stock production 
DMSO stocks of E. coli DH5α expressing plasmids and Salmonella typhimurium SL 
1344 were stored at -80 ºC and were used for starter cultures. 900 µL of cultures (either 
1 mL of a maxi prep culture for E. coli, or aliquots of 1 mL from a 20 mL culture from 
an overnight incubation of salmonella) were mixed with 100 µL of DMSO in a cryovial 
(Corning) for freezing and storage at -80 ºC. 
 
2.3.10 Primers 
All primers were purchased from Sigma. 
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Chapter 2 Materials and Methods 
 
 88 
2.3.11 Plasmids 
Table 2.5 Plasmids used in this thesis 
Name Insert Vector Resistance Source 
pEGFP-C1 GFP pEGFP-C1 Kanamycin Clontech 
GFP-WIPI2b WIPI2b pEGFP-C1 Kanamycin H. Polson 
GFP-WIPI1a WIPI1a pEGFP-C1 Kanamycin 
T. Proikas-
Cezanne 
GFP-WIPI2a WIPI2a pEGFP-C1 Kanamycin M. Clague 
GFP-Rab33B Rab33B pEGFP-C2 Kanamycin F. Barr 
pcDNA3.1(-)   pcDNA3.1(-) Ampicillin   
GFP-Atg16L1 Atg16L1 pEGFP-C1 Kanamycin T. Yoshimori 
HA-Atg16L1 (mus) 
1-207 Atg16L1 1-207 pcDNA3.1(-) Ampicillin H Dooley 
pRK5mycApg5 Atg5 pRK5 Ampicillin A Tolkovsky 
myc-WIPI1a WIPI1a pCMVTag3 Kanamycin 
T. Proikas-
Cezanne 
myc-WIPI2b WIPI2b pCMVTag3 Kanamycin H. Polson 
pMRXires-puro-
Atg16L WT 
Atg16L-WT 
(human) 
pMX-IRES-
GFP (GFP 
removed) Ampicillin T. Yoshimori 
pMRXires-puro-
Atg16L delta CCD 
Atg16L Δ69-
213 (human) 
pMX-IRES-
GFP (GFP 
removed) Ampicillin T. Yoshimori 
pMRXires-puro-
Atg16L delta WD 
Atg16L 1-249 
(human) 
pMX-IRES-
GFP (GFP 
removed) Ampicillin T. Yoshimori 
pcDNA3.1-Flag 
Atg16L WT 
Atg16L1 WT 
(Mus) pcDNA3.1 Ampicillin T Yoshimori 
pcDNA3.1-Flag 
Atg16L ΔN 
Atg16L1 79-
623 pcDNA3.1 Ampicillin T. Yoshimori 
pcDNA3.1-Flag 
Atg16L ΔC Atg16L1 1-265 pcDNA3.1 Ampicillin T. Yoshimori 
pcDNA3.1-Flag 
Atg16L1 1-242 Atg16L1 1-242 pcDNA3.1 Ampicillin H. Dooley 
pcDNA3.1-Flag 
Atg16L1 1-230 Atg16L1 1-230 pcDNA3.1 Ampicillin H. Dooley 
pcDNA3.1-Flag 
Atg16L1 1-207 Atg16L1 1-207 pcDNA3.1 Ampicillin H. Dooley 
Flag-Atg16L2 Atg16L2 pcDNA3.1 Ampicillin M. Fukuda 
Flag-Atg16L1 
E208R 
Atg16L1 
E241R (mus) pcDNA3.1 Ampicillin H. Dooley 
Flag-Atg16L1 
D212R 
Atg16L1 
D212R (mus) pcDNA3.1 Ampicillin H. Dooley 
Flag-Atg16L1 Atg16L1 pcDNA3.1 Ampicillin H. Dooley 
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E226R E226R (mus) 
Flag-Atg16L1 
E230R 
Atg16L1 
E230R (mus) pcDNA3.1 Ampicillin H. Dooley 
Flag-Atg16L1 
E235R 
Atg16L1 
E235R (mus) pcDNA3.1 Ampicillin H. Dooley 
Flag-Atg16L1 
D237R 
Atg16L1 
D237R (mus) pcDNA3.1 Ampicillin H. Dooley 
Flag-Atg16L1 
D238R 
Atg16L1 
D238R (mus) pcDNA3.1 Ampicillin H. Dooley 
Flag-Atg16L1 
D239R 
Atg16L1 
D239R (mus) pcDNA3.1 Ampicillin H. Dooley 
Flag-Atg16L1 
E241R 
Atg16L1 
E241R (mus) pcDNA3.1 Ampicillin H. Dooley 
Flag-Atg16L1 
E246R 
Atg16L1 
E246R (mus) pcDNA3.1 Ampicillin H. Dooley 
Flag-Atg16L1 
D249R 
Atg16L1 
D249R (mus) pcDNA3.1 Ampicillin H. Dooley 
Flag-Atg16L1 
E253R 
Atg16L1 
E253R (mus) pcDNA3.1 Ampicillin H. Dooley 
Flag-Atg16L1 
E226R E230R 
Atg16L1 
E226R E230R 
(mus) pcDNA3.1 Ampicillin H. Dooley 
Flag-Atg16L1 
D237R D239R 
Atg16L1 
D237R D239R 
(mus) pcDNA3.1 Ampicillin H. Dooley 
pEGFP-WIPI2b 
delta CT WIPI2b 1-360 pEGFP-C1 Kanamycin H. Polson 
pEGFP-WIPI1a 
delta CT WIPI1a 1-362 pEGFP-C1 Kanamycin H. Polson 
GFP-WIPI2b FRRG 
siRES Qiagen #3 
WIPI2b FTTG 
siRES pEGFP-C1 Kanamycin H. Dooley 
pEGFP-WIPI2b 
R108E WIPI2b R108E pEGFP-C1 Kanamycin H. Dooley 
pEGFP-WIPI2b 
R125E WIPI2b R108E pEGFP-C1 Kanamycin H. Dooley 
pEGFP-WIPI2b 
R108E R125E 
WIPI2b R108E 
R125E pEGFP-C1 Kanamycin H. Dooley 
pEGFP-WIPI2b 
R125K WIPI2b R125K pEGFP-C1 Kanamycin H. Dooley 
pEGFP-WIPI2a 
E26K WIPI2a E26R pEGFP-C1 Kanamycin H. Dooley 
pEGFP-WIPI2a 
R31E L35E 
WIPI2a R31E 
L35E pEGFP-C1 Kanamycin H. Dooley 
pEGFP-WIPI2b 
siRES Qiagen #3 WIPI2b siRES pEGFP-C1 Kanamycin H. Dooley 
pEGFP-WIPI2b 
R108E R125E 
WIPI2b R108E 
R125E siRES pEGFP-C1 Kanamycin H. Dooley 
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siRES Qiagen #3 
GFP-WIPI2b R108E 
R125E FRRG siRES 
Qiagen #3 
WIPI2b R108E 
R125E FTTG 
siRES pEGFP-C1 Kanamycin H. Dooley 
myc-DFCP1 DFCP1   Ampicillin N. Ktistakis 
pcDNA3.1(-) 
mCherry mCherry pcDNA3.1 Ampicillin H. Jefferies 
mCherry-WIPI2b-
CAAX RR 
mCherry-
WIPI2b-CAAX 
FTTG pcDNA3.1 Ampicillin H. Dooley 
mCherry-WIPI2b- 
RR WIPI2b FTTG pcDNA3.1 Ampicillin H. Dooley 
mCherry-WIPI2b-
CAAX RR R108E 
R125E 
WIPI2b-CAAX 
FTTG R108E 
R125E pcDNA3.1 Ampicillin H. Dooley 
HA-WIPI2b-CAAX 
RR 
WIPI2b-CAAX 
FTTG pcDNA3.1 Ampicillin H. Dooley 
GFP-LC3 LC3 pEGFP-C1 Kanamycin T. Yoshimori 
GFP-WIPI2b S395A WIPI2b S395A pEGFP-C1 Kanamycin H. Dooley 
GFP-WIPI2b S395E WIPI2b S395E pEGFP-C1 Kanamycin H. Dooley 
GFP-WIPI2b S394A 
S395A 
WIPI2b S394A 
S395A pEGFP-C1 Kanamycin H. Dooley 
GFP-WIPI2b S394E 
S395E 
WIPI2b S394E 
S395E pEGFP-C1 Kanamycin H. Dooley 
 
2.3.12 Sequencing 
Sequencing was carried out using BigDye Terminator v3.1 (BDT) (LRI) sequencing 
reactions.  
 
Reaction mix: 
8 µL  BDT 
3.2 pMol Sequencing primer 
150 ng  DNA 
Made up to 10 µL in dH2O 
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PCR cycle: 
Segment Cycles Temperature (ºC) Time  
1 1 96 3 min 
2 25 96 10 sec 
50 5 sec 
60 4 min 
3 1 4 ∞ 
 
Sequencing reactions were cleaned up using the DyeEx 2.0 Spin Kit (Qiagen) according 
to the manufacture’s instructions. Cleaned reactions were dried using a vacuum 
centrifuge for 20 minutes. Sequencing was performed using capillary sequencing on an 
Applied Biosystems 3730Xl DNA analyser by LRI sequencing services. DNA 
sequences were analysed and aligned using ApE (Universal) and MegAlign 
(DNASTAR) software.  
 
2.4 Analysis 
2.4.1 Imaris image software 
LC3 and WIPI2 puncta were quantified using Imaris X64 software. Thresholds for 
detection limits (size and intensity of puncta) were set manually by comparing puncta 
detection in starved (+ Bafilomycin) vs fed cells. The same set-up was used for each 
condition of an experiment. Cells were counted manually. LC3 and p62-positive 
Salmonella were quantified using Imaris-assisted manually counting: detection limits 
were set using Imaris, and identified LC3- or p62-positive Salmonella were manually 
counted.  
 
2.4.2 Image J densitometry 
ImageJ (National Institute of Health) was used for quantification of western blots by 
measuring the density of film exposure.  
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2.4.3 Statistical analysis 
Statistical analysis was performed using Prism6 (GraphPad software) as indicated in 
figure legends. Asterisk(s) indicate significance: *, p ≤ 0.05, **, p ≤ 0.01, ***, p ≤ 
0.001, ****, p ≤ 0.0001. Data shown is the mean of the indicated number of 
experiments. Error bars are standard error of the mean. 
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Chapter 3. Validation of Atg16L1 as a WIPI2b 
binding partner and mapping the Atg16L1-WIPI2b 
interaction 
3.1  Introduction and aim 
3.1.1 Introduction 
Both the function of PtdIns(3)P at the omegasome and the function of mAtg9 remain 
outstanding questions in our understanding of autophagy. PtdIns(3)P production is 
essential for both mammalian and yeast autophagy, however the molecular mechanisms 
underpinning this requirement are not known. It is probable that in both yeast and 
mammalian cells PtdIns(3)P acts, at least in part, to recruit PtdIns(3)P binding proteins. 
In S. cerevisiae, PAS-localised PtdIns(3)P recruits the Atg18-Atg2 complex through 
PtdIns(3)P binding protein Atg18, and this complex subsequently exerts an essential 
function (Obara et al., 2008). The functions that Atg18 and Atg2 exert at the PAS are 
not fully understood. The complex is required for Atg9 recycling from the PAS 
(Reggiori et al., 2004), and has been implicated in other roles such as protection of 
Atg8-PE from premature cleavage by Atg4 (Nair et al., 2010). Atg2 can be localised to 
the PAS via a FYVE domain, and this Atg2-FYVE protein partially rescues autophagy 
in atg18Δ cells (Kobayashi et al., 2012). Thus, one of the molecular functions of Atg18 
is the PtdIns(3)P-dependent localisation of Atg2 at the PAS. In a similar manner, the 
molecular requirement for PtdIns(3)P in mammalian autophagy may be explained by 
the recruitment of a omegasome-localised PtdIns(3)P binding protein which 
subsequently exerts an essential function.  
Atg18 is a WD-40 domain-containing protein. WD-40 domains frequently 
function as protein-protein interaction platforms (Xu and Min, 2011). In light of this, it 
is possible that the function of the mammalian Atg18 homologues, WIPI (WD-40 repeat 
containing proteins that interact with phosphoinositides) proteins, is similarly to act as 
protein interaction platforms to recruit proteins to the phagophore in a PtdIns(3)P-
dependent manner. WIPI1 and WIPI2 both localise to the omegasome during amino 
acid starvation in a PtdIns(3)P dependent manner and are thought to exert a function, 
Chapter 3 Results 
 
 94 
which is currently not known (Proikas-Cezanne et al., 2004, Polson et al., 2010). 
Hannah Polson, a previous Postdoctoral researcher in the lab, performed a mass 
spectrometry-based screen to find WIPI1a and WIPI2b interactors. Hannah established 
and used HEK293A GFP, GFP-WIPI1a and GFP-WIPI2b stable cell lines for GFP-Trap 
immunoprecipitation before mass spectrometry analysis of proteins co-
immunoprecipitated with the GFP-tagged proteins. Hannah used GFP-WIPI2b rather 
than GFP-WIPI2a as she observed that WIPI2a does not form puncta during starvation, 
whereas WIPI2b does (Dooley et al., 2014), an observation that has been repeated by 
another lab (Mauthe et al., 2011). A separate set of interactors was pulled down with 
both WIPI1a and WIPI2b. Notably, GFP-WIPI1a interacted with a number of coatomer 
(COP) proteins; whereas GFP-WIPI2b interacted with the Atg12–5-16L1 complex. 
Hannah validated these interactors using co-immunoprecipitation of GFP-tagged WIPI 
(Figure 3.1 c). Hannah further validation between the Atg12–5-16L1 complex and GFP-
WIPI2b using immunofluorescence. She found that GFP-WIPI2b puncta, but not GFP 
alone or GFP-WIPI1a, colocalised with Atg16L1 puncta (Figure 3.1 d, e and f). 
Yeast and mammalian Atg9 proteins have six transmembrane domains, and in 
both Atg9 is the only known transmembrane protein that is required for autophagy. 
However, the function of this protein remains elusive. The origin of the autophagosome 
membrane is an area of high interest and it is thought that there are multiple sources of 
membrane including ER (Axe et al., 2008), recycling endosomes (Longatti et al., 2012), 
Golgi (Geng et al., 2010, Ohashi and Munro, 2010, van der Vaart et al., 2010), 
mitochondria (Hamasaki et al., 2013), and plasma membrane (Ravikumar et al., 2010). 
The current consensus is that Atg9 may function to supply membrane to the growing 
autophagosome and, although this has not been directly shown, mAtg9 has been shown 
to partly localise to a number of possible autophagosome membrane sources including 
the trans-Golgi network (Young et al., 2006), recycling endosomes (Orsi et al., 2012) 
and plasma membrane (Puri et al., 2013). If mAtg9 is responsible for membrane supply, 
then the targeting and trafficking of this protein must be highly controlled and regulated. 
mAtg9 traffics between a juxtanuclear localisation in starvation conditions and 
peripheral localisation during amino acid starvation and this movement is controlled by 
ULK1 (Young et al., 2006), WIPI2 (Orsi et al., 2012) and through Atg9 interaction with 
p38IP (Webber and Tooze, 2010). Additionally, mAtg9 may be involved in other 
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protein-protein interactions which are unrelated to membrane trafficking but which may 
help elucidate the function. Andrea Orsi, a previous Postdoctoral researcher in the lab, 
used HEK293A cells transiently overexpressing HA-Atg9 for a mass spectrometry 
screen for mAtg9 interacting partners. He identified Transferrin receptor and Syntaxin 
13, among others, as potential mAtg9 interacting partners (Orsi et al., 2012). 
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Figure 3.1 Mass spectroscopy screen for and validation of WIPI1 and WIPI2 interactors 
(a) HEK293A cell lines stably expressing GFP, GFP-WIPI1a or GFP-WIPI2b were 
treated in full medium (F) or starved in EBSS (S) for two hours before being used for 
GFP-TRAP. Colloidal Coomassie stained SDS-PAGE gel of purified protein complexes 
is shown. (b) A list of identified GFP-WIPI1a and GFP-WIPI2b interacting proteins. 
Proteins found in GFP or untransfected HEK293A control cell lines were removed from 
these lists. (e-f) HEK293A cells stably expressing GFP (d), GFP-WIPI1a (e) or GFP-
WIPI2b (f) were starved for two hours before being fixed and analysed by confocal 
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microscopy using antibodies against endogenous WIPI2 and Atg16L1 as indicated. 
Scale bars are 10 µm. Molecular weights are in kDa. Data and Figure provided by 
Hannah Polson 
 
3.1.2  Aim 
In order to further characterise the functions of both mAtg9 and WIPI2, I began by 
trying a crosslinking-mass spectrometry based approach in order to find novel 
interacting partners. I began by using a crosslinker-based approach in order to identify 
interactions that may have been missed in previous interaction screens due to their 
transient or weak nature. In addition to this, I continued work begun by Hannah Polson 
and Andrea Orsi on WIPI2 and Atg9, respectively. 
 Cell-permeable crosslinkers provide a method by which protein-protein 
interactions can be stabilised in intact cells to allow for detection of transient or weak 
interacting partners. In addition, identification of peptides that covalently attached to 
WIPI2 or mAtg9 via the crosslinker would help identify the interaction sites on both the 
binding partners and the protein of interest (mAtg9 or WIPI2) and so allow a low-
resolution model of the interaction to be formed. There are a wide variety of cell-
permeable crosslinkers that are commercially available, and these include general and 
site-specific crosslinkers. As my aim was to identify novel interactors, we had no 
specific site of interest that we wanted to target by using site-specific crosslinkers and 
so I chose to use amine-reactive crosslinkers. The detection of crosslinked peptides in 
the mass spectrum is challenging as they make up a small proportion of the total 
peptides detected. Using deuterated crosslinkers can make crosslinked peptides easier to 
identify. By using a 1:1 ratio of non-deuterated and deuterated crosslinker, any mass 
spectrum peaks that are a result of two peptides attached by the crosslinker should be a 
specific molecular weight apart from an identical set of peaks (the molecular weight 
difference dictated by the difference in molecular weights of the deuterated and non-
deuterated crosslinkers). This very specific pattern of molecular weight difference has 
been previously used to successfully identify crosslinked peptides (Ihling et al., 2006). 
My experiment plan was to crosslink intact cells with the amine-reactive crosslinker 
DSS and its deuterated partner DSS-d4, immunoprecipitate mAtg9 or WIPI2 to enrich 
for their interactors, followed by mass spectrometry analysis (Figure 3.2) 
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The Atg12–5-16L1 complex localises to the phagophore in a PtdIns(3)P 
dependent manner (Fujita et al., 2008). However, none of the three complex members 
(Atg5, Atg12 and Atg16L1) process any known PtdIns(3)P binding. Furthermore, there 
is no known binding partner of the Atg12–5-16L1 complex with PtdIns(3)P binding 
ability. From Hannah Polson’s previous work, the Atg12–5-16L1 complex was the 
interactor that had the most direct link with autophagy, and was the most exciting when 
the results were viewed with the aim of finding the function of either WIPI1a or 
WIPI2b in autophagy, as WIPI2b may be the PtdIns(3)P binding protein through which 
the Atg12–5-16L1 complex is recruited. I therefore chose to concentrate on validating 
and mapping the possible interaction between WIPI2b and the Atg12–5-16L1 complex, 
alongside performing a crosslinking-mass spectrometry screen for additional WIPI2b 
and mAtg9 interactors. To validate and map the WIPI2-Atg12–5-16L1 interaction, I 
used a number of approaches, including endogenous co-immunoprecipitation, site 
directed mutagenesis and protein truncation to map the interaction, and a charge 
swapping approach to show a direct binding between WIPI2b and Atg16L1. During my 
work in mapping the interaction between Atg16L1 and WIPI2b, the work showing that 
FIP200 binds Atg16L1 was published (Gammoh et al., 2013, Nishimura et al., 2013, 
Fujita et al., 2013). I therefore mapped the region of Atg16L1 that interacts with FIP200. 
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Figure 3.2 Crosslinking - mass spectrometry experiment schematic 
Figure adapted from (Sinz, 2010). Crosslinkers DSS and deuterated analogue DSS-d4 
would be added to HEK293A cells in a 1:1 ratio before WIPI2 or mAtg9 
immunoprecipitation followed by mass spectroscopy analysis for identification of 
binding partners and interacting regions. 
 
3.2 Crosslinking – mass spectrometry 
3.2.1 Crosslinking optimisation 
 I optimised mAtg9 and WIPI2 crosslinking with an amine-specific crosslinker, 
BSOCOES. BSOCOES has a spacer length of 13.0 Å, is base cleavable, has been used 
in the lab before (Otto et al., 2010), and has the same amine-reactive group as DSS. 
HEK293A cells were treated with either full medium (Fed) or EBSS (Starved) for two 
hours before being treated with BSOCOES between 0.5 and 2 mM, or with DMSO as a 
control for 30 minutes before SDS-PAGE and western blot analysis (Figure 3.3). EEA1 
forms a dimer (Callaghan et al., 1999) and was used as a positive control. Both EEA1 
and mAtg9 showed a shift in molecular weight with BSOCOES treatment at all 
concentrations in both fed and starved conditions. These molecular weight shifts 
appeared to be discrete, suggestive of distinct protein complexes. In addition, the 
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molecular weight shifts seen with mAtg9 in fed and starved conditions appear to differ, 
suggesting that the mAtg9 complexes may change between fed and starved conditions. 
A smear of WIPI2 was consistently seen after treatment with crosslinker with no 
distinct changes in molecular weight and the majority of the WIPI2 signal was still 
present as a major band at around 49 kDa, representing monomeric WIPI2, even with 
treatment of 2 mM BSOCOES, and with UV-activated crosslinkers tried (data not 
shown). The reasons for this are unclear. The antibodies used for western blotting pick 
up all of the WIPI2 isoforms and a number of isoforms, including isoforms WIPI2a and 
WIPI2c, do not form starvation-induced puncta (Mauthe et al., 2011). Additionally, a 
large proportion of WIPI2 protein is cytosolic, while a smaller portion of the protein 
binds the membrane in a wortmannin-independent manner (Polson et al., 2010). It may 
be that WIPI2 forms isoform-specific complexes, and that these complexes make up the 
smear upon crosslinking, while some isoforms remain monomeric. To clarify this, 
crosslinking would have to be performed on cells expressing tagged isoforms of WIPI2. 
I continued crosslinking optimisation by focusing on mAtg9. 
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Figure 3.3 BSOCOES optimisation 
HEK293A cells were treated with full medium (Fed) or starvation medium (Starved) for 
two hours before treatment with the indicated concentration of BSOCOES for 30 
minutes. Cells were then lysed in 0.3% triton X-100 TNTE and used for western blot 
with antibodies against EEA1 (a), mAtg9 (b) or WIPI2 (c). Molecular weights are in 
kDa. 
 
3.2.2 Deuterated crosslinking and mAtg9 immunoprecipitation 
DSS and BSOCOES crosslinkers have the same amine-reactive groups. BSOCOES 
effectively crosslinked mAtg9 at all three concentrations tried (0.5, 1.0, 2.0 mM). In 
order to minimise the time for which the cells were treated with crosslinker, I used 2 
mM DSS and tried varying the time of cell incubation with crosslinker (Figure 3.4 a and 
b). The most effective crosslinking (as judged by appearance of higher molecular 
weight EEA1) was at 1 hour crosslinking with 2 mM DSS.  
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Following time optimisation, I ensured that I could effectively 
immunoprecipitate mAtg9 from crosslinked cell lysates. HEK293A cells were treated 
with 2 mM DSS on ice for 1 hour before cell lysis in RIPA buffer and mAtg9 
immunoprecipitation. RIPA buffer contains the ionic detergents SDS and NP-40 and is 
therefore more denaturing than milder lysis buffers such as TNTE. I decided to use 
RIPA in order to try and increase the proportion of crosslinked interactions detected 
during mass spectroscopy by minimising non-crosslinked interactions between mAtg9 
and its interactors. I had previously optimised mAtg9 immunoprecipitation in RIPA 
buffer (data not shown). mAtg9 was effectively immunoprecipitated from DSS-treated 
samples (Figure 3.4 c). The mAtg9 band at its monomeric molecular weight of 95 kDa 
can be faintly seen in the input and beads alone unbound lane with no DSS treatment. 
This band is not present in the input after DSS treatment, and a higher molecular weight 
band at a molecular weight of 225 kDa appears and is effectively immunoprecipitated, 
suggesting that both crosslinking and immunoprecipitation worked. The ladder of 
higher molecular weight bands seen after immunoprecipitation of mAtg9 (in both 
DMSO and DSS treated samples) have been seen previously by Jemma Webber (a 
previous PhD student in the lab) following endogenous mAtg9 immunoprecipitation. It 
is not clear whether they are SDS-resistant complexes of mAtg9 or background bands 
from the rabbit anti-Atg9 antibody used for immunoprecipitation that are cross-reacting 
with the hamster anti-Atg9 used for western blot. 
 To ensure that I could immunoprecipitate enough mAtg9 to be detected by mass 
spectrometry, I scaled-up the endogenous immunoprecipitation of mAtg9 from one 10 
cm plate per immunoprecipitation, to four 15 cm plates and found that with this number 
of HEK392A cells, a band that could be mAtg9 can be seen at the correct molecular 
weight for monomeric mAtg9 by colloidal Coomassie staining (data not shown). 
Following this, I performed a large-scale crosslinking and immunoprecipitation 
experiment in which I used four 15 cm plates treated with negative control DMSO, and 
four 15 cm plates treated with a 1:1 ratio of DSS and DSS-d4 at a total concentration of 
2 mM for 1 hour on ice. The cells were subsequently lysed using RIPA buffer and 
immunoprecipitated with rabbit anti-mAtg9 antibody. The products of 
immunoprecipitation were run on an SDS-PAGE gel and stained with colloidal 
Coomassie stain. The immunoprecipitation product from the DMSO-treated control 
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showed a band at the correct molecular weight along with banding above this weight, 
and the crosslinked-treated immunoprecipitation showed a reduced band at the correct 
size for monomeric mAg9, a reduced banding above this size and an increase in the 
high molecular weigh complexes at the top of the colloidal Coomassie-stained gel (data 
not shown). The samples were analysed by Mark Skehel and colleagues at the LRI mass 
spectrometry facility at the Clare Hall laboratories. Unfortunately, they were unable to 
detect any mass spectra peaks that corresponded to deuterated and non-deuterated 
crosslinked peptides, either because the spectrum was too complex to analyse or 
because the peptides were below the detection threshold. At this stage other areas of my 
work were showing more promise and so this area of my project was stopped. 
 
 
Figure 3.4 DSS optimisation and mAtg9 immunoprecipitation following crosslinking 
(a,b) HEK293A cells were treated with 2 mM DSS for the indicated time before 
western blotting analysis with (a) anti-EEA1 and (b) anti-mAtg9 antibodies. (c) 
HEK293A cells were treated with either DMSO as a negative control or 2 mM DSS for 
one hour before cell lysis in RIPA buffer and mAtg9 immunoprecipitation and western 
blot analysis. Molecular weights are in kDa. EEA1 and mAtg9 monomers and higher 
molecular weigh complexes are as indicated in Figure 3.3 
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3.3 mAtg9 interactor validation 
Andrea Orsi found transferrin receptor (TfR) and Syntaxin 13 (Stx13) in his mass 
spectrometry screen for mAtg9 interactors using HA-mAtg9 transiently transfected 
HEK293A cells. TfR is a carrier for transferrin (which binds free iron) and is removed 
from the plasma membrane by clathrin-mediated endocytosis into early endosomes, 
before being sorted in recycling endosomes and recycled to the plasma membrane (van 
Dam and Stoorvogel, 2002). Syntaxin 13 is a Q-SNARE required for recycling of 
internalised proteins, including TfR, to the plasma membrane and is localised on early 
and recycling endosomes (Prekeris et al., 1998). mAtg9 binding to, or colocalising in 
the same compartment as, TfR and Stx13 would suggest that mAtg9 is at least partially 
localised to the recycling endosome. I used endogenous immunoprecipitation of mAtg9 
to try and validate Andrea Orsi’s data suggesting that mAtg9 interacts with TfR and 
Stx13. I found that TfR, but not Stx13, co-immunoprecipitated with endogenous mAtg9 
after cell lysis using CHAPS buffer (Figure 3.5 a and b). CHAPs lysis buffer was used 
as it results in efficient Atg9 immunoprecipitation (Jemma Webber, thesis). CHAPS is a 
non-denaturing lysis buffer and so it is possible that the mAtg9-TfR interaction is not 
direct and may instead be the result of mAtg9 and TfR interacting through another 
protein or their colocalisation within a lipid raft. This result supports other data 
suggesting that mAtg9 is localised in the Atg9 compartment, as in yeast, which are 
thought to be tubular-vesicular clusters which traffic through other membrane 
compartments, including early and recycling endosomes (Mari et al., 2010, Orsi et al., 
2012). 
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Figure 3.5 Atg9 co-immunoprecipitates TfR, but not Stx13 
(a) HEK293A cells were lysed with CHAPS lysis buffer before immunoprecipitation 
with anti-mAtg9 antibodies, or beads alone control before western blot analysis. (b) 
Cells lysed as for (a) and immunoprecipitated with anti-mAtg9 antibody or controls 
beads alone, and non-relevant antibody (N.R.) (WIPI1 polyclonal antibody) at 1X or 2X 
the concentration of mAtg9 antibody before western blot analysis. 
 
3.4 Validation of the Atg16L1-WIPI2b interaction 
3.4.1 Validation of the interaction between the Atg12–5-16L1 complex and 
WIPI2b using GFP-tagged proteins 
The main approach to interactor validation is usually endogenous co-
immunoprecipitation of the complex. However, co-immunoprecipitation of the Atg12–
5-16L1 complex with WIPI2 had proven difficult and had not been achieved in attempts 
made previously by Hannah Polson before she left the lab. I therefore began my 
approach to validating the interaction by repeating some of Hannah’s work done using 
GFP-tagged proteins. As expected, GFP-Trap of transiently over expressed GFP-
WIPI2b co-immunoprecipitated endogenous Atg16L1 in both fed and starved 
conditions, whereas GFP-Trap of transiently over expressed GFP (control) did not 
(Figure 3.6 a). Similarly, endogenous Atg16L1 co-immunoprecipitated with GFP (or 
CFP)-tagged proteins from cells transiently transfected with WIPI2b or known 
interactors Atg5 and Rab33B, but not with WIPI2a or WIPI1a (Figure 3.6 b). WIPI2a is 
an isoform of WIPI2 that differs from WIPI2b by an 18 amino acid insert in blade 1 of 
the 7-bladed β propeller of WIPI2 (Figure 1.8b). This insertion renders WIPI2a both 
unable to bind Atg16L1 (Figure 3.6 b) and unable to form puncta upon autophagy 
initiation (Dooley et al., 2014, Mauthe et al., 2011). 
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In Hannah Polson’s validation of WIPI2b interaction with the Atg12–5-16L1 
complex, she established that the interaction was likely to be mediated through 
Atg16L1 by co-immunoprecipitating FLAG-Atg16L1 ΔN (which can not bind the 
Atg5–12 conjugate) through GFP-WIPI2b (Figure 3.11). Therefore, I tried to validate 
the interaction between WIPI2b and the Atg12–5-16L1 complex by overexpressing 
GFP-Atg16L1 and using GFP-Trap to look for co-immunoprecipitated endogenous 
WIPI2 (Figure 3.7). While positive control FIP200 came down with GFP-Atg16L1, 
WIPI2 did not.  
 
 
Figure 3.6 GFP-WIPI2 co-immunoprecipitates the Atg12–5-16L1 complex 
(a) HEK293A cells transiently transfected with either GFP or GFP-WIPI2b were treated 
with full medium (F) or EBSS (S) for two hours as indicated before cell lysis and GFP-
Trap. Protein complexes were analysed by western blot. (b) HEK293A cells were 
transiently transfected with the indicated constructs before cell lysis and GFP-Trap. 
Protein complexes were analysed by western blot. All molecular weights are shown in 
kDa. 
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Figure 3.7 GFP Trap of GFP-Atg16L1 
Cell lysates from HEK293A cells transiently overexpressing GFP or GFP-Atg16L1 
were used for GFP-Trap followed by western blot using the indicated antibodies. 
Molecular weights are shown in kDa. 
 
3.4.2 Validation of the interaction between the Atg12–5-16L1 complex and 
WIPI2b using myc-WIPI2b 
At this stage in my project I was unable to co-immunoprecipitate endogenous Atg12–5-
16L1 with endogenous WIPI2b and as the only way in which I could demonstrate the 
WIPI2-Atg16L1interaction was though GFP-Trap of GFP-WIPI2b, I was concerned that 
the interaction could be an artefact of the GFP-WIPI2b construct. I therefore tried to co-
immunoprecipitate in vitro translated, [35S] methionine-labelled HA-Atg16L1 with 
myc-tagged WIPI2b. Hannah Polson mapped the WIPI2b-Atg16L1 interaction to the 
coiled coil domain of Atg16L1 (Figure 3.11) and so I used Atg16L1 FL and HA-
Atg16L1 1-207 to try to begin mapping the WIPI2 binding site more finely. Although 
myc-Atg5 co-immunoprecipitated in vitro translated Atg16L1 FL and HA-Atg16L1 1-
207, myc-WIPI2b did not co-immunoprecipitate Atg16L1 (Figure 3.8a). However, co-
immunoprecipitation of in vitro translated Atg16L1 FL, but not 1-207, with GFP-Trap 
of GFP-WIPI2b worked (Figure 3.8b). This result suggests that the interaction observed 
between GFP-WIPI2b and Atg16L1 is not an artefact and further suggests that WIPI2b 
binds between 207 and 265 of Atg16L1.The western blot of the myc-
immunoprecipitation, performed before mixing the myc-immunoprecipitation beads 
with the in vitro translated Atg16L1, showed a large amount of myc-tagged protein in 
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the unbound lysates (Figure 3.8a), whereas the GFP-Trap completely cleared GFP-WIPI 
from the unbound (Figure 3.8b). By running the myc-IP and GFP-Trap alongside each 
other and using an anti-WIPI2 antibody for western blot, the efficiencies of transfection 
and immunoprecipitation can be directly compared (Figure 3.8c). While the expression 
levels of myc-WIPI2b and GFP-WIPI2b were similar (input lanes), the myc-
immunoprecipitation was very inefficient compared to GFP-Trap. This may provide an 
explanation as to why co-immunoprecipitation of Atg16L1 with myc-WIPI2b had not 
worked so far. The inefficiency of the myc-immunoprecipitation may have been due to 
the myc-WIPI constructs having a single myc-tag; multiple myc-tags may have 
improved the efficiency of the immunoprecipitation. 
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Figure 3.8 Comparison of myc- and GFP-tagged WIPI2b immunoprecipitation 
(a) Cell lysates from HEK293A cells transiently transfected with pcDNA3.1(-) control, 
myc-tagged Atg5, WIPI1a or WIPI2b were used for immunoprecipitation with anti-myc 
antibodies. Immunoprecipitated product was mixed with in vitro translated [35S] 
methionine labelled HA-Atg16L1 1-207 or full length Atg16L1, and the co-
immunoprecipitated radiolabelled protein was visualised using autoradiography (left 
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hand panel). Right hand panel shows western blot of myc-IP. (b) As for (a) but using 
cell lysates from HEK293A cells transiently transfected with pcDNA3.1(-) control, 
GFP-WIPI1a or GFP-WIPI2b for GFP-Trap. Right hand panel shows western blot of 
GFP-Trap. (c) comparison of the efficiency of immuoprecipitation of myc- and GFP-
WIPI2b using anti-myc antibodies and GFP-Trap, respectively. Immunoprecipitated 
tagged WIPI2b was visualised by immunoblotting using anti-WIPI2 antibody. 
Molecular weights are in kDa. 
 
3.4.3 Validation of the endogenous interaction between the Atg12–5-16L1 
complex and WIPI2b using crosslinking 
The difficulty of co-immunoprecipitating the Atg12 5-16L1 complex with endogenous 
WIPI2b is suggestive of a weak or transient Atg16L1-WIPI2 interaction. If so, this 
would be similar to the Atg16L1-FIP200 interaction, which can only be co-
immunoprecipitated using endogenous proteins when the interaction is stabilised either 
in Atg3 KO MEFs, where the phagophore is stalled before LC3 lipidation, or using the 
amine-reactive crosslinker DSP (Nishimura et al., 2013, Gammoh et al., 2013). I 
investigated whether DSP could stabilise any interaction between the Atg12–5-16L1 
complex and WIPI2b sufficiently to enable co-immunoprecipitation by treating HEK 
293A cells with DSP at either 0.5 or 1.0 mM for 30 minutes before cell lysis and 
subsequent immunoprecipitation using antibodies against WIPI2 (Figure 3.9). Treating 
the cells with either 0.5 or 1.0 mM DSP resulted in co-immunoprecipitation of the 
Atg12–5-16L1 complex with WIPI2.  
 After successfully co-immunoprecipitating the Atg12–5-16L1 complex through 
WIPI2, I tried to perform the reverse co-immunoprecipitation through endogenous 
Atg16L1 (Figure 3.10). Attempts to do this were unsuccessful, even though endogenous 
Atg16L1 was effectively depleted from the unbound lysate. WIPI2 runs at 
approximately 49 kDa, and so the signal is often obscured by signal from the heavy 
chain (even when different species of antibody are used for immunoprecipitation and 
western blotting as in Figure 3.10). Given more time I would readdress this issue by 
crosslinking the Atg16L1 antibody to beads prior to immunoprecipitation as it may be 
possible that WIPI2 signal is obscured by the heavy chain in Figure 3.10. 
 As described in 3.4.1, the interaction between GFP-WIPI2b and the Atg12–5-
16L1 complex is not starvation-dependent. To confirm that this is also the case with the 
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interaction between endogenous proteins, I compared co-immunoprecipitation between 
fed and starved HEK 293A cells and saw no change in interaction with a change in 
starvation state (data not shown). This result is consistent with data using GFP-WIPI2b 
(Figure 3.6), and is also similar to the Atg16L1-FIP200 interaction, which is starvation 
independent (Nishimura et al., 2013). 
 
 
Figure 3.9 Endogenous co-immunoprecipitation of WIPI2 and Atg12-5-16L1 
HEK293A cells were treated with DSP crosslinker at the indicated concentrations, 
before being lysed and used for WIPI2 immunoprecipitation followed by SDS-PAGE 
and western blot analysis. Molecular weight is in kDa. 
 
 
Figure 3.10 Endogenous immunoprecipitation of Atg16L1 
HEK293A cells were treated with DSP crosslinker at the indicated concentrations, 
before being lysed and used for Atg16L1 immunoprecipitation followed by SDS-PAGE 
and western blot analysis. Molecular weight is in kDa. 
 
3.5 Mapping the WIPI2b binding site on Atg16L1 
3.5.1 Atg16L1 is the member of the Atg12–5-16L1 complex that is 
responsible for interacting with WIPI2b 
Previous work has shown that Atg16L1 is the member of the Atg12–5-16L1 complex 
through which the whole complex is recruited to the forming autophagosome membrane 
(Fujita et al., 2008). Specifically, the region of Atg16L1 that contains the coiled coil 
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domain, the region encompassing amino acids 79-265, is the region that is thought to 
mediate membrane localisation (Fujita et al., 2008) (see Chapter 1.3.5.3). Hannah 
Polson used fragments of Atg16L1 in her initial validation experiments to determine 
whether the interaction between the Atg12–5-16L1 complex and WIPI2b is mediated 
through Atg5–12 or Atg16L1. She transiently overexpressed FLAG-tagged Atg16L1 
constructs in stably expressing GFP-WIPI2b HEK 293A cells before utilising GFP-Trap 
to look for co-immunoprecipitation of FLAG-Atg16L1 with GFP-WIPI2b (Figure 3.11 
a and b). Deletion of the N- or C-terminus of Atg16L1 had no effect on binding to 
WIPI2b (Figure 3.11a). The interaction between Atg16L1 and the Atg5–12 conjugate is 
mediated by Atg5 and the N-terminal domain of Atg16L1 and so Atg16L1 ΔN does not 
bind the Atg5–12 conjugate. Therefore, the interaction between FLAG-Atg16L1 ΔN 
and GFP-WIPI2b demonstrates that the Atg5–12 conjugate is not needed for the 
interaction between Atg16L1 and WIPI2b, indicating that the interaction with WIPI2b 
is mediated by Atg16L1. In addition, deletion of either the N- or C-terminus of 
Atg16L1 had no effect on WIPI2b binding, showing that the Atg16L1-WIPI2b 
interaction must be mediated through the middle region of Atg16L1: amino acids 79-
265. These results were supported by results that Hannah obtained when using transient 
overexpression of untagged human Atg16L1 in the GFP-WIPI2b stable cell line. She 
found that Atg16L1 full length and ΔWD were co-immunoprecipitated with GFP-
WIPI2b. However, deletion of the coiled coil domain (amino acids 69-213) rendered 
Atg16L1 unable to bind WIPI2b (Figure 3.11b). 
Chapter 3 Results 
 
 113 
 
Figure 3.11 WIPI2b binds Atg16L1 between amino acids 79 and 265 
(a) Schematic of mouse Atg16L1 constructs used. White N-terminal box represents the 
Atg5 binding domain. Black box represents the coiled-coil domain of Atg16L1. 
Stripped box represents the WD-40 domain. Adapted from (Fujita et al., 2008). (b) 
Untransfected (Un), full length (FL), 79-623 or 1-265 FLAG-tagged Atg16L1 
constructs were transiently transfected in HEK293A cells stably expressing GFP-
WIPI2b before being used for GFP-Trap. Tags were visualised by immuoblot. (c) 
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Schematic of human Atg16L1 constructs sued. Boxes as for (a). Adapted from (Fujita et 
al., 2009). (d) Untransfected, full length, ΔCCD and ΔWD Atg16L1 were transiently 
transfected into HEK293A cells stably expressing GFP-WIPI2b and the cell lysates 
were used GFP-Trap. Protein complexes were visualised by immunoblot using the 
indicated antibodies. Molecular weights are in kDa. (b) and (d): data and panels 
provided by Hannah Polson. 
 
3.5.2 The WIPI2b binding site on Atg16L1 is located between amino acids 
207-230 
As the interaction between Atg16L1 and WIPI2b seems to be mediated by a region 
contained within 207-265 of Atg16L1 (Figures 3.8 and 3.11), I used site directed 
mutagenesis to produce a series of C-terminal truncations of FLAG-Atg16L1 to further 
map the interaction site on Atg16L1 (Figure 3.12 a). The truncations at amino acids 242 
and 230 were chosen in light of data published on Atg16L2 (Ishibashi et al., 2011). This 
study showed that Atg16L2, a homologue of Atg16L1, can form an Atg12–5-16L2 
complex but cannot function in autophagy due to its inability to bind the phagophore 
membrane. The authors postulated that amino acids 229-242 of Atg16L1 are the 
residues that are required for Atg16L1 localisation to membrane, possibly through 
binding either directly to the phagophore membrane or an unidentified phagophore-
localised protein. Our working model is that WIPI2b may be the membrane-localised 
protein that is binding Atg16L1 and subsequently recruiting the Atg12–5-16L1 complex 
to the site of autophagosome formation. If this is true then loss of amino acids 229-242 
may result in loss of WIPI2b binding. Atg16L1 forms homodimers through its coiled 
coil domain (Fukuda and Itoh, 2008). I was concerned that when overexpressed in HEK 
293A cells the C-terminal deletions would form heterodimers with endogenous 
Atg16L1, which would then able to bind to WIPI2b. In an attempt to minimise this, I 
used in vitro translation using [35S] methionine to express radioactive FLAG-Atg16L1 
truncations in a cell-free system before mixing with GFP (negative control), CFP-Atg5 
(positive control), GFP-WIPI2b or GFP-WIPI1a attached to GFP-Trap beads (Figure 
3.12 b and c). Atg16L1 1-265 was co-immunoprecipitated with GFP-WIPI2b and CFP-
Atg5, as expected, but not GFP or GFP-WIPI1a, as is seen with full length FLAG-
Atg16L1 (Figures 3.1 c and 3.6 b). The same result was seen for Atg16L1 1-242. 
Atg16L1 1-230 bound GFP and CFP-Atg5 as expected, but I repeatedly saw an increase 
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in binding of this truncation to GFP-WIPI2b and GFP-WIPI1a when compared to 
binding seen for Atg16L1 1-265 or 1-242. Truncation of Atg16L1 at amino acid 207 
abolished binding to either GFP-WIPI1a or GFP-WIPI2b, but not to CFP-Atg5. These 
results suggest that the binding site for WIPI2b on Atg16L1 is located between amino 
acids 207 and 230, and that the truncation at amino acid 230 may reveal some 
conformation-sensitive binding site that enables an increased binding of Atg16L1 to 
both WIPI1a and WIPI2b. From these results, it appears that wild-type binding to 
WIPI2b is conferred by amino acids 207-242. 
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Figure 3.12 WIPI2b binds Atg16L1 between amino acids 207 and 230 
(a) Schematic of mouse Atg16L1 constructs used. White N-terminal box represents the 
Atg5 binding domain. Black box represents the coiled-coil domain of Atg16L1. 
Stripped box represents the WD-40 domain. Adapted from (Fujita et al., 2008). (b) 
HEK293A cells transiently expressing controls GFP, CFP-Atg5, GFP-WIPI1a or GFP-
WIPI2b were used for GFP-Trap, the products of which were mixed with the indicated 
in vitro translated [35S] methionine-labelled FLAG-Atg16L1 before protein complexes 
were resolved by SDS-PAGE and visualised by autoradiography (upper panel). Lower 
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panel is colloidal Coomassie-stained gel. (c) Western-blot of GFP-Traps used for (b). 
Molecular weights are in kDa. 
 
3.5.3 WIPI2b does not bind Atg16L2 
Amino acids 207-242 encompass the region 229-242, which was identified as being 
important for Atg16L1 puncta formation following amino acid starvation and which is 
not conserved in Atg16L2, possibly rendering Atg16L2 unable to bind to the 
phagophore membrane or a membrane localised protein (Ishibashi et al., 2011). It 
therefore follows that if WIPI2b is the protein that localises Atg16L1 to the phagophore, 
Atg16L2 will not bind WIPI2b. GFP-Trap of Flag-Atg16L2 shows that this is the case 
(Figure 3.13). GFP-WIPI1a binding to Atg16L1 seems to be variable. When over 
expressed Atg16L1 is used, GFP-Trap of GFP-WIPI1a co-immunoprecipitates Atg16L1 
to a greater extent than the GFP control does. However, when only GFP-WIPI1a is 
overexpressed, GFP-trap of GFP-WIPI1a does not co-immunoprecipitate endogenous 
Atg16L1 to a greater degree than the GFP control. It may be that the WIPI1a-Atg16L1 
interaction is much weaker than that of WIPI2b-Atg16L1, and so the WIPI1a-Atg16L1 
interaction is only detected when both proteins are overexpressed. 
 
 
Figure 3.13 GFP-WIPI2b does not bind Atg16L2 
Cell lysates from HEK293A cells transiently overexpressing GFP, GFP-WIPI1a or 
GFP-WIPI2b were mixed with cell lysates from FLAG-Atg16L1 or FLAG-Atg16L2 
transiently expressing cells and used for GFP-Trap. Immuoprecipitated protein 
complexes were visualised using western blot. Molecular weights are in kDa. 
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3.5.4 Atg16L1 E226 and E230 are required for WIPI2b binding 
WIPI2b does not bind Atg16L2 and the binding region for WIPI2b on Atg16L1 is 
between 207 and 242. Therefore, alignment of Atg16L1 and Atg16L2 in this region 
may provide some indication of the residues that are important for WIPI2b binding. In 
collaboration with Dr Michael Wilson at the Babraham Institute, Cambridge, UK, we 
identified from the alignment of Atg16L1 and Atg16L2 between amino acids 207 and 
242 of Atg16L1 that this stretch of Atg16L1 is much more acidic than that of Atg16L2 
(Figure 3.14). To determine whether or not these acidic residues in Atg16L1 are 
important for interaction with WIPI2b, I point mutated each of the non-conserved acid 
residues to arginine to mimic the charge on Atg16L2 (Figure 3.14). GFP-Trap of GFP-
WIPI2b shows that mutation of either Atg16L1 E226 or E230 significantly reduces 
FLAG-Atg16L1 interaction with GFP-WIPI2b (Figure 3.15 a and b). This result 
suggests that these sites are critical for WIPI2b binding and explains why FLAG-
Atg16L1 1-207 cannot bind WIPI2b, and may also explain why FLAG-Atg16L1 1-230 
shows an increased binding to both WIPI1a and WIPI2b. Truncation just after E230 
may mean that the WIPI binding site is sterically unhindered, as the Atg16L1 protein C-
terminal to this is removed, and so the WIPI binding site may be able to form a complex 
with either WIPI1a or WIPI2b more readily. 
 
 
Figure 3.14 Alignment of Atg16L1 and Atg16L2 between amino acids 207 and 265 
Alignment between Atg16L1 and Atg16L2 in the WIPI2b binding region of Atg16L1. 
Non-conserved acidic residues on Atg16L1 are coloured red. Basic residues on 
Atg16L2 are blue, and non-charged residues are green. 
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Figure 3.15 WIPI2b binds amino acids E226 and E230 of Atg16L1 
(a) Cell lysate from HEK293A cells transiently overexpressing GFP-WIPI2b was mixed 
with cell lysates from HEK293A cells overexpressing the indicated FLAG-tagged 
Atg16L1 and Atg16L2 constructs before being used for GFP-Trap. Protein complexes 
were visualised by western blot. Molecular weights are in kDa. (b) Statistical analysis 
of (a). The SEM for four independent experiments is shown. Statistical analysis was 
performed by Student’s t test. ***, p ≤0.001, ****, p ≤0.0001. 
 
3.5.5 Atg16L1 D237, D238, D239 and E241 are required for FIP200 binding 
At this stage of characterising the Atg16L1-WIPI2b interaction, two separate studies 
showing that FIP200 binds Atg16L1 and that this interaction is required for Atg12–5-
16L1 complex recruitment to the forming autophagosome were published (Nishimura et 
al., 2013, Gammoh et al., 2013). These papers demonstrated that the FIP200 binding 
domain (FBD) is between amino acids 230 and 300 of Atg16L1 (Nishimura et al., 2013) 
or amino acids 229 and 242 (Gammoh et al., 2013). From these data, the minimal 
region required for FIP200 binding can be assumed to be 230-242. This region includes 
amino acid E230 of Atg16L1 that is required for WIPI2b binding (Figure 3.15). FIP200 
binds Atg16L1 directly (Nishimura et al., 2013, Gammoh et al., 2013) and so the 
overlap of the WIPI2b and FIP200 binding sites on Atg16L1 raises the possibility that 
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FIP200 mediates the interaction between WIPI2b and Atg16L1, or that FIP200 and 
WIPI2b binding sites are mutually exclusive. To establish if the binding sites of WIPI2b 
and FIP200 overlap, I investigated the effect of the Atg16L1 point mutants (Figure 
3.14) on FIP200 binding (Figure 3.16 a and b). I found that mutation of Atg16L1 D237, 
D238, D239 or D241 to arginine significantly reduced the binding of endogenous 
FIP200 to FLAG-Atg16L1, and that E235R reproducibly reduced binding although this 
effect was not significant. Results shown in Figures 3.15 and 3.16 demonstrate that 
WIPI2b and FIP200 have independent binding sites. The charge change mutations that 
affect WIPI2b binding have no significant effect on FIP200 binding, and vice versa. 
Note, FIP200 did not bind FLAG-Atg16L2 as expected from previous work (Gammoh 
et al., 2013). 
 Following this fine mapping of the FIP200 interaction site, a third paper was 
published detailing the Atg16L1-FIP200 interaction (Fujita et al., 2013). This paper 
mapped the interaction using alanine scanning in sets of five amino acids in a yeast two-
hybrid experiment, therefore mapping the interaction site more finely than previous 
papers to between Atg16L1 239-246. In light of results from this paper, I extended the 
region over which I mutated acidic residues that are not conserved on Atg16L2. I used 
FLAG-tagged Atg16L1 E246R and Atg16L1 D249R to determine whether endogenous 
FIP200 can bind these charge changed mutants (Figure 3.17). I found that FIP200 co-
immunoprecipitation with FLAG-Atg16L1 mutants was recovered to near wild type 
levels for E246R and D249R when compared to D235 and D237. This is similar to 
published results, although I did not find that mutants at Atg16L1 E246 or D249 had an 
effect, which I was expecting in light of previous work (Fujita et al., 2013). The reason 
for this difference could be either because of the difference between yeast two hybrid 
and co-immunoprecipitation using over expressed Atg16L1 or because of the difference 
in mutations: previous work by Fujita et al. used five adjacent alanine mutations, 
whereas I used single charge changed mutations. 
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Figure 3.16 FIP200 binds amino acids D237, D238, D239 and E241 of Atg16L1 
(a) Cell lysates from HEK293A cells overexpressing the indicated FLAG-tagged 
Atg16L1 and Atg16L2 constructs were used for FLAG immunoprecipitation with 
FLAG M2 agarose beads. Protein complexes were visualised by western blot. (b) 
Statistical analysis of (a). The SEM for three independent experiments is shown. 
Statistical analysis was performed by Student’s t test. *, p≤0.05. **, p≤0.01. Molecular 
weight is shown in kDa. 
 
 
Figure 3.17 Atg16L1 E246R and D249R do not affect FIP200 binding 
HEK293A cells transiently overexpressing the indicated FLAG-Atg16L1 constructs 
were used for FLAG immunoprecipitation using FLAG M2 agarose beads. Protein 
complexes were visualised using western blot. Molecular weight is shown in kDa. 
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3.5.6 WIPI2b and FIP200 bind separate sites on and bind independently 
to Atg16L1 
Fine mapping of the WIPI2b and FIP200 binding sites on Atg16L1 show that the acidic 
residues required for the interactions do not overlap. However, the footprint of the 
proteins at the binding sites may be larger than the size of the sites suggested by the fine 
mapping experiments. This leads to the possibility that there may be some form of 
regulation of Atg16L1 binding between WIPI2b and FIP200, which result in 
cooperative or mutually exclusive binding. 
 In order to determine if there is cooperation or mutual exclusion between 
WIPI2b and FIP200 binding to Atg16L1, I used double charge change point mutants of 
Atg16L1. Results in Chapters 3.5.4 and 3.5.5 strongly suggest that there is no 
requirement for WIPI2b binding to allow FIP200 binding to Atg16L1, or vice versa, as 
mutations that significantly reduced either WIPI2b or FIP200 binding had no significant 
effect on Atg16L1 interaction. However, to make sure that the point mutants used 
completely abolish binding to Atg16L1, I used double charge change point mutants: 
FLAG-Atg16L1 E226R E230R (ERER) to disrupt WIPI2b binding and FLAG-Atg16L1 
D237R D239R (DRDR) to disrupt FIP200 binding, before looking for co-
immunoprecipitation of FIP200 and WIPI2b respectively (Figure 3.18). Abolition of 
WIPI2b binding had no effect on FIP200 binding, and vice versa in this system. 
Interestingly, endogenous FIP200 was co-immunoprecipitated through FLAG-Atg16L1 
WT when using GFP-Trap for GFP-WIPI2b immunoprecipitation, showing that a 
trimeric complex of FIP200-Atg16L1-WIPI2b can be formed when both Atg16L1 and 
WIPI2b overexpressed. Endogenous co-immunoprecipitation of Atg16L1 with WIPI2 
from FIP200 knockout MEFs shows that WIPI2 and Atg16L1 interact in the absence of 
FIP200 (Figure 3.19 a). There was a general trend, seen in all three experiments, for a 
greater amount of Atg16L1 to be co-immunoprecipitated with WIPI2 from FIP200 KO 
MEFs compared the to co-immunoprecipitation seen from the FIP200 wild type MEFs. 
However, this trend was not significant (Figure 3.19 b). Together, these result show that 
FIP200 binding to Atg16L1 is not required for WIPI2b to bind Atg16L1, and vice versa, 
and that WIPI2b and FIP200 are able to bind Atg16L1 at the same time. 
 The binding sites on Atg16L1, as mapped by charge change point mutations 
(Figures 3. 15 and 3.16) place the WIPI2b and FIP200 binding sites on either side of a 
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four amino acid stretch that includes two prolines (Figure 3.14). Modelling of the region 
207- 265 of Atg16L1 by Michael Wilson predicts that the WIPI2b and FIP200 binding 
sites lie on either side of this proline-induced loop that separates the sites (Figure 3.20). 
It is possible that the separation of the sites by this loop would allow for both proteins to 
bind either independently or together.  
 
 
Figure 3.18 Atg16L1 mutants unable to bind WIPI2b can bind FIP200, and vice versa 
HEK293A cells stably expressing GFP-WIPI2b were transiently transfected with mock 
transfection, Atg16L1 WT, E226R E230R (ERER), or D237R D239R (DRDR) were 
used for GFP-Trap or FLAG-immunoprecipitation using FLAG M2 agarose beads. 
Protein complexes were visualised by western blot using the indicated antibodies. 
Molecular weights are in kDa. 
 
 
Figure 3.19 Atg16L1-WIPI2 co-immunoprecipitation in FIP200 KO MEFs 
(a) FIP200 wild type (WT) and knock out (KO) MEF cells were treated with 0.5 mM 
DSP crosslinker for 30 minutes before cell lysis and immunoprecipitation with anti-
WIPI2 antibodies and protein complex analysis by western blot. (b) Statistical analysis 
of (a). The SEM for three independent experiments is shown. Results were analysed by 
Student’s t-test, ns, not significant. Molecular weights are in kDa. 
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Figure 3.20 Structural model of Atg16L1 207-265 
Structural model of the region of Atg16L1 (207-246) that interacts with WIPI2b and 
FIP200. Residues required for FIP200 or WIPI2b binding are labelled in blue and 
purple, respectively. Modelling and figure provided by Michael Wilson. 
 
3.6 Mapping the Atg16L1 binding site on WIPI2b 
3.6.1 WIPI2b binds Atg16L1 through its WD-40 domain 
The mammalian WIPI proteins, along with their yeast homologues, are members of the 
PROPPIN (β-propellers that bind polyphosphoinositides) family. These proteins contain 
WD-40 domains, which form β-propellers. WD-40 domains are one of the most 
abundant protein motifs in the eukaryotic genome and are involved in protein-protein or 
protein-DNA interactions (Xu and Min, 2011). In light of this, it is highly probable that 
WIPI2b binds Atg16L1 through a region on its β-propeller, rather than through its C-
terminal extension. Hannah Poslon previously showed that deletion of the C-terminus of 
WIPI2b did not disrupt Atg16L1 binding (data not shown). To confirm this, I used a C-
terminal deletion of GFP-WIPI2b (WIPI2b ΔCT) to test for an effect on Atg16L1 
binding. I used GFP and GFP-WIPI2b as negative and positive controls respectively, 
and at the same time tested for Atg16L1 binding by GFP-tagged WIPI2a, WIPI1a, and 
WIPI1a ΔCT (Figure 3.21). GFP-WIPI2b bound as expected. GFP-WIPI2b ΔCT 
retained the ability to bind Atg16L1, demonstrating that the interaction is not mediated 
by the C-terminus. Surprisingly, the interaction with Atg16L1 was significantly 
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increased by deletion of the C-terminus of WIPI2b and similarly, deletion of the C-
terminus of WIPI1a conferred Atg16L1 binding ability to a significantly higher degree 
than full length GFP-WIPI1a. The C-termini of WIPI1 and WIPI2 are relatively 
different when compared to the WD-40 domain of the proteins (Figure 1.9) and this, 
along with differences within their β-propellers, may be a possible explanation for the 
different binding partners of WIPI1 and WIPI2.  
 The WIPI2-Atg16L1 interaction is not affected by starvation (Figures 3.1 and 
3.6) and Hannah Polson previously showed that WIPI2 with a mutated PtdIns(3)P 
binding domain (FTTG) also had an unaltered Atg16L1 binding ability (data not shown). 
I also found that GFP-WIPI2b FTTG showed no significant difference in Atg16L1 
binding (Figure 3.22 a and b). These results suggest that the binding site for Atg16L1 is 
not altered by WIPI2 binding PtdIns(3)P. GFP-WIPI2a or GFP-WIPI1a did not co-
immunoprecipitate endogenous Atg16L1 (Figure 3.21 and 3.22). WIPI2a is identical to 
WIPI2b except for an 18 amino acid insertion between sheets β1 and β2 of the first 
blade of the 7-bladed β-propeller (Figure 1.8). This insertion renders WIPI2a both 
unable to bind Atg16L1 (Figure 3.21 a and 3.22) and unable to form puncta upon 
autophagy initiation (Dooley et al., 2014, Mauthe et al., 2011). Because WIPI2b can 
bind Atg16L1 during fed conditions, a condition in which WIPI2b does not make 
puncta, it is unlikely that it is the inability of WIPI2a to form spots that makes this 
protein unable to interact with Atg16L1, and therefore it is possible that the insertion in 
WIPI2a is directly obstructing the Atg16L1 binding site on WIPI2.  
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Figure 3.21 WIPI C-terminal deletion increases Atg16L1 binding 
(a) HEK293A cells were transiently transfected with the indicated GFP-tagged 
constructs before cell lysis and GFP-Trap. Protein complexes were visualised using 
western blot. (b) Statistical analysis of (a). SEM from two independent experiments, 
statistical analysis was performed by one-way ANOVA with Tukey post-test. *, p ≤ 
0.05. ****, p ≤0.0001. Molecular weight is in kDa. 
 
 
 
Figure 3.22 WIPI2b FTTG binds Atg16L1 
(a) HEK293A cells were transiently transfected with the indicated GFP-tagged 
constructs before cell lysis and GFP-Trap. Protein complexes were visualised using 
western blot. (b) Statistical analysis of (a). SEM from three independent experiments, 
statistical analysis was performed by one-way ANOVA with Tukey post-test. *, p ≤ 
0.05. ***, p ≤0.001. Molecular weight is in kDa. 
 
3.6.2 WIPI2b binds Atg16L1 through a basically charged cleft 
The crystal structure of Hsv2, a K. lactis yeast PROPPIN protein in the same family as 
Atg18, has been published by three independent groups (Krick et al., 2012, Baskaran et 
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al., 2012, Watanabe et al., 2012). These papers showed that the PROPPIN proteins form 
seven-bladed β-propellers with an open-Velcro topology and two PtdIns(3)P binding 
sites formed from the non-canonical PtdIns(3)P binding motif, FRRG. Michael Wilson 
used a crystal structure of Hsv2 to build a model of WIPI2b (Figure 3.23). He found 
that there is a basically charged, solute-exposed cleft between blades 1 and 2 of the β-
propeller. This cleft is proximal to the site at which WIPI2a has an 18 amino acid 
insertion (between β-sheets 1 and 2 of the first blade of the propeller, coloured yellow in 
Figure 3.23) and so may be obscured in WIPI2a. In addition, this cleft is positioned 
opposite the PtdIns(3)P binding motif and hydrophobic membrane insertion loop, 
meaning that the cleft is suitably positioned for binding Atg16L1 when WIPI2 is bound 
to the membrane. This region of Atg18 is known to bind Atg2 (Watanabe et al., 2012). 
Michael proposed that this cleft would be ideal for binding the acidic stretch of 
Atg16L1 on which the WIPI2b binding site is located and he identified two solute-
exposed arginines (R108 and R125) within this cleft. I cloned point mutants of GFP-
WIPI2b, changing the arginine residues to glutamic acid, and making both single and 
double point charge-change mutants. I overexpressed these point mutants and used 
GFP-Trap to test for binding to in vitro translated and endogenous Atg16L1 (Figure 
3.24). I found that mutation of either of the residues disrupted Atg16L1 binding and that 
mutation of both residues abolished binding to both in vitro translated Atg16L1 and the 
endogenous Atg12–5-16L1 complex (Figure 3.24 a and b). These results suggest that 
the Atg16L1-WIPI2b interaction is mediated between an acidic stretch on Atg16L1 and 
a basically charged cleft on WIPI2b.  
 Arginines 108 and 125 in WIPI2b are partially conserved in WIPI1a, with a 
lysine at the position equivalent to 125 (Figure 1.9). I used site directed mutagenesis to 
produce a R125K point mutant of GFP-WIPI2b to test for any change in Atg16L1 
binding. I found that the arginine to lysine mutation had no effect on Atg16L1 binding 
(Figure 3.24 a and b) and so this cannot explain the difference between WIPI1a and 
WIPI2b in Atg16L1 binding ability. 
In order to test whether the 18 amino acid insert in WIPI2a in blade 1 is 
positioned so that the Atg16L1 binding site on WIPI2 is obscured in this isoform, I used 
site directed mutagenesis to try to dislodge the loop. The insertion contains a number of 
acidic residues  and also a number of hydrophobic residues, any of which may mediate 
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binding to the basically charged cleft between blades 2 and 3. I used site directed 
mutagenesis to produce GFP-WIPI2a point mutants E26K and R21E L35E to try and 
introduce a repulsion between the residues in the loop and the basically charged cleft. 
Neither of these mutations had any affect on Atg16L1 binding (Figure 3.24 a and b) and 
so I can not confirm whether or not the loop is positioned over the Atg16L1-binding 
cleft between blades 1 and 2 of WIPI2.  
 
 
Figure 3.23 Model of WIPI2b Model	  for	  human	  WIPI2b	  (14-­‐377)	  based	  on	  the	  X-­‐ray	  structure	  of	  Kluyvelomyces	  
marxianus	  Hsv2	  homologue	  ((Watanabe	  et	  al.,	  2012);3vu4.pdb)	  made	  with	  the	  iterative	  threading	  assembly	  refinement	  (I-­‐TAASER;(Roy	  et	  al.,	  2010)).	  The	  cartoon	  is	  coloured	  from	  the	  N-­‐terminus	  with	  blue	  to	  red	  gradient.	  The	  β1-­‐β2	  and	  β9-­‐β10	  loops	  are	  coloured	  yellow,	  R108	  and	  R125	  are	  shown	  as	  sticks.	  Residues	  that	  bind	  PtdIns(3)P	  and	  sulfates	  bound	  in	  3vu4.pdb	  are	  shown	  as	  sticks	  and	  sphere	  representations,	  respectively.	  Modelling	  done	  and	  figure	  provided	  by	  Michael	  Wilson. 
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Figure 3.24 Mutation of WIPI2b R108E or R125E reduces Atg16L1 binding 
HEK293A cells were transiently transfected with the indicated GFP constructs. (a) 
Transfected cell lysates were used for GFP-Trap before being mixed with in vitro 
translated [35S] methionine-labelled FLAG-Atg16L1. The resulting protein complexes 
were visualised using autoradiography. (b) GFP-Traps products from cells transfected 
as for (a) were probed for endogenous Atg16L1 and Atg5–12 as indicated. 
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3.7 Atg16L1 and WIPI2b bind directly 
In order to determine whether the interaction between the acidic stretch on Atg16L1 and 
the basic cleft on WIPI2b is direct, I performed a charge change experiment using the 
WIPI2b and Atg16L1 point mutants. If the interactions between any of the residues that 
have been implicated in the WIPI2b-Atg16L1 interaction are direct, I expected to see 
the charge change mutants of these sites co-immunoprecipitate. I used cell lysates from 
cells overexpressing GFP-WIPI2b WT, R108E, R125E and R108E R125E, and FLAG-
Atg16L1 WT, E226R, E130R and E226R E230R and mixed the cell lysates in all 
possible permutations before performing a GFP-Trap assay (Figure 3.25 a and b). The 
WIPI2b-Atg16L1 interaction is significantly restored when the GFP-WIPI2b R108E 
mutant is mixed with FLAG-Atg16L1 E230R when compared to the interaction 
between GFP-WIPI2b R108E and FLAG-Atg16L1 WT (Figure 3.25b and c). This 
result strongly suggests that residues arginine-108 on WIPI2b and glutamic acid-230 on 
Atg16L1 are directly interacting. A proposed model of the WIPI2b-Atg16L1 interaction 
was constructed by Michael Wilson based on these results is shown in Figure 3.26. 
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Figure 3.25 WIPI2b and Atg16L1 bind directly through WIPI2b R108 and Atg16 E230 
Cell lysates from HEK293A cells transiently transfected with GFP-WIPI2b WT, 
R108E, R125E and R108E R125E were mixed in all possible permutations with FLAG-
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Atg16L1 WT, E226R, E230R and E226R E230R before GFP-Trap of resulting protein 
complexes. (a) Schematic showing permutations of cell lysate mixes.  Red boxes 
indicate combinations which resulted in co-immunoprecipitation of indicated GFP-
WIPI2b and FLAG-Atg16L1 proteins. (b) Western blot analysis of protein complexes 
with indicated antibodies. (c) Statistical analysis of (b). The SEM for three independent 
experiments is shown. Statistical analysis was performed by one-way ANOVA with 
Tukey post-test. *, p≤0.05. Molecular weight markers are shown in kDa. 
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Figure 3.26 Model of Atg16L1 docked to WIPI2b 
Model of Atg16L1 (207-265) (pink) docked onto WIPI2b (14-377) (rainbow). WIPI2b	  was	  modelled	  using	  3vu4.pdb	  (Watanabe	  et	  al.,	  2012)	  and	  Atg16L1	  was	  modelled	  
ab	  initio	  using	  I-­‐TASSER	  (Roy	  et	  al.,	  2010).	  Both	  models	  were	  initially	  docked	  using	  ZDOCK	  for	  rigid-­‐body	  protein-­‐protein	  docking	  (Pierce	  et	  al.,	  2011),	  constrained	  by	  requiring	  E226	  and	  E230	  of	  Atg16L1,	  R108	  and	  R125	  of	  WIPI2b	  to	  be	  in	  the	  binding	  site.	  The	  top	  scoring	  docked	  model	  was	  then	  refined	  using	  RosettaDock	  (Lyskov	  and	  Gray,	  2008)	  for	  local	  docking	  optimization.	  In	  the	  docking	  model	  shown,	  E230	  interacts	  with	  R108.	  Modelling	  done	  and	  figure	  provided	  from	  Michael	  Wilson. 
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3.8 Discussion 
In this chapter I have shown that WIPI2b and Atg16L1 bind directly, and have 
identified some of the residues required for this interaction.  
WIPI1a and WIPI2a cannot bind Atg16L1 to the same extent as WIPI2b. The 18 
amino acid insertion in WIPI2a is likely to be somehow disrupting Atg16L1 binding. 
The amino acids required for binding Atg16L1 in WIPI2b (R108 and R125) are well 
conserved in WIPI1a and, unlike for WIPI2a, there are no amino acid insertions that are 
likely to be blocking the interaction. Therefore, the difference in binding ability can not 
be explained by poor conservation of residues so far identified as important for 
Atg16L1 binding and so must be due to some other feature of WIPI1a. I have seen that 
the C-terminus of WIPI1a is somehow disrupting Atg16L1 binding. The C-terminus of 
WIPI2b contains a potential phosphorylation site (Hsu et al., 2011), and therefore may 
provide a mechanism of regulating the Atg16L1 interaction. This is investigated further 
in Chapter 5. 
The region of Atg16L1 that binds WIPI2 is adjacent to the FIP200 binding 
region on Atg16L1. The close proximity of the two binding sites suggests that there 
may be some form of cross talk or regulation in the binding of FIP200 and WIPI2b. 
However, I have not seen any evidence of this – mutants of Atg16L1 unable to bind 
WIPI2b can still bind FIP200 and vice versa. Also, when using overexpressed proteins, 
a trimeric complex of WIPI2b-Atg16L1-FIP200 can exist. Investigation into any cross 
talk or regulation would require further work. It appears that in order to bind WIPI2b, 
Atg16L1 must be a homodimer. Figure 3.11d shows that human Atg16L1 ΔCCD, which 
lacks amino acids 69-213, cannot bind WIPI2b. This construct is unable to form 
homodimers (Fukuda and Itoh, 2008) but does contain residues E226 and E230, which 
are required for WIPI2b binding. In contrast, FIP200 is able to bind to Atg16L1 mutants 
that do not form homodimers (Nishimura et al., 2013). It is possible that the Atg16L1 
interaction with WIPI2b is weaker than that with FIP200 and the interaction stabilised 
when a dimer of Atg16L1 binds to two WIPI2b proteins. If this is true, then it would be 
interesting to investigate whether the inability of WIPI2b to bind monomeric Atg16L1 
provides any function or regulation during autophagy. 
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FIP200 has been shown to be responsible for recruiting the Atg16L1 complex to 
forming autophagosomes (Nishimura et al., 2013, Gammoh et al., 2013). Interestingly, 
the Atg16L1 constructs lacking FIP200 binding ability used for rescue of autophagy in 
Atg16L1Δ/Δ MEFs in these papers lacked Atg16L1 amino acid 230 and so will have 
disrupted WIPI2b binding. Therefore, lack of autophagy rescue seen when using these 
mutants in these experiments could be, at least partially, attributable to loss of WIPI2b 
interaction. Intriguingly, in the study by Nishimura et al., an Atg16L1 1-230 construct 
was used to rescue autophagy in Atg16L1Δ/Δ MEFs. The authors found that although 
unable to bind FIP200, this construct was able to rescue LC3 lipidation, p62 
degradation, LC3 and Atg16L1 spot formation and GFP-LC3 lysosomal degradation to 
the same extent as full length Atg16L1 (Nishimura et al., 2013). If WIPI2b is capable of 
recruiting the Atg12–5-16L1 complex to the phagophore, then these results can be 
explained in terms of the Atg16L1-WIPI2b interaction. 
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Chapter 4. WIPI2b recruits the Atg12–5-16L1 
complex to the phagophore 
4.1 Introduction and aim 
4.1.1 Introduction 
The recruitment of the Atg12–5-16L1 complex is dependent on production of 
PtdIns(3)P at the forming autophagosome (Itakura and Mizushima, 2010). However, 
there is currently no explanation for this observation; there has been no observed 
PtdIns(3)P-binding ability of the Atg12–5-16L1 complex and there is no known 
phagophore-localised PtdIns(3)P binding protein that binds the complex. As described 
in Chapter 3, I have shown that WIPI2b binds Atg16L1. Our working model is that 
WIPI2b recruits the Atg12–5-16L1 complex in a PtdIns(3)P-dependent manner to the 
site of LC3 lipidation. Previous work on WIPI2b by Hannah Polson has shown that 
WIPI2 acts as an early autophagy protein, required for and functioning upstream of LC3 
lipidation (Polson et al., 2010). Hannah’s previous findings are consistent with WIPI2 
acting to recruit the Atg12–5-16L1 complex during starvation-induced autophagy. This 
function has been ascribed to FIP200 (Nishimura et al., 2013, Gammoh et al., 2013) and 
also to FIP200- and ubiquitin-Atg16L1 acting in a redundant manner in recruiting the 
Atg12–5-16L1 complex (Fujita et al., 2013). As described in Chapter 3.8, previous 
studies do not exclude the possibility that WIPI2 may be functioning in this role either 
in parallel with or instead of FIP200.  
 The recruitment of LC3 to the growing autophagosome is dependent on Atg12–
5-16L1 in both canonical and bacterial autophagy (Itakura and Mizushima, 2010, Fujita 
et al., 2013). However, the mechanism of Atg12–5-16L1 complex recruitment to the 
membrane appears to be more complex during xenophagy than starvation-induced 
autophagy (Fujita et al., 2013). Atg16L1 recruitment to Salmonella and latex beads 
involves FIP200 and ubiquitin binding by Atg16L1, and there may be additional 
recruitment mechanisms (Fujita et al., 2013). It is possible that the WD repeat on the C-
terminus of Atg16L1, absent in yeast, may have evolved to provide additional 
recruitment mechanisms of Atg16L1 to allow for more complex autophagy in 
mammalian cells (Fujita et al., 2013). The requirement for WIPI2b during xenophagy 
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has not been studied and the requirement for PtdIns(3)P in this process is an area under 
debate (Huang et al., 2011, Kageyama et al., 2011). 
 
4.1.2 Aim 
Following from mapping the Atg16L1-WIPI2b interaction, my aim was to determine 
the function of this interaction. I investigated this by using point mutants of WIPI2b 
unable to bind Atg16L1 and Atg16L1 mutants unable to bind FIP200 or WIPI2b. 
Ectopic localisation of WIPI2b to the plasma membrane was used to investigate 
whether WIPI2b is able to recruit Atg16L1 to a membrane and xenophagy was used to 
determine how well conserved the requirement for WIPI2b is in other forms of 
autophagy. 
 
4.2 WIPI2 functions upstream of Atg16L1 and LC3 lipidation 
4.2.1 WIPI2 knockdown decreases LC3 lipidation and LC3 spot formation 
during starvation 
WIPI2 acts in early autophagy and is required for LC3 lipidation and puncta formation 
in starvation-induced autophagy, as shown by using WIPI2 siRNA knockdown(Polson 
et al., 2010). Hannah used WIPI2 siRNA #9 from Dharmacon, and noted on several 
occassions that ULK1 was depleted in WIPI2 knockdown cells (unpublished data and 
personal comunication). I used WIPI2 knockdown with the Dharmacon #9 and #12 
siRNAs to deplete WIPI2 protein and look at ULK1 levels. As Hannah had previously 
seen, I saw that Dharmacon #12 depleted WIPI2 less efficiently than #9 and did not 
reduce ULK1 levels, but that #9 very effectively reduced WIPI2 levels and also caused 
ULK1 depletion (Figure 4.1a). In order to establish whether was is an off-target result, I 
used an siRNA from Qiagen (#3) to determine whether ULK1 depletion is also seen 
using siRNA with a different target sequence. I found that this siRNA efficiently 
depeleted WIPI2, but also caused a slight decrease in ULK1 levels (Figure 4.1b). From 
this I concluded that ULK1 decrease upon WIPI2 knockdown is unlikely to be an off-
target effect and instead may be a real effect of WIPI2 depletion. As I was concentrating 
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on characterising the funciton of the Atg16L1-WIPI2 interaction, I did not pursue the 
reasons behind this decrease in ULK1 levels, which may be transcriptional or due to 
destabilisation of ULK1 upon WIPI2 depletion as seen with Atg16L1 depletion 
(Nishimura et al., 2013).  
 I generally saw a better WIPI2 knockdown using the Qiagen siRNA, and so I 
used this for subsequent experiments. As Hannah had performed previous knockdown 
experiments using the Dharmacon duplex, I ensured that I could reproduce her results 
using the Qiagen siRNA. I found that WIPI2 knockdown led to a reproducible decrease 
in starvtion-induced LC3 lipidation (Figure 4.2a and b) and a significant decrease in 
starvation-induced LC3 puncta formation (Figure 4.3a and b) as expected. 
 
 
Figure 4.1 ULK1 depletion in cells depleted of WIPI2 
(a and b) HEK293A cells were treated with the indicated siRNA for 72 hours before 
cell lysis and western blot analysis. Molecular weight markers are in kDa. 
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Figure 4.2 WIPI2 knockdown reduces starvation induced LC3 lipidation 
(a) HEK293A cells treated with RISC-free (RF) or WIPI2 siRNA for 72 hours were 
treated with full medium (F) or starvation medium (S) for two hours before western blot 
analysis. Molecular weights are in kDa. (b) Statistical analysis of (a). The SEM for four 
independent experiments is shown. The difference between RISC-free starved and 
WIPI2 knockdown starved is not significant in this set of experiments, but is 
reproducible.  
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Figure 4.3 WIPI2 knockdown reduces starvation-induced GFP-LC3 puncta 
(a) 2GL9 cells treated with RISC-free (RF) control or WIPI2 siRNA for 72 hours were 
treated with full medium (Fed) or starvation medium (Starved) for two hours before 
fixing and staining for confocal analysis. Scale bars are 20 µm. (b) Statistical analysis 
of the number of LC3 spots from (a). The SEM for three independent experiments is 
shown. Statistical analysis was performed using student’s t-test. **, p ≤ 0.01. 
 
4.2.2 Atg16L1Δ/Δ MEFs form WIPI2 puncta in fed and starved conditions 
If WIPI2 acts to recruit the Atg12–5-16L1 complex through binding Atg16L1, then 
WIPI2 would function upstream of Atg16L1. To test this, I looked for WIPI2 puncta 
formation in Atg16L1Δ/Δ MEFs. Atg16L1Δ/Δ MEFs are non-functional in autophagy: 
they do not produce LC3-II, Atg12–5 or LC3 puncta, and p62 and long-lived protein 
degradation is severely impaired (Saitoh et al., 2008). Atg16L1Δ/Δ MEFs are not 
complete knockout cells, but contain Atg16L1 with a deleted coiled coil domain (amino 
acids 69-213) (Saitoh et al., 2008). This Atg16L1Δ/Δ protein is non functional for 
autophagy, stalling autophagosome formation before LC3 lipidation. If WIPI2 acts 
upstream of Atg16L1 then WIPI2 puncta would be formed in these MEFs, both in fed 
and starved conditions, on PtdIns(3)P positive stalled omegasome as seen with HA-
WIPI1a and GFP-DFCP1 in Atg5 KO MEFs (Itakura and Mizushima, 2010). I found 
that WIPI2 puncta were formed in Atg16L1Δ/Δ MEFs in both fed and starved condition 
(Figure 4.4 a and b). This result and previous work on WIPI2 (Polson et al., 2010) 
shows that WIPI2 functions downstream of PtdIns(3)P formation and upstream of 
Atg16L1, therefore supporting the model of PtdIns(3)P-dependent WIPI2b recruitment 
of the Atg12–5-16L1 complex. The number of WIPI2 starvation-induced puncta in 
Atg16L1Δ/Δ MEFs is significantly fewer than in WT MEFs. I have not investigated the 
reason for this, but it may be due to the decrease in the protein levels of the ULK1 
kinase complex in Atg16L1Δ/Δ MEFs (Nishimura et al., 2013). 
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Figure 4.4 Atg16L1Δ/Δ MEFs form WIPI2 puncta 
(a) Atg16L1 WT and Δ/Δ MEFs were treated with full medium (Fed) or starvation 
medium (Starved) for two hours before being fix, stained for WIPI2 and visualised by 
confocal microscopy. Scale bars are 10 µm. (b) Statistical analysis of (a). The SEM for 
three independent experiments is shown. Statistical analysis performed using unpaired 
student’s t-test. ****, p ≤ 0.0001. 
 
4.3 Atg16L1 binding by WIPI2b is required for WIPI2b function 
in autophagy 
I used WIPI2b rescue experiments in order to determine whether WIPI2b interaction 
with Atg16L1 is required for WIPI2 function in autophagy. HEK293A cells were 
treated with either RISC-free or WIPI2 siRNA before expression of either GFP as a 
negative control, or siRNA resistant GFP-WIPI2b or GFP-WIPI2b R108E R125E 
(RERE) (Atg16L1 binding mutant) before analysing starvation-induced autophagy in 
these cells by LC3 shift assay. I was surprised to find that LC3 lipidation was 
significantly inhibited in WIPI2 siRNA treated cells which were transiently expressing 
GFP-WIPI2b RERE (Figure 4.5a and b). Although not significant, there was a general 
trend in GFP-WIPI2b overexpressing cells towards an increase in LC3 lipidation in both 
RISC-free and WIPI2 siRNA treated cells, suggesting that WIPI2 overexpression may 
be able to drive autophagy to some extent.  
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 I postulated that WIPI2b-RERE may have an inhibitory effect in WIPI2 depleted 
cells because overexpressed GFP-WIPI2b RERE may be able to successfully out-
compete residual endogenous WIPI2 for PtdIns(3)P binding and therefore blocking 
Atg12–5-16L1 recruitment and subsequent LC3 lipidation. To test this, I expressed a 
PtdIns(3)P binding mutant of WIPI2b that was unable to bind Atg16L1 (GFP-WIPI2b 
FTTG RERE). If GFP-WIPI2b RERE inhibits autophagy by blocking PtdIns(3)P sites 
on the forming autophagosome then a PtdIns(3)P binding mutant of this protein should 
have no inhibitory effect on autophagy. Consistently, I found that GFP-WIPI2b FTTG 
RERE had no inhibitory effect on autophagy as measured by LC3 lipidation or p62 
degradation (Figure 4.6a, b and c), whereas GFP-WIPI2b RERE did. The effects of 
GFP-WIPI2b RERE overexpression on autophagy inhibition were most apparent when 
looking at p62 degradation. p62 is an autophagy-specific substrate (Bjorkoy et al., 
2005) and a cargo adaptor in the degradation of  ubiquitinated proteins and organelles 
(Kim et al., 2008). In cells overexpressing the Atg16L1 binding mutant, p62 was 
significantly increased compared to expressing GFP alone (significance not indicated on 
graph) or other GFP-WIPI2b constructs (Figure 4.6c). However, expression of the 
Atg16L1 binding mutant which could not bind PtdIns(3)P (GFP-WIPI2b FTTG RERE) 
did not significantly accumulate p62. These results were supported by LC3 spot 
formation assays carried out by Minoo Razi. HEK293A cells transiently overexpressing 
GFP-WIPI2b RERE after WIPI2 depletion showed significantly fewer endogenous LC3 
spots compared to GFP-WIPI2 WT and FTTG RERE cells (Figure 4.6d and e). 
GFP-WIPI2b formed starvation-induced puncta as expected. These puncta were 
not formed in cells expressing WIPI2b unable to bind PtdIns(3)P: either GFP-WIPI2b 
FTTG or GFP-WIPI2b FTTG RERE (Figure 4.6 d and f). GFP-WIPI2b RERE formed 
large, LC3-negative ring shaped structures (Figure 4.6e and 4.7) and Minoo found that 
they colocalised with myc-DFCP1 and p62. Although the degradation of p62 requires 
interaction with LC3 through the LIR of p62 (Pankiv et al., 2007), p62 localisation to 
the site of autophagosome formation does not require p62 binding to LC3 and instead 
requires p62 self-oligomerisation through its PB1 domain (Itakura and Mizushima, 
2011). Therefore, the GFP-WIPI2 RERE structures are likely to be omegasomes. This is 
supported by correlative light and electron microscopy (CLEM) samples of GFP-
WIPI2b samples analysed by Minoo (Dooley et al., 2014). 
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These experiments show that WIPI2b that is unable to bind Atg16L1 blocks 
autophagosome maturation and LC3 lipidation in WIPI2 depleted cells. Furthermore, 
this inhibition is dependent on the ability of WIPI2b RERE to localise to omegasomes 
through PtdIns(3)P binding. Together these data demonstrate that WIPI2b must be able 
to bind both PtdIns(3)P and Atg16L1 in order to function in autophagy. Additionally, 
GFP-WIPI2b RERE can form puncta, showing that Atg16L1-WIPI2b binding is not 
required for PtdIns(3)P-dependent WIPI2b recruitment to the forming autophagosome. 
This can also be concluded by WIPI2 puncta formation in Atg16Δ/Δ MEFs (Figure 4.4). 
In conjunction with results showing that the GFP-WIPI2 FTTG mutant interaction with 
Atg16L1 is unaltered compared to wild type GFP-WIPI2b (Figure 3.22), it seems likely 
that the interactions of WIPI2 with PtdIns(3)P and Atg16L1 operate independently. 
However, this raises the question of why WIPI2a can neither bind PtdIns(3)P nor make 
starvation-induced puncta? The 18 amino acid insertion between β-sheets 1 and 2 in the 
first blade of the WD-40 domain of WIPI2a is the only feature that distinguishes it from 
puncta-forming and Atg16L1-binding WIPI2b. The localisation of the 18 amino acid 
insert adjacent to the Atg16L1 binding domain and opposite the PtdIns(3)P binding sites 
suggests that the insertion affects Atg16L1, but not PtdIns(3)P-binding. However, 
perhaps this insert destabilises the protein or protein folding. Consistent with this, GFP-
WIPI2a does not express as well as GFP-WIPI2b even though they have the same 
vector backbone. 
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Figure 4.5 GFP-WIPI2b RERE inhibits LC3 lipidation in WIPI2 knockdown cells 
HEK293A cells were treated with either RISC-free (RF) or WIPI2 siRNA for 72 hours 
and transiently transfected with the indicated GFP-tagged constructs for 48 hours before 
being treated with full medium (F), starvation medium (S) or starvation medium and 
Bafilomycin A (B) for two hours. (a) Cells were lysed and LC3 lipidation was analysed 
by western blot. Molecular weight markers are in kDa. (b) Statistical analysis of (a). 
SEM for three independent experiments is shown. Statistical analysis performed by one-
way ANOVA with Tukey post-test. *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001. 
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Figure 4.6 WIPI2 unable to bind Atg16L1 and PtdIns(3)P does not act as a dominant 
negative inhibitor of autophagy 
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(a) HEK293A cells were treated with WIPI2 siRNA for 72 hours and the indicated 
siRNA resistant contracts were overexpressed for 48 hours before the cells were treated 
with full medium (F), starvation medium (S) or starvation medium with Bafilomycin A 
(B) for two hours. Cells were lysed and analysed for LC3 lipidation and p62 
degradation by western blot. Molecular weight markers are in kDa. (b) Statistical 
analysis of LC3 lipidation from (a). The SEM for two independent experiments is 
shown. (c) Statistical analysis of p62 degradation from (a). The SEM for four 
independent experiments is shown. Statistical analysis was performed by one-way 
ANOVA with Tukey post-test. (d) Cells were siRNA treated and transfected as for (a) 
before being treated with starvation medium or starvation medium with Bafilomycin A 
for two hours. Cells were fixed and analysed by confocal microscopy. Starvation plus 
Bafilomycin A is shown. Scale bars are 10 µm. (e) Statistical analysis of LC3 puncta 
formation from (d). The SEM for three independent experiments is shown. Statistical 
analysis was performed by one-way ANOVA with Dunn’s post-test. (f) Statistical 
analysis of GFP-WIPI2b puncta formation from (d). The SEM from 10 cells per 
condition is shown. Statistical analysis was performed by one-way ANOVA. ***, p ≤ 
0.001. Experiments in (d), (e) and (f) were performed by Minoo Razi. *, p ≤ 0.05; **, p 
≤ 0.01; ***, p ≤ 0.001; ****, p ≤ 0.0001. 
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Figure 4.7 GFP-WIPI2 RERE colocalises with p62 and DFCP1 
(a) HEK293A cells were treated with WIPI2 siRNA for 72 hours and the indicated 
siRNA resistant constructs were overexpressed for 48 hours. The cells were starved for 
two hours followed by fixation and staining with antibodies against endogenous p62 for 
confocal microscopy analysis. (b) Cells treated with siRNA and GFP-constructs as in 
(a) were co-transfected with myc-DFPC1 for 48 hours before fixation and staining with 
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an antibody against myc for confocal microscopy analysis. Scale bars are 10 µm. 
Experiment performed by Minoo Razi. 
 
4.4 WIPI2b localisation to a membrane is sufficient to drive 
LC3 lipidation 
4.4.1 WIPI2b-CAAX localises to the plasma membrane 
Data in Chapter 4.3 show that the Atg16L1-WIPI2b interaction is required for 
autophagy. This supports my hypothesis that WIPI2b is the PtdIns(3)P effector that 
recruits the Atg12–5-16L1 complex. However, my results so far do not directly 
demonstrate the ability of WIPI2 to recruit the Atg12–5-16L1 complex. In order to 
determine whether or not WIPI2b can specify the site of Atg12–5-16L1 recruitment, I 
used WIPI2b-CAAX constructs to ectopically localise WIPI2b to the plasma membrane. 
The plasma membrane contains phosphatidylethanolamine and ectopic localisation of 
Atg16L1 to the plasma membrane via a CAAX motif has been used to demonstrate the 
ability of Atg16L1 to recruit the Atg12–5 conjugate and drive LC3 lipidation (Fujita et 
al., 2008). If WIPI2b localisation to a membrane is sufficient to recruit the Atg12–5-
16L1 complex (through binding to Atg16L1) to that membrane, then WIPI2b ectopic 
localisation to the plasma membrane will result in Atg12–5-16L1 recruitment to the 
plasma membrane and subsequently lead to Atg3-LC3 recruitment and LC3 lipidation 
(Figure 4.8a). As CAAX localisation to the plasma membrane is independent of the 
usual autophagy stimuli (mTORC1 inactivation and PtdIns(3) kinase activation), LC3 
lipidation should be increased in cells overexpressing WIPI2b-CAAX constructs 
independently of these signalling inputs. 
kRAS is targeted to the plasma membrane by its C-terminus, which contains two 
signals: the CAAX motif (where C is cysteine, A is any aliphatic amino acid, and X is 
any amino acid) and a polybasic stretch of amino acids (Wright and Philips, 2006). The 
C-terminal CAAX motif undergoes a series of posttranslational modifications that result 
in the C-terminus of the protein becoming hydrophobic and suitable for interaction with 
the membrane (Figure 4.8b). I cloned the kRAS CAAX sequence (Fujita et al., 2008) 
onto the C-terminus of WIPI2b (Figure 4.8b) for this series of experiments. The WIPI2b 
constructs that I cloned are all FTTG mutants to ensure that they are not able to function 
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in canonical autophagy. mCherry-WIPI2b-CAAX localises to the plasma membrane as 
expected (Figure 4.9).  
 
 
Figure 4.8 WIPI2b targeting to the plasma membrane 
(a) Schematic of expected sequential recruitment of autophagy proteins to the plasma 
membrane after WIPI2b plasma membrane localisation. (b) Schematic of WIPI2b-
CAAX posttranslational modification. Adapted from (Wright and Philips, 2006). Step 
1: addition of a 15 carbon farnesyl isoprenoid catalysed by FTase (farnesyltransferase). 
Step 2: cleavage of the three amino acids C-terminal to the cysteine by Rce1 (Ras-
converting enzyme 1). Step 3: Methyl esterification of the carboxyl group of cysteine, 
catalysed by Icmt (isoprenylcysteine carboxyl methyltransferase). 
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Figure 4.9 mCherry-WIPI2b-CAAX localises to the plasma membrane 
HEK293A cells (2GL9) were transiently transfected with mCherry or mCherry-
WIPI2b-CAAX 48 hours before fixation for confocal microscopy analysis. Hoechst was 
used to stain nuclei. Scale bars are 10 µm. 
 
4.4.2 WIPI2b-CAAX drives LC3 lipidation and LC3 plasma membrane-
localisation dependent on Atg16L1 binding, but independently of 
mTORC1 inactivation or PtdIns(3)P production 
In order to test whether plasma membrane-localised WIPI2b can lead to Atg12–5-16L1 
complex recruitment and subsequent LC3 lipidation, I assayed LC3 lipidation in cells 
transiently overexpressing mCherry-WIPI2b-CAAX constructs. If WIPI2b directly 
recruits the Atg12–5-16L1 complex, then an increase in LC3 lipidation should be seen 
in all conditions, including during fed conditions (active mTORC1) and wortmannin 
treatment (inactive Vps34 PtdIns(3) kinase complex). mCherry-WIPI2b-CAAX 
expression resulted in a significant increase in LC3 lipidation in both fed and 
wortmannin treated cells (Figure 4.10a and b) when compared to cells expressing 
mCherry-WIPI2b with no C-terminal CAAX motif. This increase in LC3 lipidation was 
lost by using mCherry-WIPI2b-RERE-CAAX mutants unable to bind Atg16L1 (Figure 
4.10a, b and c).  All mCherry-WIPI2b-CAAX constructs used were plasma membrane 
localised and the overexpression of mCherry-WIPI2b-CAAX, but not mCherry-
WIPI2b-RERE-CAAX, resulted in plasma membrane-localised LC3 (Figure 4.11, 
experiment performed by Minoo Razi). Together, these result demonstrate that plasma 
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membrane-localised WIPI2b can recruit LC3 and the LC3 conjugation machinery (the 
Atg12–5-16L1 complex and Atg3–LC3 conjugate) through binding Atg16L1. Once 
WIPI2b is membrane localised, the recruitment of Atg16L1 by WIPI2b is independent 
of upstream signals including mTORC1 inactivation and PtdIns(3)P binding. 
 
 
Figure 4.10 WIPI2b-CAAX promotes LC3 lipidation in fed and wortmannin-treated 
conditions 
(a) HEK293A cells were transiently transfected with the indicated mCherry constructs 
before being treated with full medium (F), starvation medium (S) or starvation medium 
with wortmannin (W) for two hours. LC3 lipidation was assayed by western blot. (b) 
statistical analysis of (a). The SEM for three independent experiments is shown. 
Statistical analysis was performed by one-way ANOVA with Tukey’s post test. *, p ≤ 
0.05. (c) Cell lysates from HEK293A cells transiently transfected with the indicated 
mCherry constructs were used for RFP-Trap. Immunoprecipitated protein complexes 
were analysed by western blot. Note, all WIPI2b constructs are FTTG mutants. 
Molecular weight markers are shown in kDa. 
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Figure 4.11 WIPI2b-CAAX colocalises with GFP-LC3 on the plasma membrane 
GFP-LC3 stably expressing cells were transiently transfected with the indicated 
mCherry constructs. Cells were treated in full medium (fed), starvation medium  
(starved) or starvation medium with wortmannin (starved+wortmannin) for two hours 
before confocal microscopy analysis. Scale bars are 10 µm. Experiment was performed 
and figure provided by Minoo Razi. 
 
4.4.3 WIPI2b-CAAX promoted LC3 lipidation is independent of FIP200 
Atg16L1 binds FIP200 and this interaction is thought to be required for Atg12–5-16L1 
recruitment to the forming autophagosome (Nishimura et al., 2013, Gammoh et al., 
2013). My results so far have shown that WIPI2b is able to recruit the Atg12–5-16L1 
complex to a membrane. Although I have shown that, once WIPI2b is membrane 
localised, this recruitment is independent of upstream signalling such as mTORC1 and 
PtdIns(3)P production, the dependence on the presence of FIP200 is not known. In 
order to test this I used RISC-free control siRNA or siRNA to knockdown Atg16L1 or 
FIP200 before transiently transfecting the cells with HA-WIPI2b-CAAX (FTTG 
mutant). I have shown (Figure 4.10 and 4.11) that WIPI2b-CAAX driven LC3 
lipidation is dependent on Atg16L1 binding, and so Atg16L1 knockdown was used as a 
positive control for depleting a protein required for WIPI2-CAAX driven LC3 
lipidation. RISC-free siRNA was used as a negative control. I found that FIP200 
knockdown had no effect on WIPI2b-CAAX driven LC3 lipidation, in contrast to 
Atg16L1 knockdown where LC3 lipidation was lost in fed and wortmannin treated 
condition (Figure 4.12), showing that WIPI2b-CAAX mediated recruitment of the LC3 
lipidation machinery does not require FIP200. 
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Figure 4.12 WIP2-CAAX driven LC3 lipidation is independent of FIP200 
HEK293A cells were treated with RISC-free, Atg16L1 or FIP200 siRNA for 72 hours 
before transient transfection with HA-WIPI2b-CAAX for 48 hours. Cells were treated 
with full medium (F), starvation medium (S) or starvation medium and wortmannin (W) 
for two hours before western blot analysis. Molecular weight markers are in kDa. 
 
4.5 WIPI2b, but not FIP200, binding is required for Atg16L1 
rescue of Atg16L1Δ/Δ MEFs 
The binding sites for WIPI2b and FIP200 on Atg16L1 are very close (Chapter 3.5). 
Although I have not detected any interdependence or exclusivity in binding, it is 
possible that WIPI2b and FIP200 function together in autophagy. To further test the 
requirements for Atg16L1 interaction with WIPI2b and FIP200 in starvation-induced 
autophagy, I used point mutants of Atg16L1 that can bind WIPI2b but not FIP200 
(Atg16L1 D237R D239 R, DRDR), and vice versa (Atg16L1 E226R E230R, ERER) 
(Figure 3.18), to rescue autophagy in Atg16L1Δ/Δ MEF cells.  
 Transient transfection of Atg16L1Δ/Δ MEFs with FLAG-Atg16L1 WT or 
FIP200-binding deficient FLAG-Atg16L1 DRDR resulted in a significant restoration of 
LC3 lipidation. In contrast, transfection with WIPI2b-binding mutant FLAG-Atg16L1 
ERER did not significantly restore LC3 lipidation compared to mock transfection 
(Figure 4.13a and b). Similarly, the number of LC3 puncta formed during starvation 
was significantly fewer in Atg16L1Δ/Δ MEFs rescued with FLAG-Atg16L1 ERER than 
with Atg16L1 WT. However, there was no significant difference between rescue with 
FLAG-Atg16L1 WT and DRDR (Figure 4.14a and b). These results demonstrate that 
Atg16L1 must be able to bind WIPI2b in order function in autophagy and that binding 
to FIP200 is not required.  
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Figure 4.13 Atg16L1 unable to bind WIPI2b cannot rescue LC3 lipidation 
(a) Atg16L1Δ/Δ MEFs were transiently transfected with the indicated constructs before 
being treated with full medium (F), starvation medium (S) or starvation medium with 
Bafilomycin A (B) for two hours. LC3 lipidation was analysed by western blot. 
Molecular weight markers are in kDa. (b) Statistical analysis of (a). The SEM for three 
independent experiments is shown. Statistical analysis was performed by one-way 
ANOVA with Tukey’s post hoc test. *, p ≤ 0.05.  
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Figure 4.14 Atg16L1 unable to bind WIPI2b cannot rescue LC3 puncta formation 
(a) Atg16L1Δ/Δ MEFs were transiently transfected with the indicated constructs before 
being treated with full (F) or starvation (S) medium for two hours. Cells were fixed and 
stained with the indicated antibodies. LC3 puncta formation was analysed by confocal 
microscopy. Starved cells are shown. Scale bars are 20 µm. (b) Statistical analysis of 
(a). The SEM for three independent experiments is shown. Statistical analysis was 
performed by one-way ANOVA with Dunn post test. *, p ≤ 0.05. 
 
4.6 Atg16L1-WIPI2b interaction is required for xenophagy 
4.6.1 WIPI2 colocalises with LC3 on the SCV 
Salmonella enterica serovar Typhimurium invades non-phagocytic cells using a type 
three secretion system (TTSS) and enters the cell enclosed in a vacuole, termed the 
salmonella containing vacuole (SCV). During the first few hours of Salmonella 
infection, the SCV matures from a vacuole containing early endosome markers, to one 
which is decorated with late endosomal markers such as LAMP-1 (Gorvel and Meresse, 
2001). Autophagy limits the replication of Salmonella both in whole organisms and cell 
models (Birmingham et al., 2006, Jia et al., 2009) and it is thought that the host cell 
initiates autophagy-mediated degradation of Salmonella, a process named xenophagy, 
in response to damage to the SCV by the TTSS (Birmingham et al., 2006). Although the 
exact signals of this damage are not well understood (Gomes and Dikic, 2014), we 
know that damage results in ubiquitination of host and/or bacterial proteins 
(Birmingham et al., 2006), leading to recruitment of cargo-receptors such as p62 (Zheng 
et al., 2009) and xenophagy at PtdIns(3)P-enriched domains on the ER (Huang et al., 
2011).  
Xenophagy requires the use of the canonical autophagy machinery to produce a 
double-membraned vesicle around the SCV. However, the mechanistic details are less 
well understood than for macroautophagy. A recent study has shown that formation of 
the double-membraned phagophore surrounding the SCV requires the function of the 
ULK1 kinase complex and mAtg9 (Kageyama et al., 2011). The same study found that 
in situations where the phagophore does not form, LC3 can be recruited to the SCV 
independently of the ULK1 kinase complex, mAtg9 and the Vps34 PtdIns(3) kinase 
complex, and that this recruitment is dependent on the LC3 lipidation machinery (Atg7, 
Atg3 and the Atg12–5-16L1 complex). Kageyama, et al., reported no change in LC3 
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localisation to the Salmonella (likely the SCV surface) after wortmannin treatment, 
which is in contrast to a different study that showed that wortmannin treatment 
significantly reduces LC3 recruitment to Salmonella (Huang et al., 2011). It appears 
that xenophagy may be a more complex process than macroautophagy and that multiple 
mechanisms may be in place for recruiting the Atg12–5-16L1 complex. FIP200 and 
ubiquitin have recently been shown to bind Atg16L1 and this could subsequently lead 
to LC3 recruitment (Fujita et al., 2013). It is possible that the membrane of the SCV 
itself may provide a platform that allows for LC3 recruitment, via the Atg12–5-16L1 
complex, through an unknown mechanism in situations, such as wortmannin treatments 
and FIP200, ULK1, Atg14L or mAtg9 knockout MEFs, where phagophore formation 
has been disrupted, but that this is not the wild type scenario (Kageyama et al., 2011). 
 Although Beclin1 is needed for autophagy-mediated limitation of Salmonella 
growth (Sun et al., 2008, Jia et al., 2009), the role of PtdIns(3)P binding proteins in 
xenophagy have not yet been investigated. Ubiquitin, p62 and WIPI2 colocalise 
together around Salmonella as expected (Figure 4.15a), showing that WIPI2 localises to 
ubiquitin-labelled Salmonella. As p62 and ubiquitin colocalised on damaged SCVs as 
expected, I used p62 as a marker for ubiquitinated SCVs because the guinea pig anti-
p62 that we use in the lab allowed me more flexibility when triple labelling for 
immunofluorescence. I found that WIPI2 colocalises with LAMP1 and p62, and so 
WIPI2 is either localised to, or on a membrane surrounding, the SCV (Figure 4.15b). 
Xenophagy occurs at omegasomes on the ER (Huang et al., 2011). I found WIPI2- and 
p62-labelled Salmonella on SCVs localised to the ER (Figure 4.15 c). Therefore, 
WIPI2-labelled SCVs localise to regions of the ER that may represent omegasome, 
although co-localisation with DFCP1 would be needed to confirm this. Combined, these 
results show that WIPI2 localises to damaged SCVs and can be found on the ER, which 
is thought to be the site of bacterial autophagy. 
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Figure 4.15 WIPI2 colocalises with damaged SCVs on the ER 
HeLa cells were infected with Salmonella with an MOI of 100 for one hour before 
fixing and labelling for immunofluorescence with Hoechst dye, anti-p62, anti-WIPI2 
and (a) anti-ubiquitin (b) anti-LAMP1 and (c) anti-calreticulin. Scale bars are 5 µL. 
 
4.6.2  WIPI2 is needed for xenophagy 
As WIPI2 is found on damaged SCVs and is needed for macroautophagy, I asked if it is 
similarly required for xenophagy by depleting WIPI2 from HeLa cells and assaying the 
effect on bacterial proliferation and on LC3 recruitment to the SCV. Xenophagy 
reduces the number of Salmonella in the cell and so autophagy inhibition results in an 
increased number of Salmonella in each infected cell (Birmingham et al., 2006). Colony 
count assays can be used to estimate the number of live Salmonella in cells after 
infection. Colony count assays are performed by lysing the cells after infection, making 
serial dilutions of the cell lysates and plating the cell lysate on LB plates. Each live 
Salmonella will form a colony and so after an overnight incubation the number of 
colonies per plate represents the number Salmonella from that set of cells. WIPI2 
knockdown resulted in an increased number of colonies compared to a RISC-free 
control (Figure 4.16a), showing that WIPI2 is required for bacterial autophagy. 
Similarly to starvation-induced autophagy, WIPI2 is required for LC3 recruitment to the 
SCV; LC3 recruitment is significantly impaired in WIPI2 depleted cells (Figure 4.16b 
and c). Note that WIPI2 and LC3 colocalise on the damaged SCV. These results show 
that WIPI2 is required for autophagy-mediated degradation of cytosol-exposed 
Salmonella, and this is likely to be as a result of impaired LC3 recruitment. 
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Figure 4.16 WIPI2 knockdown reduces xenophagy and LC3 recruitment to the SCV 
(a) HeLa cells were treated with either RISC-free (control) or WIPI2 siRNA for 72 
hours before infection with Salmonella at an MOI of 100 for one hour. Infected cells 
were lysed serial dilutions were plated on LB plates. The LB plates were incubated over 
night and the number of colony forming units (CFUs) were counted. The SEM for three 
independent experiments in triplicate is shown. Statistical analysis performed using 
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unpaired student’s t-test. *, p ≤ 0.05 (b) HeLa cells were treated with siRNA and 
infected as in (a). Cells were then lysed and stained with the indicated antibodies for 
confocal microscopy analysis. Scale bars are 5 µm. (c) Statistical analysis of (b). The 
SEM for three independent experiments is shown. Statistical analysis performed using 
unpaired student’s t-test. ****, p ≤ 0.0001.  
 
4.6.3 Atg16L1-WIPI2b binding is required for LC3 localisation to the SCV 
A number of factors are thought to be required for Atg16L1 recruitment to the SCV 
(Fujita et al., 2013), therefore I used rescue of Atg16L1Δ/Δ MEFs to determine whether 
the interaction with WIPI2b is an addition mechanism of Atg16L1 recruitment. 
Atg16L1Δ/Δ MEFs rescued with FLAG-Atg16L1 WIPI2b binding mutant (ERER) 
showed significantly less LC3-positive p62-labelled bacteria than cells rescued with 
wild type Atg16L1 (Figure 4.17a and b). In contrast, there was no significant difference 
in LC3 recruitment between Atg16L1 WT and FIP200 binding mutant (DRDR), 
demonstrating that Atg16L1 must be able to bind WIPI2b to allow for Atg12–5-16L1 
recruitment and subsequent LC3 targeting during xenophagy. 
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Figure 4.17 Atg16L1 ERER shows impaired LC3 recruitment to the SCV 
(a) Atg16L1Δ/Δ MEFs were transiently transfected with FLAG-Atg16L1 WT, ERER or 
DRDR for 24 hours before being infected with Salmonella (MOI of 25) for one hour. 
Cells were fixed, labelled with the indicated antibodies and analysed by confocal 
microscopy. Scale bars are 5 µm. (b) Statistical analysis of (a). The SEM for four 
independent experiments is shown. Statistical analysis was performed by one-way 
ANOVA with Dunn’s post text. ***, p ≤ 0.001. 
 
4.6.4 Wortmannin does not inhibit WIPI1 or WIPI2 localisation to 
Salmonella 
The requirement for PtdIns(3)P in xenophagy is unclear. It is well established that 
Beclin1 is required for Salmonella clearance through xenophagy both at the organism 
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(Jia et al., 2009) and cellular level (Sun et al., 2008). Similarly, wortmannin treatment 
of cells before and during Salmonella infection results in increased intracellular bacteria 
(Steele-Mortimer et al., 2002, Brumell et al., 2002). However, the reason for this 
requirement for PtdIns(3)P production by the Beclin1-continaing Vps34 complex 
during xenophagy is unknown. In macroautophagy, wortmannin treatment completely 
inhibits LC3 recruitment to the forming autophagosomes. This does not seem to be the 
case during xenophagy. Instead, the requirement of PtdIns(3)P for LC3 recruitment is 
under debate. While one study found no effect on the percentage of LC-positive 
salmonella (Kageyama et al., 2011), others found that wortmannin treatment causes a 
significant decrease, but not complete inhibition, in LC3 recruitment to the salmonella 
(Huang et al., 2011, Birmingham et al., 2006). GFP-WIPI1 recruitment requires 
PtdIns(3)P; wortmannin treatment abolishes GFP-WIPI1 localisation to Salmonella 
(Kageyama et al., 2011). I used immunofluorescence to investigate WIPI1 and WIPI2 
recruitment to Salmonella in cells treated with wortmannin (Figure 4.18). Surprisingly, 
although wortmannin treatment abolished WIPI2 and LC3 puncta formation during 
starvation (Figure 4.18a), WIPI1 and WIPI2 localisation to Salmonella were not 
inhibited by wortmannin (Figure 4.18b and c). This is in contrast to previous work by 
Kageyama et al., 2011 described above (Kageyama et al., 2011). I repeated this 
experiment three times, and each time saw no effect on WIPI2 recruitment to 
Salmonella. The possible reasons for this disagreement are not clear. The HeLa cells 
that I used for wortmannin treatment were treated with RISC-free siRNA as they were 
from the same pool of cells used for colony counting (Figure 4.16), but this RISC-free 
treatment does not interfere with normal WIPI2 behaviour (Figure 4.16b and 4.18a). 
Due to time constraints, I did not carry out statistical analysis on the number of p62-
labelled Salmonella that were also positive for WIPI1 or WIPI2. It is therefore possible 
that wortmannin treatment causes a decrease, but not a complete abolition, in WIPI1 
and WIPI2 recruitment, as is the case for LC3 recruitment after wortmannin treatment. 
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Figure 4.18 Wortmannin treatment does not inhibit WIPI1 or WIPI2 recruitment during 
xenophagy 
(a) HeLa cells were treated with RF siRNA for 72 hours were starved in EBBS with or 
without wortmannin for 1 hour before fixing and staining with the indicated antibodies 
for immunofluorescence. Scale bars are 20 µm. (b,c) HeLa cells treated with RF siRNA 
for 72 hours were infected with Salmonella with an MOI of 100 for 1 hour before fixing 
and labelling for immunofluorescence with Hoechst dye, anti-p62, anti-WIPI2 and anti-
LC3 (b) or anti-WIPI1 (c). Scale bars are 5 µm 
 
4.7 Discussion 
In this chapter I have demonstrated that WIPI2b functions in autophagy by recruiting 
the Atg12–5-16L1 complex to forming autophagosomes (Figure 4.18). This helps 
explain two incompletely understood areas of autophagosome biogenesis: the function 
of PtdIns(3)P in autophagy initiation, and the PtdIns(3)P-dependence of Atg12–5-16L1 
recruitment, by connecting PtdIns(3)P to the Atg12–5-16L1 complex via WIPI2b. 
Previous work has shown that FIP200 is required for Atg12–5-16L1 recruitment 
in both starvation-induced autophagy and targeted autophagy of latex beads and 
Salmonella (Nishimura et al., 2013, Gammoh et al., 2013, Fujita et al., 2013). However, 
my results suggest that FIP200 is not involved in Atg12–5-16L1 recruitment. As 
discussed in Chapter 3.8, Atg16L1 mutants used by Nishimura et al., and Gammoh et 
al., will have disrupted WIPI2b binding as well as FIP200 binding. The point mutants 
of Atg16L1 used in this chapter for rescue of Atg16L1Δ/Δ MEFs dissociated Atg16L1-
FIP200 binding from Atg16L1-WIPI2b binding and showed that Atg16L1 interaction 
with WIPI2b, but not FIP200 is required for Atg16L1 function in autophagy. I could 
detect no significant autophagy impairment in cells rescued with the FIP200 binding 
mutant of Atg16L1. However, recent work showing that Atg16L1 can bind FIP200 and 
ubiquitin, and through these binding partners be recruited to Salmonella and latex beads, 
has raised the possibility that the mechanisms of Atg16L1 recruitment have become 
more complex in higher organisms, possibly to allow for more complex autophagy 
pathways than are found in yeast (Fujita et al., 2013). Therefore, the Atg16L1-FIP200 
binding may have a function in cargo-specific autophagy, or in some other regulatory or 
redundant function in macroautophagy. Although requiring further investigation, this 
hypothesis is supported by the evolutionary conservation of the WIPI2b and FIP200 
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binding sites of Atg16L1 (observation by Michael Wilson, personal communication). 
The WIPI2b binding site is found in most metazoans, whereas the FIP200 binding site 
is missing in metazoans pre-dating zebrafish, and may not be present at all in 
invertebrates (observation by Michael Wilson). Although binding site for WIPI2b (and 
FIP200) on Atg16L1 is missing in yeast, and S. cerevisiae Atg18 does not bind Atg16 
(Fulvio Reggiori, personal communication), S. pombe Atg18a binds Atg5 and is thought 
to recruit the Atg12–5-16 complex to the PAS through this interaction (Sun et al., 2013). 
Therefore, it may be that the mechanism of recruiting the Atg12–5-16 complex through 
Atg18/WIPI2b is conserved between S. pombe and mammals. 
 Results in this chapter show that WIPI2 binding to Atg16L1 is required for 
xenophagy and LC3 recruitment to Salmonella. The requirement for PtdIns(3)P binding 
proteins in control of intracellular bacteria and for the recruitment of LC3 to Salmonella 
was previously not known. However, I also found that WIPI1 and WIPI2 could be 
recruited to Salmonella even in the presence of wortmannin. As discussed in Chapter 
4.6.4, the reason for the difference between my results (Figure 4.18) and published 
work showing that GFP-WIPI1 localisation to Salmonella is inhibited by wortmannin 
treatment is not known. Similarly, the reasons behind different findings for the 
dependence of LC3 recruitment to Salmonella on PtdIns(3)P is unclear (Kageyama et 
al., 2011, Birmingham et al., 2006, Huang et al., 2011). It seems to be the case that the 
dependence on PtdIns(3)P for recruitment of LC3 is not absolute, but perhaps instead is 
partial (Huang et al., 2011). Given more time I would have quantified WIPI1 and 
WIPI2 recruitment to p62-positive Salmonella under wortmannin-treated conditions as 
these proteins may similarly be partially dependent on PtdIns(3)P for their recruitment 
during xenophagy. As discussed above, Atg16L1 appears to be recruited to Salmonella 
via multiple binding partners. WIPI2 may also be recruited to Salmonella through 
unknown binding partners. To investigate this further I would use our GFP-WIPI2b 
stably expressing cell line for Salmonella infection followed by GFP-Trap and mass 
spectrometry to identify novel proteins that bind WIPI2b during xenophagy. 
Furthermore, I would use siRNA knockdown of WIPI2 followed by rescue with siRNA 
resistant WT WIPI2, WIPI2b RERE (Atg16L1 binding mutant), WIPI2b FTTG 
(PtdIns(3)P binding mutant) and WIPI2b FTTG RERE (PtdIns(3)P and Atg16L1 
binding mutant) to determine the PtdIns(3)P- and Atg16L1-binding requirements of 
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WIPI2b in xenophagy. If Atg16L1 itself is a binding partner through which WIPI2b can 
be recruited in the absence of PtdIns(3)P (as Atg16L1 can also be recruited through 
binding FIP200 and ubiquitin (Fujita et al., 2013)) WIPI2b FTTG RERE should not be 
recruited to p62-positive Salmonella. Furthermore, if WIPI2b is the major protein 
responsible for Atg12–5-16L1 recruitment during xenophagy then overexpression of 
WIPI2b RERE after endogenous WIPI2 depletion may inhibit LC3 recruitment, as seen 
in macroautophagy. Generally, the recruitment mechanisms of Atg proteins during 
xenophagy seem to be more complex, possibly with partially redundant mechanisms, 
than macroautophagy. As work to understand xenophagy continues it will be interesting 
to see which of the autophagy proteins in higher eukaryotes have evolved features that 
are not present in their yeast counter parts and that support more complex recruitment 
and/or regulation mechanisms. 
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Figure 4.19 WIPI2b recruits the Atg12–5-16L1 complex to forming autophagosomes 
Model of WIPI2b-mediated Atg12–5-16L1 recruitment to PtdIns(3)P-positive site of 
autophagosome formation. Figure from (Dooley et al., 2014). 
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Chapter 5. Preliminary investigation of WIPI2 
phosphorylation 
5.1 Introduction and Aim 
5.1.1 Introduction 
As discussed in Chapter 3, the Atg16L1-WIPI2b interaction appears to be starvation-
independent. This raises the question of whether the Atg16L1-WIPI2b interaction is 
regulated and if it is, how it is. Similarly, WIPI2 can bind PtdIns(3)P and PtdIns(3,5)P2 
but forms PtdIns(3)P-dependent starvation-induced puncta at the omegasome (Polson et 
al., 2010). PtdIns(3)P is found on early and late endosomes as well as on omegasomes 
and PtdIns(3,5)P2 is found on late endosomes (Vicinanza et al., 2008). The regulation 
behind the specific localisation of WIPI2 to PtdIns(3)P positive omegasomes upon 
starvation is not known. Atg18 (S. cerevisiae) is required for starvation-induced 
autophagy and for the regulation of vacuole morphology, and localises to PtdIns(3)P on 
the PAS and PtdIns(3,5)P2 on the vacuole, respectively, for these functions (Barth et al., 
2001, Efe et al., 2007). Recruitment of Atg18 to the PtdIns(3)P-positive PAS requires 
Atg2 binding by Atg18 (Suzuki et al., 2007, Rieter et al., 2013) and recruitment to the 
PtdIns(3,5)P2 positive vacuole requires binding to Vac7 (Efe et al., 2007). It is possible 
that WIPI2 has an analogous binding partner, or is post-translationally modified to 
allow proper recruitment to PtdIns(3)P positive omegasome upon starvation-induced 
autophagy. 
 Work in our group (Hannah Polson, unpublished data) has suggested that WIPI2 
may be phosphorylated within its C-terminus. In the mass spectrometry screen for WIPI 
interactors using GFP-tagged stable cell lines of WIPI1a and WIPI2b (see Chapter 3.1) 
a phosphorylation of WIPI2b at serine 395 was found in all three experiments. There 
was no clear fed/starved dependence of the phosphorylation: S395 was phosphorylated 
in starved conditions of experiments 1 and 3, but in fed conditions for experiment 2 
(See Figure 5.1a). Protein phosphorylation is thought to be one of the most prevalent 
posttranslational modifications and is responsible for altering the function of a protein 
in a number of ways including disrupting or inducing protein-protein, protein-
membrane and protein-DNA interactions, changing the activity state of enzymes, and 
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stabilising or destabilising proteins (Cohen, 2002). The reversible nature of protein 
phosphorylation makes it suitable for switching a protein between two states. 
Phosphorylation of the C-terminus of WIPI2 may provide a mechanism through which 
WIPI2 interaction with membranes or proteins can be modulated. Serine 395 of WIPI2b 
is found in the C-terminus of WIPI2a and WIPI2b (Figure 1.8 and 1.9) and is conserved 
in mouse, chicken and Xenopus (observation by Michael Wilson, personal 
communication). The same site was identified as a potential mTOR phosphorylation site 
by Hsu et al., who used quantitative mass spectrometry in a proteomic screen for 
Torin1-sensitive phosphorylation sites and subsequently defined a mTOR consensus 
motif (Hsu et al., 2011). WIPI2 serine 395 fits this consensus (Figure 5.1b) (Hsu et al., 
2011). mTOR is a master controller of cell growth that forms two kinase complexes, 
mTORC1 and mTORC2 (see Chapter 1.3.1). WIPI2 S395 may be phosphorylated by 
mTORC1, mTORC2 or another kinase downstream of these master regulators. Indeed, 
this potential WIPI2 phosphorylation site has been identified in a number of 
phosphoprotein screens, as indexed by PhosphoSitePlus® (Hornbeck et al., 2012), and 
kinase predication resources such as PhosphoNET: Kexus Kinase Predictor suggest that 
kinases other than mTOR may recognise this site. 
 In addition to this potential phosphorylation site, Atg2 was identified in one of 
Hannah Polson’s mass spectrometry experiments as an interactor of GFP-WIPI2b. 
Although Atg2 binding by WIPI2b was only found in one mass spectrometry result and 
was not further confirmed, Atg18 binds Atg2 in yeast and is required for proper Atg18 
localisation to the PAS (Suzuki et al., 2007) and the Atg18-Atg2 complex regulates 
Atg9 trafficking (Obara et al., 2008, Wang et al., 2001, Reggiori et al., 2004). Binding 
of WIPI2 to Atg2 may be conserved and required for correct WIPI2 localisation to the 
omegasome as in yeast.  
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Figure 5.1 Potential phosphorylation of WIPI2 serine 395 
(a) Figure showing mass spectroscopy detection of WIPI2 peptides from Hannah’s 
GFP-WIPI2b GFP-Trap and mass spectroscopy screen. Yellow indicates peptides 
detected. Green indicates modified amino acids. 1, 2, and 3 indicate the experiment 
number. Experiment performed by and figure provided by Hannah Polson. (b) WIPI2b 
serine 395 conforms to the mTOR phosphorylation consensus. PSSM, position-specific 
scoring matrix. Pannel showing mTOR consensus is from (Hsu et al., 2011). Reprinted 
with permission from AAAS. 
 
5.1.2 Aim 
I sought to substantiate data from our lab and from published work that WIPI2 is 
phosphorylated at serine 395 and determine if phosphorylation has any effect on WIPI2 
function in autophagy. To do this I began by validating rabbit serum produced against 
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the phosphosite, and generating and testing WIPI2b phosphomutants to probe the effect 
of phosphorylation on Atg16L1 binding. I investigated the function of Atg2 on 
autophagy and WIPI2 function using Atg2 knockdown. I performed this work before a 
study on the role of Atg2 in starvation induced autophagy and lipid droplet formation 
was published (Velikkakath et al., 2012). 
 
5.2 Phosphospecific antibody validation 
5.2.1 Antibody validation by Western blot 
Rabbits were immunised with an 11 amino acid phosphopeptide corresponding to the 
human WIPI2 phosphosite (Figure 5.2). Cysteine or lysine was used for peptide 
conjugation to the carrier protein in the production of STO 313, 314 and 315, and STO 
316, 317 and 318, respectively. The peptide was made and conjugated by LRI peptide 
synthesis unit and the serum generated by LRI polyclonal antisera services. 
 I validated the antiserum against endogenous WIPI2 by using cell lysates from 
WIPI2 siRNA treated HEK293A and western blot analysis. The anti-WIPI2 polyclonal 
rabbit antibody serum that was previously developed by our lab (Polson et al., 2010) is 
used at a concentration of 1:250 and gives a very clear band corresponding to WIPI2 
just below the marker for 52 kDa (WIPI2 has a molecular weight of 49 kDa) (Figure 5.3, 
top panel). I tested serums STO 313-318 over a range of concentrations: 1-100 – 1:1000 
(Figure 5.3). STO 313, 314, 317 and 319 did not give any specific bands that decreased 
with WIPI2 knockdown. STO 315, 316 and 318 all showed a band at the correct 
molecular weight for WIPI2 that decreased upon knockdown that was not present in the 
pre-immune (PI) serum. Therefore it is likely that these sera recognise endogenous 
WIPI2 protein from human cells. These sera showed a clear WIPI2 signal at 1:200 or 
1:1000. 
 WIPI2 is well conserved between mouse and human. The peptide used for 
polyclonal antibody production differs by two amino acids when compared to mouse 
WIPI2 over the same stretch (the extreme N-terminus is an alanine and the extreme C-
terminus is a glycine in the mouse peptide). I used cell lysates from wild-type and TSC2 
knock out (TSC2-/-) MEFs to validate recognition of mouse WIPI2 by STO 315, 316 
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and 318. TSC2 is one member of TSC1/TSC2, a heterodimeric complex that, together 
with TDC1D17, is a GAP for Rheb (Chapter 1.3.1). TSC2 loss results in increased 
mTORC1 signalling (Zhang et al., 2003). If WIPI2 is phosphorylated by mTORC1, or 
via a downstream pathway activated by mTORC1, WIPI2 phosphorylation should also 
be increased in TSC2-/- MEFs. I used both the wild type and knockout cell lysates to 
investigate if there was any difference in the WIPI2 as detected by phosphospecific 
antibody serum in mTORC1 activated cell lysates. As a control for WIPI2 recognition, I 
used HEK293A lysates from RISC-free and WIPI2 siRNA treated cells (Figure 5.4). 
Again, all three antibodies showed a WIPI2 band just below the 52 kDa marker (shown 
in yellow) that decreased after WIPI2 knockdown in HEK293A cells and all three 
recognised mouse WIPI2. However, there was no difference in WIPI2 signals between 
WT and TSC2-/- lysates, indicating that there is no change in WIPI2 phosphorylation 
between the two cell types or that the phosphoantibodies require optimising for 
phospho-WIPI2 recognition. Although WIPI2 S395 has been reported to be mTOR 
regulated, with a decrease in phospho-detection by mass spectrometry after Torin1 
treatment (Hsu et al., 2011), I also saw no difference in signal when cells were treated 
with the mTOR inhibitor Torin1 (data not shown). Because the conditions under which 
WIPI2 is phosphorylated were unclear, I decided to use ELISA (enzyme-linked 
immunosorbent assay) for further optimisation and validation of phosphopeptide 
recognition by the phospho-antibodies. Serum STO 316 and 318 were used for further 
optimisation; STO 315 was not optimised further due to the non-specific band seen just 
above the WIPI2 band, which may render interpretation of western blots with this 
antibody difficult. 
 
 
Figure 5.2 WIPI2 peptides used for rabbit immunisation 
An 11 amino acid phosphopeptide was used for immunisation. Either lysine (STO 313, 
314 and 315) or cysteine (STO 316, 317 and 318) was used for conjugation of the 
peptide to the carrier protein. 
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Figure 5.3 STO 315, 316 and 318 recognise human WIPI2 
Cell lysates from HEK293A cells treated with RISC-free (RF) or WIPI2 siRNA for 72 
hours were used for western blot analysis of the indicated immunoserum. STO 280 is a 
positive control for a rabbit polyclonal serum that recognises WIPI2. Molecular weight 
markers are in kDa. WIPI2 has a molecular weight of 49 kDa and runs just below the 52 
kDa marker. 
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Figure 5.4 STO 315, 316 and 318 recognise mouse WIPI2 
Cell lysates from HEK293A cells treated with RISC-free (RF) or WIPI2 siRNA for 72 
hours, and cell lysates from TSC2 knockout (-/-) or wild-type (WT) MEFs were used 
for western blot analysis of recognition of mouse WIPI2 by the indicated serum. Serum 
were used at the indicated dilution. Molecular weight markers are in kDa. 
 
5.2.2 Antibody validation by ELISA 
The 11 amino acid polypeptide (Figure 5.2) used for antibody production will have a 
number of epitopes, resulting in the production of a polyclonal antiserum and probably 
the production of antibodies that can recognise the peptide irrespective of its 
phosphorylation status (i.e. non-phosphospecific). Preincubating the polyclonal serum 
with a non-phosphorylated version of the peptide used for immunisation results in 
formation of peptide-antibody complexes between the non-phospho peptide and non-
phosphospecific antibodies present in the polyclonal serum. Therefore, preincubation of 
serum with non-phosphopeptide can be used to remove the non-phosphospecific 
antibodies from the ELISA reaction. After removal of the non-phospho antibodies from 
the ELISA reaction, the titre of the phosphospecific antibodies in STO 316 and STO 
318 serum can be compared. 
 Before investigating the relative titre of phosphospecific antibodies in STO 316 
and STO 318, I found the peptide concentration over which epitope recognition by the 
whole sera (with no preincubation) increase linearly with increase of peptide on the 
ELISA well surface. I used serum dilutions of 1:250, 1:2000 and 1:20000 and 
phosphopeptide range of 0.01 – 100 ng per well (concentration range: 0.0002 – 2 
ng/µL) in duplicate. The increase in absorption at 490 nm (the absorption wavelength 
for the substrate, OPD) was roughly linear between 0.01-1 ng (0.0002 – 0.002 ng/µL) of 
peptide for both STO 316 and 318 for all serum dilutions before levelling off for higher 
peptide amounts (Figure 5.5a, b and c). Results are shown on a logarithmic scale so that 
the data points at low peptide concentrations can be distinguished. Left hand panels 
shown show no serum control, right hand panel show serum results in more detail. 
Serum dilution of 1:20000 showed the greatest difference in A490 between the peptide 
concentrations in this range. 
 I subsequently wanted to validate phosphopeptide recognition by the two 
antisera. I decided to use 0.01, 0.05 and 0.1 ng of peptide per well (concentration range 
Chapter 5. Results 
 
 179 
of 0.0002 – 0.002 ng/µL) in an attempt to ensure that the increase in antibody binding is 
linear with increase in peptide. I used serum dilutions of 1:250, 1:2000 and 1:20000. No 
peptide controls and no serum controls were used for each serum concentration and 
peptide amount, respectively. I used three conditions for each set of peptide 
concentrations and serum dilutions: no preincubation with peptide, preincubation with 
non-phosphopeptide to remove non-phosphospecific antibodies, and preincubation with 
non-phospho and phosphopeptide to remove all antibody from the sera and reduce 
absorbance to background levels (Figure 5.6a, b and c). Preincubation peptide was 
added at a final concentration of 1 µg/mL. I did not conduct this ELISA in duplicate, 
limiting its accuracy and making the results difficult to interpret. 
For both STO 316 and 318, the increase of absorbance with peptide 
concentration (with no preincubation) was as expected: as the concentration of peptide 
increased, so did the absorbance (Figure 5.6a, b and c). However, the increase in 
absorbance with peptide concentration was not linear, and it may be that the substrate 
(OPD) became saturated at the higher peptide concentrations. Generally, serum at 1:250 
and 1:200 had similar absorbances over the peptide concentration range, and this was 
similar between the two sera (with a maximum OD A490 of approximately 2.5 for both 
STO 316 and 318). However, at a dilution of 1:20000 STO 318 resulted in a higher 
OD490 than for STO316, suggesting that the antibody tire may be higher in STO318. 
For both sera, peptide competition with both the phospho and non-
phosphopeptide reduced absorbance to basal levels for serum at 1:20000 dilution, and 
almost basal levels for 1:2000 dilution. This indicates that the reactivity between the 
antisera and peptide on the ELISA plate is specific. However, at a dilution of 1:250 both 
STO 316 (Figure 5.5b) and STO 318 (Figure 5.5c) showed above basal absorbance 
when preincubated with both peptides. This above basal absorbance was consistent for 
all concentrations of peptides attached to the ELISA plate, including no peptide control, 
but was not seen for no peptide on the ELISA plate when the antiserum was not 
preincubated with peptide. It could be that the sera at a dilution of 1:250, when 
preincubated with peptide, are being retained in the wells between washes. Similarly, 
sera at 1:250 in wells with no peptide produced above basal absorbance when pre-
incubated with just the non-phosphopeptide.  
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 Preincubation with non-phosphopeptide alone did not reduce absorbance to 
basal levels, but did reduce the absorbance range for each antiserum dilution compared 
to the absorbance seen with no peptide competition. This suggests that non-
phosphospecific antibodies are being successfully removed from the antisera and that 
there are phosphospecific antibodies present. Generally, the absorbance seen with STO 
316 and 318 after preincubation with non-phosphopeptide was similar, suggesting that 
they have a similar titre of phosphospecific antibodies. This ELISA needs repeating in 
duplicate or triplicate, using a lower range of peptide concentrations for coating the 
ELISA plate, in order to be able to distinguish which is the better phosphospecific 
antiserum. 
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Figure 5.5 STO 316 and 318 validation by ELISA 
(a) Key for ELISA graphs. Black line with black circular points: serum control, blue 
line with black square points, 1:20000 dilution; green line with upright black triangle, 
1:2000 dilution; and red line with upside down black triangle, 1:250 dilution. (b) STO 
316 was used at the indicated dilutions for ELISA against phosphopeptide at the 
indicated concentrations. (c) STO 316 was used at the indicated dilutions for ELISA 
against phosphopeptide at the indicated concentrations. 
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Figure 5.6 STO 316 and 318 show some phospho-specificity by ELISA 
(a) Key for ELISA graphs. Black boxed points indicate no peptide competition, white 
boxes incicate non-phosphopeptide competition, and black triangles indicate completion 
with both non-phospho and phosphopeptide. Serum dilutions: black line, serum control; 
blue line, 1:20000; green lines, 1:2000; red line, 1:250. (b) STO 316 was used at the 
indicated dilutions for ELISA against phosphopeptide at the indicated concentrations 
with the indicated peptide competition. (c) STO 316 was used at the indicated dilutions 
for ELISA against phosphopeptide at the indicated concentrations with the indicated 
peptide competition. 
 
5.3 Phosphomutant effect on Atg16L1 binding 
The C-terminus of WIPI2 is thought to be unstructured (Krick et al., 2012) and so is it 
possible that this region of the protein could affect Atg16L1 binding. It may be that the 
C-terminus hinders Atg16L1 binding through binding to the Atg16L1-binding region on 
Chapter 5. Results 
 
 183 
the surface of the β-propeller of WIPI2, or it may enhance Atg16L1 binding by forming 
a secondary Atg16L1 binding site. Serine 395 could therefore play a role in regulation 
of Atg16L1 binding through the phosphorylation of this residue altering the interaction 
between the C-terminus and the β-propeller of WIPI2 or between the WIPI2 C-terminus 
and Atg16L1.  
 In order to test the effect of phosphorylation of Serine 395 on Atg16L1 binding, 
I produced GFP-tagged phospho-null (alanine) and phospho-mimetic (glutamic acid) 
point mutants of GFP-WIPI2b. Serine 395 is immediately preceded by another serine 
(394), therefore I made single mutants (S395A and S396E) and double mutants (S394A 
3S95A, and S394E S395E) in case serine 394 can be phosphorylated in situations where 
S395 is mutated. I used these mutants for GFP-Trap and analysed endogenous Atg16L1 
co-immunoprecipitation by western blot (Figure 5.7). There was no difference in 
Atg16L1 co-immunoprecipitation, suggesting that the phosphorylation state of serine-
395 has no effect on Atg16L1 binding. Note: removing the whole C-terminus of 
WIPI2b increases Atg16L1 binding (Chapter 3.6.1). These experiments were performed 
in the same experimental set as C-terminus deletion experiments which show that 
removing the whole C-terminus of WIPI1 or WIPI2 significantly increases Atg16L1 
binding (Figure 3.21), this experiment set was performed three times and I have shown 
a different experiment below from that used for Figure 3.21. I have separated the 
phosphomutant and C-terminal deletions results for clarity. GFP-WIPI2a cannot be seen 
in the input as this protein does not overexpress well, even though it is in the same 
vector as other GFP-WIPI constructs. 
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Figure 5.7 Phospho-null and -mimetic mutants have no effect on Atg16L1 binding 
HEK293A cells were transiently transfected with the indicated GFP-tagged constructs 
for 24 hours before GFP-Trap and western blot analysis. Molecular markers are in kDa. 
 
5.4 Atg2 
5.4.1 Atg2 knockdown optimisation 
Mammals have two Atg2 homologues. Atg2a and Atg2b have 44.5% amino acid 
identity and have redundant funcitons (Velikkakath et al., 2012). I used siRNA for each 
homologue simultaneously to knockdown both proteins at the same time. As no 
commercial antibodies that worked for western blot were available, I assessed mRNA 
depletion using qPCR (quantitative PCR) (Figure 5.8). Atg2a was significantly depleted 
by Atg2a siRNA duplexes 17, 19 and 20 (Figure 5.8a) and Atg2b was significantly 
depleted by all four Atg2b siRNAs (Figure 5.8b). Atg2a siRNA had no significant 
effect on Atg2b mRNA levels, however Atg2b siRNA generally decreased Atg2a levels 
(this was statistically significant for Atg2b duplex 18 and 21). Consistently, published 
work has subsequently shown that depletion of Atg2a mRNA upon Atg2b knockdown 
is reflected at the protein level; Atg2b knockdown reduces Atg2a protein (Velikkakath 
et al., 2012). This depletion of Atg2a protein was seen after using a different siRNA 
duplex to the one that I used in work for this thesis, suggesting that it is a biological 
rather than an off-target effect. I used the siRNAs that most effectively depleted their 
target proteins; therefore I used Atg2a siRNA duplex #20 and Atg2b siRNA deplex #21 
to knockdown Atg2a and Atg2b for autophagy assays. 
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Figure 5.8 Optimisation of Atg2a and Atg2b knockdown 
HEK293A cells were treated with RISC-free (RF) control, the indicated Atg2a siRNA 
(a) or Atg2b siRNA (b) for 72 hours before RNA extraction and qPCR analysis for 
change in Atg2a levels (left hand panels) and change in Atg2b levels (right hand 
panels). The mean is shown from three independent experiments in triplicate. Statistical 
analysis performed by student’s t-test. Where the difference is significant, the p value is 
shown. 
 
5.4.2 Atg2 knockdown increases LC3 lipidation and LC3 and WIPI2 
puncta 
The function of Atg2 and its position within the sequential and hierarchical action of 
mammalian Atg proteins was not published when I started this work. It has since been 
published that Atg2 acts during the late stages of autophagosome formation, after LC3 
recruitment and lipidation but before autophagosome closure. Atg2a and b depletion 
leads to an accumulation of LC3-II and unclosed LC3 positive autophagosomes in fed 
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and starved conditions, with no further accumulation with lysosomal inhibitors, 
suggestive of a maturation block (Velikkakath et al., 2012).  
 I found that knockdown of Atg2a and b resulted in a consistent increase in LC3-
II in fed conditions (Figure 5.9a and b). Furthermore, LC3 and puncta increased 
significantly in fed and starved conditions, while WIPI2 puncta were significantly 
increased in starved conditions (Figure 5.9c, d and e). LC3 puncta further increased 
with Bafilomycin A treatment, however Bafilomycin A treatment was only used in two 
of the three experiments and so was not included in the statistical analysis (shown as a 
grey bars in Figure 5.9d and e). LC3 and WIPI2 puncta appeared larger in Atg2a and b 
knockdown cells than in RISC-free control. My results support an enhancement of 
autophagy when Atg2a and b are depleted as I repeatedly see a further increase in LC3 
lipidation and puncta formation with Bafilomycin A treatment. However, in light of 
published data, it may be that the knockdown that I was achieving was not sufficient to 
fully block autophagosome formation.  
 The data shown in Figure 5.9 is from the same set of experiments as that shown 
in Figure 4.3. The immunofluorescence images are from the same experiment repeat. 
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Figure 5.9 Atg2a and b knockdown increases LC3 lipidation and LC3 and WIPI2 puncta 
formation 
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(a) 2GL9 cells treated with RISC-free or Atg2a and b siRNA for 72 hours were treated 
with full medium (F), starvation medium (S) or starvation medium with Bafilomycin A 
(B) for two hours before LC3 lipidation analysis by western blot. Molecular weight 
markers are in kDa. (b) Quantification of (a). The SEM for three independent 
experiments is shown. (c) Cells treated as in (a) were analysed by confocal microscopy 
for GFP-LC3 and endogenous WIPI2 puncta formation. Scale bars are 10 µm. (d) 
Statistical analysis of GFP-LC3 puncta from (c). The SEM from three (outlined in 
black) or two (outlined in grey) independent experiments is shown. Statistical analysis 
was performed by Student’s t test. *, p ≤ 0.05; **, p ≤ 0.01; ****, p ≤ 0.0001.  
 
5.5 Discussion 
In this chapter I have begun investigations into the possible function of WIPI2b 
phosphorylation on Serine 395 and the function of Atg2. I have validated two 
polyclonal antibodies for recognition of endogenous WIPI2. Further work is needed to 
fully characterise the specificity of these antibody for phosphorylated WIPI2. Given 
more time I would use ELISAs to validate the specificity of STO 316 and 318 for the 11 
amino acid phosphopeptide used for antibody production, using a lower peptide 
concentration on the ELISA wells to ensure a proper linear relationship between 
increasing the peptide concentration and increased antibody binding. Once I had found 
the peptide concentration range over which a linear relationship is shown, I would use 
peptide competition to determine which immunoserum has the highest tire of 
phosphospecific antibodies. As the conditions under which WIPI2 Serine 395 is 
phosphorylated are unknown, following selection of the better phosphospecific antibody, 
immunoprecipitation of WIPI2 and in vitro dephosphorylation using calf intestinal 
phosphatase could be used for validation of the phosphospecific antibody by western 
blot. 
 I have shown that phospho-mimetic and phospho-null point mutants of WIPI2b 
do not affect Atg16L1 binding. This suggests that phosphorylation of serine 395 does 
not play a role in regulating the Atg16L1-WIPI2b interaction. However, removal of the 
whole C-terminus of WIPI2b does increase Atg16L1 binding (Figure 3.21). Similarly, 
removal of the C-terminal of WIPI1a increases Atg16L1 binding to WIPI1a. Clearly the 
C-termini of these proteins affect Atg16L1 binding in some manner. Whether this plays 
a functional role requires further work. Although it is seems likely that Serine 395 
phosphorylation does not affect Atg16L1 binding, phosphorylation at this site may 
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affect WIPI2 binding to the membrane or to PtdIns(3)P. Using the WIPI2 Serine 395 
point mutants for phospholipid binding assays and membrane fractionation would help 
determine whether this is the case. Furthermore, this site may affect some other as yet 
undiscovered autophagy-related function of WIPI2. Using the phospho-mimetic and 
phospho-null WIPI2b mutants for rescue experiments following WIPI2 knockdown 
would give an indication of whether this is the case. 
 I began to characterise the function of Atg2 in autophagy and have shown that 
knockdown results in an increase in WIPI2 and LC3 puncta and LC3 lipidation. 
Published work from another lab has shown that Atg2 acts downstream of LC3 
lipidation and is required for autophagosome closure (Velikkakath et al., 2012), putting 
it downstream of WIPI2 function. The same study also showed that Atg2 binds WIPI4, 
and that Atg2 localisation to the forming autophagosome requires PtdIns(3)P. WIPI4 is 
a homologue of WIPI2, and the WIPI4 homologue in C. elegans, Epg-6, has been 
shown to act downstream of C. elegans Atg18 (WIPI2 homolgoue) (Lu et al., 2011), 
suggesting that WIPI4 and Epg-6 have conserved functions. It is possible that each 
member of the WIPI family performs a different function, perhaps each recruiting its 
own subset of interacting proteins to the omegasome in a PtdIns(3)P dependent manner. 
I did not look for WIPI2 binding of Atg2, which would have to be done before an Atg2-
WIPI2 interaction could be discounted, but it possible that Atg2 present in Hannah 
Polson’s mass spectrometry results could have been pulled down as a false positive 
through an intermediate interacting protein or through immunoprecipitating 
autophagosomal membranes. 
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Chapter 6. Discussion 
In my PhD work I have sought to identify the molecular functions of mAtg9 and WIPI2 
in autophagy. To do this I attempted to identify novel mAtg9 and WIPI2 interactors 
before concentrating my efforts on validating and characterising interacting partners 
previously identified within the lab. In the preceding chapters I have described the 
function of WIPI2b as a PtdIns(3)P effector whose function is to directly bind and 
recruit the Atg12–5-16L1 complex to forming autophagosomes. This function of 
WIPI2b explains both why Atg12–5-16L1 recruitment to forming autophagosome is 
PtdIns(3)P-dependent and also why PtdIns(3)P is so essential for autophagosome 
formation. Previous chapters also detail work done to validate TfR as a mAtg9 binding 
partner. This work contributed to Andrea Orsi’s study describing mAtg9 localisation to 
tubular-vesicular compartments and the importance of these in autophagy (Orsi et al., 
2012). 
Using the limited approaches that I set up, I did not identify any novel mAtg9 or 
WIPI2 interactors, which was disappointing. Given more time I would use BioID 
technology in combination with mass spectrometry to screen for new interacting 
proteins (Roux et al., 2012). BioID is a technology involving fusion of a promiscuous E. 
coli biotin ligase to a target protein (in this instance either WIPI2b or mAtg9). Once 
expressed in cells, this fusion protein then biotinylates neighbouring proteins in a 
proximity-dependent manner. These proteins can be isolated by biotin affinity capture 
using streptavidin-conjugated beads and subsequently identified using mass 
spectrometry (Roux et al., 2012). In terms of the mass spectra produced, this technique 
is much simpler than using crosslinking and has now been successfully used in our lab. 
Identification of new mAtg9 interactors is still an important problem as this will shed 
some light on the function of this protein, and characterisation of additional WIPI2b 
interactors may help explain some of the remaining questions about this protein (see 
below). 
Given that WIPI2 is a WD-40 domain containing protein that forms a 7-bladed 
β-propeller, it is likely that it functions to mediate protein interactions. Indeed, it seems 
probable that the other PROPPIN proteins similarly mediate protein interactions. The 
combination of the PtdIns(3)P- and protein-binding ability of the PROPPIN family 
Chapter 6. Discussion 
 
 191 
makes them ideally suited to recruiting Atg proteins during the early stages of 
autophagy, where the activation signal comprises PtdIns(3)P production at the ER. 
Consistently, Atg18, WIPI4 and EPG-6 all bind Atg2 (Obara et al., 2008, Velikkakath 
et al., 2012, Lu et al., 2011). The PROPPIN family are thought to be the first group of 
β-propeller proteins acting to mediate protein-lipid complexes (Rieter et al., 2013). 
Intriguingly, Atg18 and WIPI2b seem to be binding their interacting partners (Atg2 and 
Atg16L1, respectively) at similar locations within their β-propellers. The loops between 
β-sheets of each blade of the β-propeller are often where interactions occur. Loops in 
blades 2 that are proximal blade 3 and the loop connecting blades 2 and 3 are important 
for Atg2 binding (Watanabe et al., 2012, Rieter et al., 2013). Atg2 binds to two sites 
within blade 2 of Atg18: at F54 S55 and P72 R73 (Watanabe et al., 2012). These 
residues are conserved in WIPI2b (Figure 1.9). Results in Chapter 3 show that 
Arginines 108 and 125 within loops of blade 3 of WIPI2b are essential for Atg16L1 
binding. These Arginines are in loops of blade 3 that form a solute-expose basically 
charged cleft between blades 2 and 3 of WIPI2. Interestingly, modelling of WIPI2b by 
Michael Wilson (based on a crystal structure of Hsv2 (Watanabe et al., 2012)) shows 
that R108 and R125 are proximal to F65 and S66 (corresponding to Atg2 binding site 
F54, S55 on Atg18) (Figure 6.1). Blades 5 and 6 of proteins in the PROPPIN family 
mediate membrane interactions (Krick et al., 2012, Baskaran et al., 2012, Watanabe et 
al., 2012). Therefore, blades 1, 2 and 3 are well positioned to mediate interactions when 
the β-propeller is membrane bound and it is possible that other PROPPIN proteins 
function in autophagy by binding their interacting partners at binding sites formed by 
the loops of blades 2 and 3. Consistently, WIPI1a R110 (the equivalent of WIPI2b 
R108) is required for WIPI1a function in autophagy (Gaugel et al., 2012). WIPI1a 
R110A mutants formed starvation- and PtdIns(3)P-independent puncta although the 
PtdIns(3)P binding ability of this mutant is not changed. These puncta and their effect 
on autophagy has not been fully characterised, but they are Atg12 positive during 
starvation conditions. Further work on identifying interacting partners of the PROPPIN 
family and characterising the functions of these interactions will shed light on the 
molecular functions of uncharacterised PROPPIN family members such as WIPI1, 3 
and 4. 
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Our model for WIPI2b function is that WIPI2b is recruited to the PtdIs(3)P-
positive omegasome, where it subsequently binds Atg16L1 and consequently recruits 
the Atg12–5-16L1 complex. Evidence for this sequential recruitment comes from live 
cell imaging: starvation-induced WIPI2b puncta become Atg16L1 positive over time 
(Dooley et al., 2014). However, in a manner similar to interactions between Atg18 and 
Atg2 or PtdIns(3)P, the WIPI2b-Atg16L1 and WIPI2b-PtdIns(3)P interactions seem to 
be independent of each other (Rieter et al., 2013, Obara et al., 2008) (Figures 3.22 and 
4.6d). Furthermore, the WIPI2b-Atg16L1 interaction seems to be starvation 
independent (Figure 3.6). This raises the question of how this interaction is regulated. 
Although the Atg18-Atg2 interaction is independent of PtdIns(3)P at the whole-cell 
level, the interaction between these two proteins at the PAS is PtdIns(3)P dependent 
(Rieter et al., 2013). This was shown using bimolecular fluorescence complementation 
(BiFC), an assay in which N- and C-terminal fragments of Venus (a yellow fluorescent 
protein protein) are each fused to the proteins of interest. When the fusion proteins form 
a complex, the N- and C-terminal fragments are brought into close enough proximity to 
form a functional fluorescent protein. WIPI2b and Atg16L1 may transiently interact 
under all conditions, which would make an increase in interaction during starvation or 
inhibition of PtdIns(3)P binding hard to detect. BiFC assays using fusion proteins of 
Atg16L1 and WIPI2b could be used to assay the ability of WT WIPI2b and WIPI2b 
FTTG to form a complex in vivo with Atg16L1. Preliminary observations suggest that 
clustering of WIPI2b, perhaps as a result of concentrated PtdIns(3)P production, may 
itself be required for Atg16L1 binding. WIPI2b cannot bind to Atg16L1 that does not 
form dimers even when the residues required for WIPI2b interaction (E226 and E230) 
are present (Figure 3.11d). The inability of WIPI2b to bind Atg16L1 Δ69-213 could 
either be because there is a second Atg16L1 binding site within Atg16L1 69-230 (N-
terminal to the site that we have identified) or because the weak interaction of WIPI2b 
and Atg16L1 must be stabilised by two WIPI2b molecules interacting with a dimer of 
Atg16L1 (Figure 6.2). Validation of this would require detailed mutation analysis of 
Atg16L1 to disrupt coiled-coil homodimerisation and subsequent analysis of WIPI2b 
binding. If true, WIPI2b oligomerisation at the omegasome could theoretically be 
needed to achieve a 2:2 stoichiometry for binding. 
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Alternatively, WIPI2b-Atg16L1 interaction could be regulated by some as yet 
undiscovered mechanism. Phosphorylation of WIPI2b S395 does not seem to affect 
Atg16L1 binding, but paradoxically removing the C-terminus of WIPI2 increases 
Atg16L1 binding (Figures 5.7 and 3.21). As discussed in Chapter 5.5, investigation of 
the function of this potential phosphorylation site requires more extensive functional 
assays. The C-termini of WIPI1 and WIPI2 are not well conserved (Figure 1.9). 
Therefore, the C-terminus of WIPI1 and WIPI2 may modulate the function of these 
proteins, as seems to be the case with their ability to bind Atg16L1. The C-terminus of 
WIPI2b is predicted to be unstructured (Krick et al., 2012) and it is possible that it could 
function in obscuring binding sites on WIPI2 or enhancing WIPI2 interactions. 
Similarly to regulation of Atg16L1 binding, the mechanisms controlling WIPI2-
localisation, and that of other PROPPIN family members, to membranes are very poorly 
understood. Hsv2 binds PtdIns(3)P through a conserved PtdIns(3)P binding FRRG 
motif and through a membrane insertion loop (Krick et al., 2012, Baskaran et al., 2012, 
Watanabe et al., 2012) and it is probable that WIPI2 also associates with the membrane 
through both the FRRG and membrane insertion loop. However, WIPI2 localisation is 
restricted to PtdIns(3)P pools at the omegasome, rather than other PtdIns(3)P-positive 
endomembrane structures (Polson et al., 2010). Hydroponic residues within the 
membrane insertion loop of HSV2 are required for membrane binding (Baskaran et al., 
2012). However, whether or not the membrane insertion loop itself plays a role 
determining the membrane to which PROPPIN proteins are localised remains to be seen. 
Localisation of Atg18 is restricted both by its binding partner and by PtdIns(3)P binding 
(Obara et al., 2008, Efe et al., 2007). Although WIPI2b does not need to bind Atg16L1 
to localise to omegasomes (Figures 4.4 and 4.7), perhaps its localisation is similarly 
controlled by an additional interaction partner. Interestingly, a number of ER-localised 
proteins were identified in Hannah Polson’s mass spectrometry screen for WIPI2b 
interactors (data not shown). Furthermore, Atg18 binding to PtdIns(3,5)P2 is controlled 
by phosphorylation within a loop in blade 7 of the β-propeller (Chapter 1.3.4.2) 
(Tamura et al., 2013). WIPI2 binding to PtdIns(3)P may similarly be controlled by 
phosphorylation, as discussed in Chapter 5.5. Alternatively, other post-translational 
modifications may be involved in regulating WIPI2 localisation to the omegasome. 
Ambra1-dependent ubiquitination of ULK1 promotes ULK1 stabilisation, self-
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association and function in autophagy (Nazio et al., 2013). Three sites in WIPI2 were 
identified in a global screen for ubiquitinated proteins (K198, K205 and K219) (Kim et 
al., 2011b). These three sites are within blade five of the β-propeller and could 
potentially interfere with PtdIns(3)P binding if modified with ubiquitin (the FRRG 
motif is within blade 5).  
Results in Chapter 4 show that WIPI2b binding, rather than FIP200 binding, is 
required for autophagy rescue in Atg16Δ/Δ MEFs (Figures 4.13 and 4.14). This raises the 
question of what the function of FIP200 in starvation-induced autophagy is. Atg16L1 
binds FIP200 and ubiquitin and, although when these interactions are inhibited 
separately there is no effect on starvation-induced autophagy, Atg16L1 unable to bind 
either protein is not fully functional in starvation-induced autophagy (Fujita et al., 2013). 
This suggests that FIP200 and ubiquitin binding of Atg16L1 are redundant. PtdIns(3)P 
production at the omegasome is required for stabilisation of the ULK1 complex 
(Karanasios et al., 2013a) and it is conceivable that Atg16L1 binding by FIP200 is 
needed for this stabilisation. ULK1 activation and PtdIns(3)P production on 
omegasomes by the Vps34 PtdIns(3) kinase complex recruits WIPI2b and subsequently 
the Atg12–5-16L1 complex. Atg16L1 binding to FIP200 could stabilise ULK1 complex 
association with the forming autophagosome and, as Atg16L1 recruitment is PtdIns(3)P 
dependent (through its interaction with WIPI2b), any stabilisation would be PtdIns(3)P 
dependent. Further work is needed to clarify the function of the Atg16L1-FIP200 
interaction.  
Atg16L1Δ/Δ MEFs have been extremely useful in rescue experiments dissecting 
the requirement for WIPI2b binding by Atg6L1. Production of a WIPI2 knock out 
mouse and subsequently a WIPI2-/- cell line would allow further validation of the 
function of WIPI2b in autophagy and would also be useful in the continuing 
characterisation of WIPI2. I found that the effect of rescue experiments with WIPI2b 
RERE (Atg16L1 binding mutant) on autophagy were markedly different in RISC-free 
treated cells compared to WIPI2 knockdown cells (Figure 4.5). The inhibitory effect of 
WIPI2b RERE is dependent on depletion of endogenous WIPI2. Using WIPI2-/- MEFs 
for rescue experiments would ensure that cells contain no residual WIPI2. 
In combination with crystal structures of Hsv2, identification of the WIPI2b-
Atg16L1 interaction and the mechanism of Atg12–5-16L1 complex recruitment raises 
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some interesting questions about the orientation of these proteins on the omegasome 
and forming autophagosome. The orientation of Hsv2 on PtdIns(3)P-positive membrane 
is restricted by its PtdIns(3)P binding domain and membrane insertion loop, resulting in 
Hsv2 docking on the membrane through the sides of the β-propeller (rather than face 
down) with blades 5 and 6 in contact with the membrane (Figure 1.7) (Krick et al., 2012, 
Baskaran et al., 2012, Watanabe et al., 2012). WIPI2 is probably similarly orientated on 
PtdIns(3)P-positive omegasomes. Molecular modelling of WIPI2b and Atg16L1 207-
165 by Michael Wilson suggests that when WIPI2b binds dimers of Atg16L1 (Atg16L1 
forms a parallel coiled-coil dimer (Fujioka et al., 2010)) Atg16L1 must be positioned 
perpendicular to the membrane on which WIPI2b is docked (Michael Wilson, personal 
communication). If this is correct, binding of Atg16L1 to WIPI2b in this manner would 
position the Atg12–5 complex away from the membrane onto which WIPI2b is docked 
(Figure 6.2) (Michael Wilson, personal communication). Phagophores can form 
between two leaves of ER cisternae (probably the omegasome) in a manner by which 
lipidated LC3 does not spread from the phagophore to the ER and PtdIns(3)P is only 
produced on the omegasome and does not spread to the phagophore (as labelled by 
DFCP1 localisation) (Yla-Anttila et al., 2009, Hayashi-Nishino et al., 2009, Karanasios 
et al., 2013a). This arrangement suggests that PtdIns(3)P and its binding partners are 
spatially distinct from LC3 lipidation and this could be achieved by Atg16L1 being 
positioned perpendicularly to the omegasome membrane (Figure 6.2). This is a very 
speculative model and further structural analysis of the positioning of the WIPI2b-
Atg16L1 complex on forming autophagosomes will hopefully shed light on this area. 
 In summary, I have demonstrated that WIPI2b is responsible for Atg16L1 
recruitment to PtdIns(3)P-positive forming autophagosomes. Detailed mapping of 
WIPI2b and FIP200 binding sites on Atg16L1 has enabled me to differentiate between 
the functions of WIPI2b- and FIP200-binding to Atg16L1 in both starvation- and 
Salmonella-induced autophagy. The close proximity of the WIPI2b and FIP200 binding 
sites on Atg16L1 suggest that Atg16L1, WIPI2b and FIP200 may be interconnected in 
some functional or regulatory manner. Furthermore, further work on the PtdIns(3)P-
dependent anchoring of the Atg12–5-16L1 complex to membranes by WIPI2b may 
shed light on the complex membrane dynamics underpinning formation of the 
autophagosome double membrane. 
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Figure 6.1 Model of WIPI2b 
(a) Model	  for	  human	  WIPI2b	  (14-­‐377)	  based	  on	  the	  X-­‐ray	  structure	  of	  Hsv2	  ((Watanabe	  et	  al.,	  2012);3vu4.pdb)	  made	  with	  the	  iterative	  threading	  assembly	  refinement	  (I-­‐TAASER;(Roy	  et	  al.,	  2010)).	  The Atg16L1-binding cleft between blades 
2 and 3 and the membrane binding region in blades 5 and 6 are labelled. (b) Zoom of 
the Atg16L1 binding region circled in (a). F65 is S. cerevisiae Atg18 F54. Modelling 
done and figure provided by Michael Wilson. 
 
 
Figure 6.2 Possible arrangement of autophagy proteins on the forming autophagosome 
Phagophores can form between two cisternae of the ER (shown with ribosomes). 
PtdIns(3)P production by the Beclin1 Vps34 PtdIns(3) kinase complex leads to WIPI2b 
binding. WIPI2b recruits the Atg12–5-16L1 complex, possibly in a perpendicular 
orientation to the omegasome.  
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